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Abstract 
 
Given the increasing worldwide obesity epidemic, there exists a need for 
development of alternative therapies for lipid-induced insulin resistance and 
associated increases to hepatic glucose production – a key driver of type 2 diabetes 
(T2D). The complexity of insulin resistance hinders attempts to find therapies that 
are effective on a population scale with minimal side effects, and remain viable 
treatments over the lifetime of a patient. We propose that embracing this 
complexity by using unbiased global approaches to characterise both the induction 
(“diseased” state) and reversal (“recovered from disease” state) of lipid-induced 
alterations to hepatic glucose production will prove effective for the identification 
of additional targets and therapies. Modelling both the induction and reversal of 
such a state is a relevant representation of route to recovery from disease that an 
individual faces. Microarray technology provides two key methods to investigate 
such a model. Firstly, the identification of a small subset of genes (gene expression 
signature; GES) with the best ability to discriminate between “diseased” and 
“recovered from disease” states. Identification of these genes would enable GES-
based small molecule screens to find therapeutics that can match an individual’s 
GES profile. We propose that this personalised medicine approach will allow for 
identification of therapies with optimised efficacy. Secondly, by identifying 
regulated signalling and metabolic pathways between the “diseased” and 
“recovered from disease” states, we may discover novel metabolic regulation 
occurring in parallel with the disease. Such a finding would provide additional 
targets for the development of treatments for patients with T2D. 
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Cellular insulin resistance and elevated basal glucose production were induced in 
rat FAO hepatoma cells treated with 0.075 mM palmitate (PA-treated) for 48 h. In 
this in vitro model, insulin resistance was not reversed using a series of known anti-
diabetes drugs including biguanides, salicylates, thiazalidinidiones or the traditional 
Chinese herbal extract berberine, in contrast to the effects of these drugs in other 
cell types where they have been shown to improve insulin sensitivity. However, the 
reversal of elevated glucose production was achieved via combination treatment 
with 0.25 mM metformin and 2 mM sodium salicylate (PAMN-treated) added in the 
final 24 h of PA-treatment. Combination treatment was a deliberate feature of the 
model – making the GES characteristic of a multi-target approach to reverse 
dysregulated glucose production, rather than characterising the effects of one 
specific anti-diabetic. We propose that this modelling approach will enhance the 
ability to identify optimal therapies during drug screening. 
 
cDNA microarrays were utilised to profile the global transcriptional changes 
associated with the onset and reversal of PA-induced dysregulated glucose 
production in the cells. Diagonal linear discriminate analysis (DLDA) of the 
microarray dataset identified a set of 7 genes that best discriminated between the 
induction and reversal of PA-induced dysregulated glucose production. The gene set 
included annexin a3 (Anxa3); glutathione-s-transferase m-3 (Gstm3); phospholipase 
A2, group 1b (Pla2g1b); ras-related protein Rab-33a (Rab33a); serine peptidase 
inhibitor, clade A, member 5 (Serpina5); solute carrier family 2, member 2 
(Slc2a2/GLUT2) and stannin (Snn). The gene expression levels of these genes were 
not reproducibly validated via RT-PCR, therefore preventing the development of a 
PA-based GES at this time. The expression levels of each GES gene was determined 
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in a human lymphocyte dataset from the San Antonio Family Heart Study (n = 
1,240), and Anxa3 gene expression levels were positively and negatively correlated 
with total serum triglyceride and fasting plasma glucose levels, respectively. After 
using linear regression analysis to adjust for age, sex and BMI, Anxa3 was not found 
to be an independent predictor of either of these phenotypes. 
 
Gene set enrichment analysis of the microarray dataset demonstrated that the 
pathways being regulated at the transcriptional level were different in PA-induced 
dysregulated glucose production compared with those involved in the reversal with 
PAMN. The effects of PA were characterised by transcriptional regulation of cell 
cycle, immune function and inositol phosphate metabolism – the latter of particular 
relevance to insulin signalling. In contrast, PAMN-treatment was characterised by a 
significant decrease in the metabolic pathways regulating the synthesis of 
cholesterol and bile acids from acetyl-CoA, which have proposed roles in regulating 
fatty acid uptake, insulin sensitivity and hepatic glucose production, respectively.  
 
A global mass spectroscopy-based lipidomic profile was generated to investigate 
the effects of transcriptional regulation on lipid metabolism. PAMN-treatment was 
characterised by decreased levels of multiple diacylglycerols (DAGs), triacylglycerols 
(TAGs) and cholesterol ester species that contained at least one C18:1 side chain in 
parallel with decreased glucose production following PAMN-treatment. Given the 
role these unsaturated species have been suggested to play in activation of PKC 
isoforms (specifically PKCε in the liver), this finding may indicate a role for PKCε 
activation in this model. The total levels of intracellular or secreted cholesterol and 
bile acids between cell treatment groups were not different; however, whether the 
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transcriptional changes described above indicate altered metabolic flux through 
these pathways remains to be confirmed. A comprehensive analysis of the 
phosphatidylinositol (PI) content of vehicle-, PA- and PAMN-treated cells identified 
PI 38:5 as a candidate target mediating the effects of PA-treatment on hepatic 
glucose production, as it was decreased in parallel with insulin sensitivity. Further 
analysis revealed the major identity of the side chains of PI 38:5 as oleic acid (C18:1) 
and arachidonic acid (C20:4). Currently, the contribution of specific PI species in 
insulin signalling and hepatic glucose production remains unresolved.   
 
Taken together, the results implicate the rate of acetyl-CoA to cholesterol synthesis 
as a possible key regulator of hepatic glucose production. There is also evidence for 
the identity of PI side chains to modulate insulin signalling, providing an entirely 
new class of lipid targets for the reversal of lipid-induced insulin resistance and/or 
elevated glucose production. In addition, while development of a PA-based GES was 
unsuccessful at this time using DLDA for gene identification, the development of 
such a GES remains possible using alternative Bayesian statistical approaches. 
Candidate gene identification via DLDA did identify both Anxa3 and Pla2g1b, one of 
which (Pla2g1b) has been previously implicated in lipid-induced dysregulation of 
hepatic glucose production. Therefore, this study has implicated the following three 
metabolic targets in regulation of hepatic glucose production – acetyl-CoA to 
cholesterol metabolism, lipid species with C18:1 side chains, and PI 38:5. These 
potentially novel mediators of hepatic glucose production may therefore provide 
targets for development of therapeutic agents for T2D. Characterising both the 
induction and reversal of PA-induced dysregulated glucose production identified 
these metabolic targets. This approach may therefore have similar utility in future 
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studies identifying novel therapeutic targets for alternative disease states that can 
be modelled in vitro. 
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Chapter 1: Introduction 
 
1.1. Complexity of Diabetes Mellitus 
Diabetes is a complex and heterogeneous disease. Combinations of varying 
causative factors, as well as interactions between environmental and genetic 
factors all play a role in the onset of the disease. This complexity has hindered the 
development of long-term effective treatment options for patients, and makes 
understanding the onset of the disease difficult. This thesis focuses on using whole 
genome microarray technology to study type 2 diabetes (T2D) with unbiased 
approaches in order to develop individualised therapeutics for individuals with 
diabetes. 
 
1.1.1. Prevalence and cost of the worldwide diabetes burden 
There are almost one million Australians currently diagnosed with diabetes, 
however it has been estimated that the total number of Australians suffering from 
diabetes may be closer to 1.7 million due to chronic levels of patients who remain 
undiagnosed [1]. A further 275 individuals develop diabetes every day in Australia, 
and the total number of diabetic and pre-diabetic (as determined by fasting blood 
glucose or HbA1c levels) Australians may number up to 3.2 million [2]. The annual 
health system costs associated with T2D in Australia has recently been reported as 
$1.07 billion [3], however the total economic burden of T2D in Australia has been 
estimated to be as high as $10.3 billion [4]. In the Unites States of America, there 
are currently 25.8 million people living with diabetes, and this accounts for 8.3% of 
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the population [5]. This alarming figure is growing rapidly, with 1.9 million people 
being newly diagnosed in 2010 alone [5]. It has been estimated that there are 
currently 79 million adults in the US who are pre-diabetic [5]. The costs associated 
with managing the diabetes epidemic in America were recently estimated at $174 
billion annually, and this figure will increase in the coming years as the prevalence 
of diabetes increases [5]. The projected increase in the prevalence of diabetes, 
coupled with the already significant economic costs associated with the disease; 
make the development of alternative effective treatments an urgent priority. 
 
1.2. Diagnosis and Treatment of Type 2 Diabetes (T2D) 
 
1.2.1. Metabolic staging of T2D 
The development of T2D is a progressive condition. The onset of insulin resistance 
can occur in many cases before a clinical diagnosis has been made [6]. The 
development of insulin resistance leads to hyperinsulinemia, when insulin resistant 
tissues require higher levels of circulating insulin to maintain glucose homeostasis. 
This pre-diabetic state is termed impaired glucose tolerance (IGT), in which 
normoglycaemia is observed along with insulin resistance and hyperinsulinemia. 
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FIGURE 1.1: Metabolic staging of T2D. 
Progression of T2D from early insulin resistance through to beta cell failure and the 
development of frank T2D. Adapted from [7]. 
 
IGT develops to overt T2D when the production of insulin by the pancreas is no 
longer sufficient to counteract the rising insulin resistance in the peripheral tissues. 
As blood glucose levels rise, so does the strain on pancreatic β-cells to produce 
insulin increase. The onset of chronic hyperglycaemia eventually exhausts β-cells 
and leads to deficient insulin production. When the pancreas is no longer able to 
cope with the increasing demands of rising blood glucose, overt T2D results (Fig. 
1.1). 
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1.2.2. Diagnosis of T2D 
Diagnosis of T2D, and its precursor insulin resistance, is made difficult by the lack of 
symptoms early in the development of the disease, and it has been estimated that 
up to half of all cases are undiagnosed [1]. Predictors of risk for the development of 
T2D and cardiovascular disease include body mass index (BMI), ethnic origin, blood 
pressure and cholesterol levels [8]. Current clinical guidelines for the diagnosis of 
diabetes however are based upon blood glucose measures. The World Health 
Organisation (WHO) standard criteria for diagnosis of T2D involve fasting plasma 
glucose (FPG) and the response to an oral glucose tolerance test (OGTT). FPG is a 
measure of plasma glucose after 8 hours of fasting, while the OGTT measures 
plasma glucose 2 hours following an intake of 75 g glucose. The current guidelines 
are outlined in Table 1.1. IGT is characterised by peripheral insulin resistance, while 
defects in insulin secretion coupled with increased hepatic glucose output 
characterise impaired fasting glucose (IFG) [9]. IGT and IFG are individually strong 
indicators of risk for the development of T2D, with individuals suffering from both 
conditions placed at even higher risk [8].  
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TABLE 1.1: WHO guidelines for the diagnosis of diabetes and other 
hyperglycaemic states. 
 FPG OGTT 
NGT < 6.1 mmol/L < 7.8 mmol/L 
IGT < 7.0 mmol/L 7.8 – 11.1 mmol/L 
IFG 6.1 – 6.9 mmol/L < 7.8 mmol/L 
Diabetes ≥ 7.0 mmol/L ≥ 11.1 mmol/L 
NGT – normal glucose tolerance, IGT – impaired glucose tolerance, IFG – impaired 
fasting glucose [10]. 
 
1.2.3. Current treatments for individuals with T2D 
The development of both insulin resistance and impaired glucose tolerance, 
conditions that precede the onset of T2D, are closely linked with obesity [11]. 
Excess visceral fat, and the hormones and inflammatory factors it releases, coupled 
with excess free fatty acid release have been implicated in the development of T2D 
[12]. For obese patients exhibiting these symptoms, changes to healthier eating 
patterns and increased exercise can result in improvements to glucose tolerance. 
However this approach often fails within the first year of treatment, and therefore 
the use of multiple medications is often required [13]. Lifestyle changes 
immediately following the diagnosis of T2D can be successful in the early treatment 
of the disease [14]. The benefit of weight loss on improving glycaemic profile has 
been convincingly observed in follow up studies of patients with T2D who have had 
bariatric surgery, with mean sustained weight loss after 10 years >20 kg normalising 
plasma glucose, HbA1c and plasma insulin levels [15, 16]. However, a lack of 
diagnosis during the early stages of disease progression, coupled with difficulties in 
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maintaining non-surgical lifestyle modifications, means that lifestyle interventions 
are not a treatment option that has been effective in the long term for the majority 
of patients [13].  
 
Metformin is an oral antidiabetic agent, based upon the molecule biguanide. The 
primary mechanism of action of metformin involves inhibition of hepatic 
gluconeogenesis, leading to a reduction in blood glucose levels [17], and a 
subsequent decrease in blood insulin levels. Metformin has a number of side effects 
including gastrointestinal symptoms and has been linked with rare cases of lactic 
acidosis which can be fatal, although evidence for this has been contradicted in 
some studies [18]. Metformin is one of only two oral anti-diabetic agents on the 
WHO list of essential medicines. The second oral anti-diabetic to be listed by WHO 
is the drug family known as the sulfonylureas, the most commonly used drug of 
which is glibenclamide. The sulfonylureas’ mechanism of action involves inhibition 
of the pancreatic K-ATP channel sulfonylurea receptor (SUR1/Kir6.2) [19], leading to 
a depolarisation of the plasma membrane and opening voltage gated Ca2+ 
channels, which cause increased fusion of insulin-containing granules to the plasma 
membrane, thereby, increasing insulin secretion [20]. For this reason, the 
sulfonylureas show their best efficacy in the early stages of the disease when β-cell 
function is still viable. Side effects associated with the sulfonylureas include 
hypoglycaemia due to their long half-life in plasma, and weight gain. 
 
The glinides are a family of drugs with a mechanism of action similar to the 
sulfonylureas, in that they bind to and inhibit the same K-ATP channel (SUR1/Kir6.2) 
– although at an alternate binding site – to induce insulin secretion from the β-cells 
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of the pancreas [19]. The glinides have is a shorter half-life in blood plasma than the 
sulfonylureas. As such, some glinides pose a lower risk of hypoglycaemia than some 
sulfonylureas [21]. 
 
Thiazolidinediones (TZDs or glitazones) are an insulin sensitising family of 
compounds. TZDs are ligands for the nuclear transcription factor peroxisome 
proliferator-activated receptor γ (PPARγ), as well as weak activators of other PPAR 
isoforms. It is through activation of the transcriptional regulatory PPAR family that 
this family of compounds increase the sensitivity of muscle, liver and adipose tissue 
to the effects of insulin [22]. However, this family of drugs has been linked to 
serious long-term side effects. Troglitazone, first approved for use in T2D patients in 
1997, was withdrawn from the market in 2000 after it was linked to a number of 
cases of liver dysfunction and failure [23]. Pioglitazone has been linked with 
increased risk of bladder cancers in adults with T2D [24]. The widely used 
alternative rosiglitazone has in recent years been linked to increased cardiovascular 
disease [25]. The drug has been withdrawn from sale in the UK and New Zealand. 
While still available in the US, rosiglitazone is currently branded with additional 
safety warnings and restrictions on its use, and sales in recent years have fallen 
significantly [26]. 
 
Glucagon-like peptide 1 agonists (GLP-1 agonists) are mimics of a protein secreted 
by the L-cells of the small intestine, and act on GLP-1 receptors in pancreatic β-cells 
to induce insulin release. GLP-1 agonists have also been shown to stimulate β-cell 
proliferation [27, 28] and suppress glucagon release and gastric motility, while 
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inducing weight loss. Side effects of GLP-1 agonists include a decrease in gastric 
motility, responsible for the nausea commonly experienced by patients [29]. 
 
Amylin is a β-cell hormone co-secreted with insulin. Amylin lowers blood glucose 
levels by inhibiting glucagon secretion following a meal, and induces satiety by 
acting upon the area postrema (AP) neurons within the brain stem [30]. While 
amylin forms aggregates, which make it unsuitable as a therapeutic agent, amylin 
agonists such as pramlintide can effectively simulate the effects of the physiological 
amylin. Like GLP-1 agonists, amylin agonists can induce nausea in patients [31].  
 
Exogenous insulin is a key therapeutic agent for the treatment of diabetes, capable 
of increasing blood insulin levels when β-cell function has been impaired, and can 
be given in increasing amounts – alongside other insulin sensitising agents – to 
overcome insulin resistance [32]. However, insulin is also associated with increases 
in weight gain, as well as risk of hypoglycaemia if monitoring of blood glucose levels 
is not rigorously performed. 
 
1.2.4. Problems and adverse effects of current drug therapies 
As highlighted above, the currently used range of anti-diabetic medicines have a 
number of adverse side effects, including hypoglycaemia, fluid retention and weight 
gain, and gastro-intestinal symptoms. As T2D generally progresses over time to a 
worsening in glycaemic control, the need to utilise multiple therapies together is 
unfortunately the reality for many patients with T2D [13]. Difficulties in managing 
T2D are exacerbated by the fact that the various drugs available have a wide range 
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of effects in individual patients, in terms of the magnitude of both efficacy and side 
effects [32]. In addition to these factors, many of the current drugs used to treat 
T2D lose their efficacy over time [32]. Therefore, the focus of new treatments has 
progressed towards personally tailoring pharmacotherapy to suit each patient’s 
individual characteristics.  
 
We therefore propose that the reason why current therapies do not offer a 
comprehensive treatment for T2D is that they do not address the underlying 
heterogeneous nature of the disease. A number of different subtypes of insulin 
resistance have been described, across a range of different tissues and due to 
varying insults (see Section 3.1 below). If effective treatments for T2D are to be 
developed, there is a need to gain a better understanding of the different subtypes 
of insulin resistance.  
 
1.3. Complexity of T2D and insulin resistance subtypes 
 
1.3.1. Insulin resistance subtypes 
Multiple clinical phenotypes such as abdominal obesity [33], polycystic ovary 
syndrome (PCOS) [34], Cushing’s syndrome [35], lipodystrophy [36], chronic levels 
of insulin [37], acromegaly (elevated growth hormone) [38], glucocorticoid 
treatment (eg. during acute lymphoblastic leukemia) [39] and chronic infection [40] 
are all associated with insulin resistance. The links between the causes of insulin 
resistance associated with these phenotypes is not obvious since multiple pathways 
have been implicated in the development of insulin resistance, such as 
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hyperlipidemia [41], elevated levels of pro-inflammatory cytokines [42] and/or 
induction of oxidative [43] or endoplasmic reticulum (ER) [44] stress pathways 
which may be activated individually or concurrently [45]. Superimposed on this 
network of interactions is the genetic variability of each individual that confers a 
differential susceptibility to each insult, adding another layer of complexity [46]. 
However, all of these insults can cause insulin resistance individually or in concert 
via a number of different mechanisms (Fig. 1.2).  
 
 
 
FIGURE 1.2: The multifactorial nature of T2D. 
A patient’s own genetic susceptibility (I-IV), coupled with multiple insults (A-F) can 
lead to insulin resistance via multiple mechanisms. Insulin resistance can therefore 
lead onto frank T2D via numerous routes (from NHMRC grant #533824, Molero, 
Konstantopoulos, Jowett and Segal). 
 
 
Insulin resistance is a major risk factor for the development of T2D [47]. Combating 
insulin resistance provides a key to developing effective treatments for T2D. The 
aetiology of T2D is multifactorial, with both genetic and environmental factors 
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involved [48]. Likewise, the onset of insulin resistance is multifactorial and can 
occur in different tissues and arise from multiple causes as depicted in Fig. 1.2. 
There are numerous known insults to insulin signalling and action. Insults to insulin 
action can be both endogenous, such as inflammatory cytokines released in 
response to a fatty meal, and exogenous, such as the fatty acids themselves, which 
can lead to the development of insulin resistance. These subtypes can be mimicked 
in cell culture based models, as shown in Table 1.2.  
 
TABLE 1.2: Proposed subtypes of insulin resistance and the insults that 
can lead to their genesis in cell models. 
Subtype Causative agents 
Inflammation Cytokines: eg. IL-6, TNFα [42] 
ER Stress Tunicamycin, Thapsigargin [44] 
Glucocorticoid Dexamethasone [49] 
Hyperinsulinemia Chronic elevated insulin levels [50] 
Oxidative stress ROS: eg. Superoxide anions [43] 
Hyperlipidemia Long chain, saturated FFAs: eg. Palmitate (PA; 16:0) [41] 
 
While there are a number of factors, which may lead to the development of insulin 
resistance in various tissues, they do not necessarily develop in complete isolation, 
and signalling crosstalk between the various models mentioned above occurs. For 
example, hyperlipidemia-induced insulin resistance has also been linked to 
increased generation of the inflammatory cytokine TNFα through activation of the 
pro-inflammatory transcription factor nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-kB) [51, 52]. 
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We therefore propose that treating the underlying subtype(s) of insulin resistance 
in a patient with either early insulin resistance or frank T2D will have increased 
efficacy for the long-term maintenance of euglycaemia. We aim to identify a gene 
expression signature (GES) based on different known causes of insulin resistance. 
The generation of a GES for the profiling of patients would then allow the 
stratification of diabetic patients according to the underlying insulin resistant 
condition(s). We therefore hypothesise that we can use the GES profiles to identify 
the subtype(s) contributing to a patient’s insulin resistance. This would allow for 
tailoring of a patient’s medication targeting their insulin resistance subtypes for 
personalised management of their metabolic dysregulation. This will be discussed in 
further detail below. 
 
1.3.2. The rising worldwide prevalence of obesity 
Obesity is a major risk factor for the development of insulin resistance and T2D [53, 
54], and the relationship between weight gain and decreased insulin sensitivity has 
been established for many years [55]. Obesity is widespread in the western world, 
with recent WHO data estimating 64% of Australians are either overweight or 
obese, with 27% being obese [56]. If weight gain in Australian adults continues at 
the current projected rate, by 2025, 80% of the population will be overweight or 
obese, along with 30% of children [57]. The recent US National Health and Nutrition 
Examination Survey (NHANES) estimated that for Americans aged 20 and above, 
67% are either overweight or obese, while 34% were obese [58]. The WHO 
estimates that in 2005 there were 1.6 billion adults worldwide who were 
overweight, at least 400 million of which were obese. These numbers are projected 
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to increase to 2.3 billion overweight and at least 700 million obese adults by 2015 
[59]. The increasing epidemic of obesity will further increase the prevalence of 
insulin resistance and T2D within society, making the development of effective 
treatments a critical challenge for the 21st century. 
 
1.4. Obesity 
 
1.4.1. Free fatty acids 
As one of the primary risk factors for the development of T2D, obesity warrants 
extensive study as a target for the development of additional and alternative 
therapies. The defining characteristic of obesity is increased adiposity. Increased 
availability of free fatty acids (FFA) in patients with obesity plays a critical role in the 
development of insulin resistance [60]. There are numerous factors in obesity which 
can lead to increases in circulating FFA levels, including exceeding the storage 
capacity of adipose tissue by excess caloric intake [61], and adipose tissue 
stimulation by the paracrine cytokine TNFα which induces triglyceride metabolism 
and FFA release [62]. Insulin resistance in adipose tissue can also lead to excess FFA 
release, due to suppression of the antilipolytic effects of insulin [62]. The direct 
effects of increased circulating FFAs on macrophages to stimulate release of pro-
inflammatory cytokines such as TNFα and IL-6 has also been recently described (for 
a review see [63]). The onset of insulin resistance caused by FFA is therefore highly 
complex, and although direct action upon target tissues have been described, there 
are secondary actions upon other tissue types that further complicate the 
pathology of the disease. For example, following both PA-treatment of mouse 
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C2C12 myotubes and lipid infusion (Liposin II) in individuals has been shown to 
induce intramuscular generation of the inflammatory cytokine TNFα through 
activation of the pro-inflammatory transcription factor NF-kB [51, 52], which in turn 
induce inflammatory-based insulin resistance in other peripheral tissues, as has 
been shown in 3T3-L1 adipocytes and FAO hepatoma cells [42]. Given the increasing 
prevalence of obesity around the world, dissecting the mechanisms by which FFAs 
contribute to insulin resistance may identify new avenues for effective treatment 
regimes. 
 
1.4.2. Effect of dietary free fatty acid composition on insulin 
signalling 
The effects of FFAs on insulin sensitivity both in vivo and in vitro have been studied 
extensively in recent times. The KANWU study (named for the locations of data 
collection centre: Kuopio, Aarhus, Naples, Wollongong and Uppsala) remains one of 
the largest controlled studies looking into the effects of fat composition in the diet 
on insulin sensitivity. Healthy individuals (n = 162) were placed on one of two 
isoenergetic diets for 90 days: either high in monounsatutrated (MUFA diet, high in 
oleic acid, n = 79) or saturated (SAFA diet, n = 83) fatty acids. Individuals on the 
SAFA diet were found to have reduced insulin sensitivity index compared to 
baseline levels (-10%, p=0.03), while no change was observed in the MUFA diet [64]. 
The study also found that only for those subjects with total fat intake below the 
median (37% of energy), there was a positive effect for substituting saturated fatty 
acids with mono-unsaturated fatty acids; individuals on the MUFA diet were found 
to have an increased insulin sensitivity index (+8.8%, p=0.03) [64]. The KANWU 
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study was one of the first human studies to link both the type and quantity of fatty 
acid in a dietary intake to decreases in insulin sensitivity. The relationship between 
dietary fatty acid composition has been extensively studied (and reviewed [65-68]), 
and it has been consistently observed that diets enriched in saturated fatty acids 
are inversely correlated with insulin sensitivity in individuals [69-73]. 
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1.4.3. Normal metabolic interplay between carbohydrate and fatty 
acid metabolism/oxidation 
 
 
 
FIGURE 1.3: Synthesis and oxidation of intracellular fatty acids. 
Intracellular fatty acids derived from de novo synthesis or uptake from the plasma is 
oxidised in the mitochondria. Synthesis and oxidation of fatty acids is metabolically 
regulated by the availability of carbohydrate as an energy source, mainly through 
the activation/inhibition of acetyl-CoA carboxylase (ACC). Figure adapted from [74]. 
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While availability of glucose can modulate the relative rates of fatty acid synthesis 
and oxidation through activation/inhibition of ACC and subsequent malonyl-CoA 
production (Fig. 1.3), in states of excess lipid availability, impaired glucose 
metabolism can arise. There have been numerous studies into the mechanism of 
fatty acid-induced insulin resistance. Although the mechanisms are not completely 
understood, there is currently a vast body of evidence pointing to a number of 
mechanisms by which FFAs induce insulin resistance in key insulin responsive 
tissues such as skeletal muscle and liver, and this will be summarised below. 
 
1.4.4. Effects of saturated free fatty acids on insulin sensitivity  
in skeletal muscle 
Increased circulating FFA levels have been shown to cause dose-dependent 
decreases in glucose uptake, a reduction in glycogen synthesis and a reduction in 
carbohydrate oxidation in muscle biopsies of healthy individuals [75]. In vitro cell 
culture studies have shown a consistent link between long chain saturated free fatty 
acids such as PA (16:0), stearate (18:0), arachidate (20:0) and lignocerate (24:0) and 
the onset of cellular insulin resistance in muscle cells such as mouse C2C12 
myotubes [41]. Shorter chain FFAs such as laurate (12:0) and myristate (14:0), as 
well as unsaturated fatty acids such as oleate (18:1) have not been shown to have 
this inhibitory effect on insulin signalling [41]. In vivo studies in mice using muscle-
specific over expression of lipoprotein lipase (LPL) have shown that by directly 
increasing lipid metabolites such as fatty acyl-CoAs and ceramides, muscle insulin 
signalling and action, as well as glucose tolerance was decreased [76]. 
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1.4.4.1.  Ceramide accumulation and the atypical protein 
kinase C-zeta (PKCζ) 
Isolated mouse soleus muscle cells incubated with the saturated fatty acid PA (1 
mM for 6 h) have increased intracellular levels of ceramide [77]. Ceramide, a key 
cellular metabolite of PA, plays a key role in the development of insulin resistance in 
skeletal muscle. PA is converted within cells to the intermediate palmitoyl-CoA. This 
intermediate is then utilised within the cell for the synthesis of ceramide and 
diacylglycerol. Ceramide is synthesised from the precursor molecule palmitoyl-CoA 
and serine, with the rate-limiting step to this reaction being the availability of these 
two molecules [61, 78]. 
 
Ceramide has been shown to down-regulate insulin signalling by inhibiting the 
kinase activity of the key insulin signalling intermediate AKT [61, 79, 80]. Ceramides 
localise within lipid rafts of plasma membranes, leading to phosphorylation of PKCζ 
at the plasma membrane. Increased activation of PKCζ leads to Ser34 
phosphorylation of AKT, inhibiting the kinase activity of AKT [81]. Inactivation of 
AKT decreases phosphorylation of glycogen synthase kinase 3 (GSK-3; leading to 
activation of GSK-3), which can then inhibit glycogen synthase activity, thus leading 
to an inhibition of glycogen synthesis from glucose. AKT inhibition also leads to a 
decrease in translocation of the insulin responsive glucose transporter GLUT4 to the 
cell membrane, due to reduction in downstream signalling of intermediates such as 
AKT substrate of 160 kd (AS160). As a result of inhibited AKT signalling, there is 
decreased glucose uptake and utilisation by the cell in response to insulin. Such 
effects upon insulin sensitivity have also been demonstrated in vivo. Diet-induced 
obese (DIO) mice exhibit a significant increase in their gastrocnemius ceramide 
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content. Upon treatment with myriocin, a specific inhibitor of de novo ceramide 
synthesis, the increase in gastrocnemius ceramide content was reversed (141.5 ± 
15.8 nmol/g dry weight in DIO controls vs. 94.6 ± 10.2 nmol/g dry weight in the 
myriocin treated DIO mice), which correlated with increased insulin sensitivity and 
glucose tolerance (R=0.61, p<0.05) as measured by GTT [82]. 
 
1.4.4.2.  Diacylglycerol (DAG) accumulation and Protein 
Kinase C activation 
DAGs have also been implicated in the development of insulin resistance in muscle 
cells. DAG has been shown in C2C12 myotubes to accumulate following 16 h 
incubation with saturated fatty acids such as PA (0.5 mM) [83]. DAG accumulation 
in C2C12 cells has been shown to inhibit upstream mediators of AKT signalling [41] 
through binding to the regulatory domain of novel PKC isoforms, thus activating 
their inhibitory signalling properties. Activation of PKCε by DAGs synthesised from 
PA leads to increased Ser/Thr phosphorylation of the insulin receptor (IR), 
decreasing its tyrosine kinase activity, and thus inducing insulin resistance by down 
regulating IR-downstream signalling (reviewed in [84]). Activation of PKCθ by DAG 
species also mediates the inhibitory effects of DAG accumulation, phosphorylating 
the insulin receptor substrate 1 (IRS-1) and decreasing downstream signalling in 
C2C12 myotubes [85]. In addition, activated PKCθ has also been implicated in the 
induction of NF-kB signalling [86], leading to pro-inflammatory cytokine production 
– another mediator of insulin resistance in muscle, adipose and the liver.  
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1.4.4.3.  Reactive oxygen species (ROS) accumulation and c-
Jun NH2-terminal kinase (JNK) activation 
FFAs also inhibit insulin signalling in skeletal muscle by generation of reactive 
oxygen species (ROS). Oxidation of PA in isolated primary rat skeletal muscle cells 
has been shown to increase production of the radical superoxide, through β-
oxidation in the electron transport chain, and also through the effects of NADPH 
oxidase [87, 88]. ROS can activate the stress kinase (JNK), which phosphorylates IRS-
1 on Ser307, inhibiting its association with IR and increasing IRS-1 protein 
degradation [89], thus impairing downstream signal transduction. 
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1.4.5. Effects of free fatty acids on insulin sensitivity in the liver  
 
FIGURE 1.4: Interplay between hepatic fatty acid utilisation and glucose 
production. 
Intracellular fatty acids are oxidised for energy, resulting in acetyl-CoA production. 
Acetyl-CoA feeds into production of ketone bodies (energy source) or via the citric 
acid cycle into hepatic glucose production. Figure adapted from [74]. 
 
In normal metabolic states, lipid availability in the liver provides an energy source 
directly to hepatocytes, as well as systemically via production of ketone bodies and 
glucose production (Fig. 1.4). When lipid-oversupply arises, these metabolic states 
are dysregulated, resulting in the induction of hepatic insulin resistance and 
increased glucose production, a key feature of T2D. 
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The general effects of saturated fatty acid oversupply on hepatic insulin sensitivity 
have previously been shown. PA-treatment (0.25 mM, 12 h) of FAO hepatoma cells 
decreased insulin-stimulated IR and IRS-2 tyrosine phosphorylation, reduced 
phosphatidylinositol 3-kinase (PI3K) activity and a reduction in AKT Ser473 
phosphorylation [90]. As the primary site of gluconeogenesis within the body, the 
onset of insulin resistance in the liver leads to increased levels of hepatic glucose 
production [91]. The liver is therefore a primary target in the development of new 
therapies against insulin resistance and T2D. 
 
1.4.5.1.  DAG accumulation and Protein Kinase C-epsilon 
(PKCε) 
DAGs and associated PKCε activation play a key role in regulating insulin sensitivity 
in the liver (reviewed in [92]). When incubated with recombinant active IR protein, 
recombinant active PKCε dose-dependently inhibited IR kinase activity [93]. 
Treatment with antisense oligonucleotides towards PKCε in rats decreased hepatic 
PKCε gene expression and protein levels, and lowered fasting plasma insulin while 
maintaining fasting plasma glucose levels [93]. Treatment with PKCε antisense 
oligonucleotide in 3 day high-fat fed rats restored impaired IR kinase activity [93]. 
Compared with wild-type littermates, PKCε-/- mice did not develop glucose 
intolerance following 1 week of high-fat feeding, and furthermore showed 
increased hepatic lipid accumulation [94]. Increased accumulation of DAGs, 
triacylglycerols (TAGs) and cholesterol in high-fat fed PKCε-/- mice compared with 
high-fat fed wild-type littermates was associated with increased fatty acid 
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esterification and altered protein levels for regulators of lipid metabolism including 
carboxylesterase ML1 and acyl carrier protein, in parallel with decreased energy 
expenditure [94]. This suggests that in the face of short-term lipid overload, PKCε 
deletion redirects fatty acids away from beta-oxidation towards esterification, 
which in primary hepatocytes from PKCε-/- mice resulted in decreased production of 
ROS [94]. These findings implicate PKCε in the induction of lipid-induced hepatic 
insulin resistance, and suggest a role for the modulation of hepatic fatty acid 
metabolism in restoring hepatic glucose metabolism. 
 
1.4.5.2.   Hepatic ceramide accumulation 
Ceramide accumulation has been associated with the development of hepatic 
insulin resistance, however the evidence supporting this link is controversial. 
Inhibition of ceramide synthesis via myriocin in DIO mice has been shown to 
increase basal and insulin-stimulated AKT phosphorylation in the liver, as well as 
skeletal muscle [95]. It is not clear however whether these effects are due to the 
prevention of ceramide accumulation in the liver or systemic effects resulting from 
increased insulin sensitivity in the muscle. While there have been reports of hepatic 
accumulation of ceramide in obese, insulin-resistant Zucker rats [96], there is some 
confusion in the literature about the role of ceramide in hepatic insulin resistance. It 
has been reported that hepatic insulin resistance can occur independently of 
ceramide accumulation [97], while other groups have reported hepatic ceramide 
accumulation without development of insulin resistance (assessed by 
hyperinsulinemic-euglycaemic clamp) in liver-specific acylCoA:diacylglycerol 
acyltrransferase 2 (DGAT2) overexpression in mice [98], although this latter finding 
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has been refuted by other groups showing hepatic DGAT2 overexpression in mice 
lead to both hepatic steatosis and insulin resistance [99]. It can be concluded from 
published studies to date that accumulation of total ceramide may not be necessary 
for the development of hepatic insulin resistance in vivo. It has recently been 
reported that the liver has the ability to rapidly excrete newly synthesised ceramide 
[100], which may explain the contradictory reports of hepatic ceramide 
accumulation across different models of hepatic insulin resistance. 
 
1.4.5.3.   Reactive oxygen species (ROS) accumulation and 
JNK activation 
ROS released by the mitochondria in response to PA β-oxidation also plays a role in 
the development of insulin resistance in the liver [88]. PA is rapidly routed via 
carnitine parmitoyltransferase-1 (CPT-1) through β-oxidation in the mitochondria, 
increasing production of ROS [90, 101]. Inhibiting β-oxidation in FAO hepatoma cells 
with etomoxir (100 μM, a competitive CPT-1 inhibitor) restored PA-induced (0.25 
mM) IR tyrosine phosphorylation defects [90], and in H4IIEC3 hepatoma cells 
reduced PA-induced (0.25 mM, 8 h) ROS production by 80% [101]. PA-induced ROS 
production in H4IIEC3 cells was observed in parallel with 2.5-fold activation of JNK 
(Thr183/Tyr185) phosphorylation [101]. Activation of JNK leads to serine 
phosphorylation of both IRS-1 and IRS-2 [102, 103], down-regulating signalling as 
described for JNK activation in skeletal muscle above. Hepatic overexpression of 
dominant-negative JNK in obese diabetic mice decreased fasting plasma glucose 
levels and decreased hepatic glucose production, while overexpression of wild-type 
JNK in normal mice elevated fasting plasma insulin and increased hepatic glucose 
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production [104]. Therefore, enhanced activation of JNK can induce decreased 
hepatic insulin action and increased hepatic glucose production both in vitro and in 
vivo. 
 
1.4.5.4.   Induction of the pro-inflammatory NF-kB pathway 
Lipid-induced activation of the pro-inflammatory NF-kB pathway has been observed 
in vivo in rodent models using lipid-heparin intraperitoneal injection [105]. While 
the induction of the NF-kB signalling pathway in hepatic lipid-induced insulin 
resistance has been consistently observed, the exact mechanism by which this 
occurs is not clear [105]. Transgenic mice lacking hepatic IKK-β retain hepatic insulin 
sensitivity, despite developing insulin resistance in muscle and fat tissues, 
suggesting that activation of the NF-kB pathway is dependent upon activation of 
IKK-β [106]. Induction of IKK-β activity leads to a ubiquitin-mediated degradation of 
the NF-kB suppressor IkB-α [107]. NF-kB is then free to translocate to the nucleus, 
where transcription of multiple inflammatory cytokines is induced including TNF-α 
and IL-6 [105], which are both established mediators of insulin resistance in adipose 
[108], muscle [109] and liver tissue [110].  
 
1.4.6.  Insulin independent effects on basal glucose production 
In addition to the inhibitory effects on hepatic insulin sensitivity, elevated lipids can 
also increase glucose production in vivo independent of insulin sensitivity [111]. 
One of the main effectors of the lipid-induced driven increase in glucose production 
is increased formation of acetyl-CoA, which along with increasing substrate 
availability for hepatic glucose production (Fig. 1.4) also acts as an allosteric 
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activator of pyruvate carboxylase (enzyme described below). The allosteric 
activation of pyruvate carboxylase by acetyl-CoA has been extensively studied 
(reviewed in [112]), and increased hepatic acetyl-CoA levels have been implicated in 
raising basal glucose production in exercise-induced states since the early 1980s 
[113].  
 
1.4.6.1.  Acetyl-CoA and pyruvate carboxylase 
Pyruvate carboxylase is a tetrameric enzyme which catalyses the initial reaction in 
the gluconeogenesis pathway, regulating the synthesis of oxaloacetate from 
pyruvate and HCO3- (reviewed in [114]). Acetyl-CoA, and to a lesser extent fatty 
acyl-CoAs, bind to and stabilise the tetrameric structure of pyruvate carboxylase. In 
addition to preventing dissociation of the tetramer [115], acetyl-CoA binding also 
enhances the coupling of the cleavage of ATP (in the first phase of the synthesis 
reaction) with pyruvate carboxylation (in the second phase of the synthesis 
reaction), thereby making the reaction more efficient [116]. Increased flux through 
pyruvate carboxylase therefore promotes downstream production of glucose in the 
liver. 
 
1.4.6.2.  p38 MAP-kinase activation by fatty acids 
Protein levels of p38 mitogen-activated protein kinase (MAPK) are elevated in the 
livers of db/db mice [88]. In primary mice hepatocytes, p38 MAPK is phosphorylated 
(Thr180/Tyr182) by a 20 min treatment with PA (0.1 – 1.5 mM), linoleate (0.1 – 1.5 
mM), oleate (0.5 – 1.5 mM) or capric acid (1 – 1.5 mM) [117]. Oleate-treatment (0.5 
mM) for 4 h in primary mice hepatocytes increased glucose production, which was 
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reversed by co-treatment with 5μM of the p38 MAPK inhibitor SB203580 [117]. The 
oleate-stimulated increase to glucose production and p38 MAPK occured in parallel 
with increased gene expression levels of phosphoenolpyruvate carboxykinase 
(PEPCK, the rate limiting enzyme in the glucose production pathway). The oleate-
induced increase to PEPCK gene expression levels was also inhibited by the p38 
MAPK inhibitor SB203580 [117]. The translation of PEPCK by p38 MAPK is 
dependent upon the transcriptional co-activator peroxisome proliferator-activated 
receptor gamma co-activator 1-alpha (PGC1α) [117], which along with FOXO1 
regulates PEPCK gene expression levels [118, 119]. 
 
1.4.7. Lack of effect of free fatty acids on insulin sensitivity in  
adipose tissue 
Incubation of 3T3-L1 adipocytes with 0.75 mM PA for 16 h did not lead to increased 
intracellular DAG or ceramide levels, nor an inhibition of AKT (Ser473) 
phosphorylation or glycogen synthesis [41]. Unlike skeletal muscle or liver cells 
[120], adipose tissue stores fatty acids mainly as triglycerides [121]. The ability of 
adipose tissue to preferentially convert fatty acyl-CoAs into triglycerides thus 
prevents the conversion of fatty acids into harmful metabolites such as DAG and 
ceramide [41], therefore protecting adipose tissue from fatty acid induced insulin 
resistance. 
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1.5. Previous approaches for characterising insulin 
resistance 
 
1.5.1. Classical single target-based approaches 
Classical approaches for dissecting insulin resistance involved targeting signalling 
defects in both in vitro and in vivo models of insulin resistance. These approaches – 
utilising western blotting for proteins and PCR for gene expression data – have 
enhanced our knowledge of insulin resistance and the mechanisms by which insulin 
signalling is impaired. However such approaches rely upon previous knowledge to 
build a network of signalling connections, and implicating signalling defects in the 
observed in vitro or in vivo model. As is becoming increasingly clear, signalling 
networks within cells are far more complicated than previously thought. Single 
insults (such as fatty acids) not only impact upon insulin signalling directly, but also 
on numerous signalling cascades such as inflammatory pathways, which may be 
either distally related to insulin signalling or not related at all. This will result in 
activation of many kinases, and modification of transcription of a number of genes, 
in the process of the cell reaching an equilibrium state. 
 
We now know that the single target or pathway approaches provide too narrow a 
window to appreciate the changes induced in complex disease states. While the 
contribution of the single target / pathway approaches cannot be denied, in terms 
of expanding our knowledge base, a wider approach is now required for the 
development of the next line of therapies. 
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1.5.2. Endpoint-based approaches 
Endpoint-based approaches have been significant in furthering our understanding 
of the development of diabetes. Utilising insulin signalling endpoints such as hepatic 
glucose production or muscle glucose transport can provide a more global overview 
of the cellular state compared with the phosphorylation of a single kinase amongst 
a signalling network. The discovery of new therapies targeted against endpoints 
allows us to bypass the upstream complexity that hinders the target-based 
approaches.  
 
1.5.3. ‘Omics’ approaches 
The development of powerful platform technologies such as microarrays has led to 
a vast increase in the utilisation of the ‘omics’ studies. Current mass spectroscopy 
techniques allow for the study of nearly the entire lipid or specific protein fractions 
within a sample, allowing characterisation of disease states in an unprecedented 
way. The requirement to investigate and treat many diseases with multifactorial 
natures has necessitated the need for more powerful, unbiased technologies to give 
researchers a “global” view of disease states. The search for effective early 
diagnostic tools, insight into the development of disease states, and the 
development of new therapies are increasingly relying on one or more of these new 
platform approaches. 
 
In the context of obesity, lipidomic approaches are proving to be very useful in 
identifying characteristic changes in tissue-specific lipid profiles of patients with T2D 
[122], which has been made possible by advances in mass spectroscopy techniques. 
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Advances have also been applied to the proteomic field. Techniques such as Stable 
Isotope Labelling by Amino acids in Cell culture (SILAC) are proving to be powerful in 
furthering our knowledge of insulin signalling cascades in both normal and insulin 
resistant states, by allowing the investigation of a large number of proteins at once 
across multiple samples [123]. 
 
1.5.4. Genomics-based approaches 
Developed in the mid 90’s for the analysis of the expression of multiple genes in 
parallel [124], microarray technology can now be used to assess the expression of 
tens of thousands of genes in a sample simultaneously. This provides a powerful 
tool to assess whole cell transcriptional events for any given cell or tissue in any 
biological state. Microarray technology has a range of applications including 
identifying disease-causing genes, identifying targets for new therapies and 
prediction of drug responsiveness [125]. 
 
Two major applications for microarray technology involve: 1) examining gene sets 
for pathway analysis, and 2) examining differentially expressed genes between two 
or more experimental conditions [126]. Gene set enrichment analysis (GSEA) 
involves analysis of a gene list, ranked according to the difference in expression 
between the phenotypes or treatments being investigated. The goal of GSEA is to 
determine whether members of specific gene sets (grouped on functional 
similarity), are ranked together towards the top or bottom of the list. GSEA 
therefore indicates whether a correlation exists between differential expression of 
that set of genes, and the specific phenotype being investigated [127, 128]. This 
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pathway analysis approach to dissecting disease is complimented well by proteomic 
approaches that can similarly be used for pathway analysis. 
 
The second of the two applications involves performing microarray analysis on gene 
sets from multiple experimental conditions, and can be used to identify 
differentially expressed genes in differing disease states. This ‘shotgun’ style 
approach to genome analysis can yield previously unknown information about the 
regulation of disease states at the transcriptional level, which can have important 
implications for understanding the pathophysiology of disease. The set of 
differentially expressed genes can also be used for a diagnostic approach to the 
disease. Applying Bayesian Linear statistical modelling to gene sets allows for 
selection of a relatively small gene set which can characterise the particular 
biological state of the cell or tissue being investigated [129]. This process 
statistically evaluates which set of genes have the greatest differential expression 
between the conditions tested, and identifies a ‘fingerprint’ indicative of the 
biological state of the cell or tissue involved, known as a gene expression signature 
(GES). Previously, GESs have been applied to the field of cancer research, for 
applications such as classifying tumour types and predicting tumour response to 
chemotherapy. By classifying tumours into distinct types, and with knowledge of 
how each type will respond to particular therapies, clinicians are therefore able to 
treat patients more effectively by personalising treatment regimens [130]. 
Personalised medicine approaches such as this are becoming increasingly important 
tools in fighting diseases and the use of GESs is likewise increasing in disease 
research. 
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1.6. Gene Expression Signatures 
 
1.6.1. Gene expression signatures as a diagnostic tool 
First described in 2000, GESs were developed in the field of cancer research. The 
differences in patient response to therapies led researchers to believe that groups 
of cancers that could not be histologically characterised were actually a 
heterogeneous group of tumours. Seeking a non-biased method for classification, 
gene expression data was investigated to search for patterns that could 
differentiate classes of B-cell lymphomas with differing patient survival rates [131]. 
The main outcome of the study was the finding of two subgroups, classified on the 
basis of differential gene expression of hundreds of genes, with differing survival 
outcomes for patients. This early study was instrumental in highlighting the use of 
gene expression data as a disease classification tool. The power of the GES 
approach is that entire genome datasets are narrowed down to the smallest 
number of genes capable of robustly characterising differences between biological 
samples. Using complex statistical analysis of large datasets, the prediction power 
of these small subsets of genes has been shown to approach equivalence to the 
whole dataset [132]. Once developed, the GES tool allows for rapid, reliable 
characterisation of various cellular states, which has a number of important 
applications. 
 
Accurate classification of disease states plays a vital role in diagnosis and treatment. 
GESs have been successfully used in a number of different cancer types including 
breast [133, 134], gastric [135], lung, colon and ovarian cancer [136] to aid in 
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prediction of survival, and to guide clinicians in choice of treatments for their 
patients. Recently, GESs have even been applied to predicting the likelihood of side 
effects in patients treated by acute radiotherapy [137]. 
 
Using GES technology for prediction and/or classification however represents only 
part of the potential of such an approach. The use of GESs for the discovery and 
development of new therapies is perhaps the most promising application of this 
technology. The use of GESs to discover new therapies is especially powerful as it 
can be applied whenever a specific disease endpoint (such as insulin resistance) is 
known, even if intermediate signalling steps or the molecular targets responsible for 
the disease state have not yet been identified. Provided a model for the disease of 
interest can been developed, high throughput screening of small molecule libraries 
can be performed by assessing the effects of those agents on the mRNA levels of 
the genes identified as the GES. The GES approach has been used in a number of 
cancer models to identify new therapies, which have increased efficacy over current 
treatments. For acute myelogenous leukaemia, the identification of inducers of 
terminal differentiation has opened up new therapeutic avenues previously 
unavailable [138]. For the treatment of Ewing sarcomas, the targeting of the 
EWS/FLI oncoprotein had previously been unsuccessful with screening approaches, 
until the GES approach was used successfully to identify cytosine arabinoside as a 
modulator of the EWS/FLI oncoprotein [139].  
 
What makes GESs unique is that the GES genes are not limited to genes known to 
be involved in the particular physiological process being investigated. A GES is the 
minimal set of genes that best defines the difference between two biological 
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samples – be that a disease state or the physiological response to a particular drug 
or chemical. While it is possible that an individual GES gene may play a role in the 
specific model being investigated (see section 7.4. below: the protective 
inflammatory response gene STEAP4 [140] was identified in the TNFα-based GES 
previously developed by our laboratory [141]), the unbiased nature of gene 
selection does not necessitate such a relationship, and therefore the role of any GES 
genes in contributing to the model phenotype must be confirmed with subsequent 
studies. 
 
1.7. Overview of GES Development  
 
FIGURE 1.5: Development procedure for a GES for insulin resistance. 
mRNA is extracted from in vitro cell culture models of insulin resistance, and 
analysed using whole genome microarrays. The GES genes are identified, and 
validated in human tissues. The validated GES can then be used to identify novel 
treatments, as well as stratify patients. This allows for the personalised treatment 
of T2D. Based upon [138]. 
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We propose that GESs can be applied to dissect and study insulin resistance 
subtypes. The GES methodology described here can be undertaken in either animal 
tissues or cell culture models. Due to the high reproducibility required when 
extracting the data from global platforms such as microarray technology, we have 
found that working in cell culture systems is the most robust and consistent 
approach. The modelling of insulin resistance subtypes in the GES models involves 
the use of a specific insults associated with the induction of insulin resistance in 
individuals, including saturated fatty acids (PA) or mediators of chronic 
inflammation (TNFα). 
 
The development of a GES in cell culture requires modelling three distinct cellular 
states relating to insulin sensitivity. The first state is that of a ‘healthy’, insulin 
sensitive cell. The second state is that of a ‘diseased’, insulin resistant cell. This is 
achieved by treatment of the target cells with the insulin resistance insult such as 
TNFα or PA. The third state represents a ‘recovered from disease’ state, which is 
achieved by treating insulin resistant cells with a cocktail of anti-diabetic agents to 
restore insulin action (Fig. 1.6). The definition of these three states is deliberate and 
critical to the integrity of the GES. Insulin resistance in this model system is 
measured using a key endpoint of insulin action, such as glucose uptake in muscle 
or adipose tissue, or glucose production in the liver, and will be discussed in further 
detail below. 
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FIGURE 1.6: Distinct cellular states required for development of a GES for 
insulin resistant subtypes. 
The development of a GES for PA-induced insulin resistance requires modelling of 
three cellular states: “healthy”, “diseased” and “recovered from disease” states – 
which model the transcriptional responses to the development and recovery from 
lipid-induced insulin resistance in the liver of a patient with T2D.  
 
1.7.1. Characterising insulin resistance in vitro 
In order to effectively model insulin resistance in vitro, an endpoint measure of 
insulin action is required. Cell-based models offer a number of assays that can be 
used to determine insulin signalling in both sensitive and insulin resistant states. In 
vitro models of insulin resistance can be developed in each of the main insulin 
sensitive tissues; muscle, adipose and liver. One key measure of insulin action in 
muscle and adipose cells is glucose uptake. In liver cells, regulation of 
gluconeogenesis by insulin is one of the key endpoints of insulin action. These 
assays work by measuring the relevant endpoint (glucose uptake or 
gluconeogenesis) in the presence and absence of an insult to characterise the level 
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of insulin sensitivity. As the in vitro cell culture model must be manipulated from 
healthy to diseased and then restored, a robust and large dynamic range is needed 
in the bioassay used to measure the insulin resistance endpoint parameter. 
 
Reversal of insulin resistance involves assessing a wide range of known insulin 
sensitisers in the model of choice. A combination therapy that is able to fully 
reverse insulin resistance is selected, based upon its ability to not only reverse 
insulin resistance, but also avoid negatively impacting upon cellular viability. 
Combination therapy is required, as this will ensure that the GES is characteristic of 
an overall insulin resistant state that has been reversed by a multi-target approach. 
There is a greater chance that in drug development the GES will identify novel 
therapies, rather than the individual therapies used in its creation – as may happen 
with a single treatment GES. Potential reversers of insulin resistance include known 
anti-diabetic drugs such as the biguanide metformin [142], TZDs such as 
rosiglitazone [143], chemical chaperones such as tauroursodeoxycholic acid 
(TUDCA) [144], antioxidants such as N-acetylcysteine (NAC) [145], and non-steroidal 
anti-inflammatory drugs (NSAIDs) such as aspirin [42, 146].  
 
1.7.2. Identification of putative GES genes 
To apply the GES approach to insulin resistance, firstly we will assess the significant 
changes in gene expression levels between the ‘healthy’ insulin-responsive cells, 
and the ‘insulin resistant’ cells to identify the genes that change in response to the 
insulin resistance-inducing insult. In order to determine which genes are being 
affected due to insulin resistance and not non-specific changes induced by the insult 
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per se, the changes induced by the ‘recovered from disease’ state will be assessed. 
Only those genes whose expression levels were significantly changed in the 
‘diseased’ state, and then changed again in the reverse direction in the ‘recovered 
from disease’ state are used for the development of the GES. It is this group of 
genes whose expression are linked to the insulin resistant state of the cell or tissue. 
 
The identification of candidate genes for GES development has been previously 
achieved using two complementary methods: (i) Diagonal Linear Discriminate 
Analysis (DLDA) coupled with signal-to-noise ratio statistic [138, 141], and (ii) 
Bayesian statistical modelling [141, 147]. Both approaches have been previously 
used to identify candidate GES genes for a TNFα-based insulin resistance GES [141]. 
The main advantage of the Bayesian modelling approach is the ability to calculate 
the β-correlation coefficient for each GES gene, which accounts for the relative 
contribution of each gene to the predictive power of the GES as a whole, as well as 
the variance of each GES gene, which allows for the predictive power of the whole 
GES to be calculated. The Bayesian approach is highly complex and requires 
powerful computing resources, and it has been previously found that the genes 
identified via DLDA have also been identified via the Bayesian approach – validating 
the use of the less complex DLDA approach as an early identifier of candidate GES 
genes [141]. 
 
Once the GES is developed from a cell culture model, the biological relevance of an 
in vitro-derived GES requires validation in human tissue. Validation of the GES in 
human cohorts tests for a correlation between phenotypes characteristic of the 
metabolic syndrome, and similarity to the GES profile for each subject. If it can be 
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shown that the patients with expression profiles most similar to the GES showed a 
greater degree of insulin resistance (such as indicated by HOMA-IR score), the GES 
is considered to be a valid discriminator of insulin resistance in human patients.  
 
1.7.3. Applications of GES in the development of personalised 
treatment for individuals with T2D 
 
1.7.3.1. Using GES to stratify patients with T2D 
The GES holds promise for personalised treatments for patients by allowing the 
stratification of patients based on subgroups of insulin resistance. Once patients are 
sub-grouped, treatments can be personalised to their individual diagnosis, leading 
to improved health outcomes. The sub-grouping of patients according to the GES 
involves measuring the expression levels of the GES genes in the patient. Regardless 
of which tissue or cell type the GES is derived from, a non-invasive, easy to obtain 
sample is needed to facilitate screening of as many individuals as possible. A blood 
sample is ideal for these requirements. Lymphocyte gene expression profiles have 
been shown to correlate well with gene expression profiles of insulin responsive 
tissues including liver and adipose tissue [148]. We propose that by measuring the 
expression levels of the GES genes in patients’ white blood cells, we can subtype 
patients according to one or more GES. The GES(s) which best correlates with the 
gene expression pattern of a patient’s white blood cells will therefore indicate a 
specific avenue of treatment(s) for that patient (see Fig. 1.7).  
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FIGURE 1.7: Stratification of patients according to their similarities to the 
GES models of insulin resistance 
Patients with insulin resistance will have their lymphocyte expression of the 
relevant GES genes compared to the relevant GES models. Patients will be stratified 
according to the most similar GES model, indicating a relevant therapeutic avenue 
for each patient. 
 
1.7.3.2. Using the GES to develop “targeted” therapies 
The GES can be used to aid in the development of new therapies for T2D, by 
allowing for high throughput screening for new drugs with insulin sensitising and 
anti-diabetic properties. Screening of chemical libraries can be rapidly performed in 
96 well-plates, alongside control wells containing the three distinct cellular 
treatments from which the GES was developed (“healthy”, “diseased” and 
“recovered from disease”, see Fig. 1.6). After measuring the mRNA levels of the GES 
genes in the treated cells, this has been previously achieved using a custom 
Insulin resistant patients 
Compare patient’s lymphocyte gene 
expression levels against GES models 
Stratify patients on a continuum 
according to their similarity to one of the GES 
models → appropriate treatment regime 
Highest similarity group → Lowest similarity 
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algorithm to transform the relative gene expression levels for each GES gene into a 
single “GES score”. Firstly, the expression for each gene was expressed relative to 
the total summed gene expression for the group of GES genes, then standardised (z 
score) to compare across all genes and samples. The β-correlation coefficient for 
each GES gene was then multiplied against the standardised gene expression levels 
and summed to form the “GES score” [141]. The chemicals with a positive “GES 
score” mimic the GES profile of successful reversal of insulin resistance, while those 
with a negative “GES score” mimic the GES profile of induced insulin resistance. The 
drugs with a positive “GES score” were then validated both in vitro and in vivo to 
assess their anti-diabetic and/or insulin sensitising properties [141, 149]. We 
propose that new therapies identified via this approach may show increased 
efficacy in treating patients subtyped by the same GES. The subtyping of patients 
according to GES, as well as the potential for targeted therapies against each 
subtype, represents a personalised medicine approach for the treatment of insulin 
resistance and T2D. 
 
1.7.4. Proof of principle: Inflammation-induced cellular “insulin 
resistance” 
As proof of principle, a GES for TNFα-induced insulin resistance was recently 
developed [141]. Using 3T3-L1 adipocytes as the cell-based model, 3325 genes were 
identified whose expression was altered by the induction of insulin resistance 
(measured as impaired insulin-stimulated 2-deoxyglucose uptake) by TNFα. Of 
those genes, only 1022 showed altered expression by the reversal of insulin 
resistance with a combination treatment of aspirin and troglitazone. From those 
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1022 genes, a set of 5 genes were selected whose combined expression profile gave 
the highest predictive power to differentiate the insulin resistant state from the re-
sensitised state. 
 
As described above, GESs may be used for screening of patients with T2D. The in 
vitro-derived GES for TNFα was assessed for its ability to characterise insulin 
resistant subtypes in a human cohort. This analysis utilised lymphocytes expression 
data from the San Antonio Family Heart Study [150], and measured the expression 
of 47,289 transcripts in 1,240 individuals from 42 extended families [151]. The TNFα 
GES of 5 genes was detected in the human profile dataset, and GES score assigned – 
comprising the sum of the absolute values of the standardised expression units of 
each of the 5 genes. This was tested for association with every phenotypic measure 
available for each subject. Those patients whose expression profiles were most 
similar to the TNFα GES showed a higher degree of insulin resistance as indicated by 
the HOMA-IR score (P<0.001) [141]. This correlation is consistent with the use of 
GES technology to characterise an insulin resistant subtype in this population. 
 
In vitro screening of compound libraries has also been used in this model, assessing 
the ability of a given compound to affect the genes identified in the GES. Screening 
for those compounds whose effects on the target genes mirrored the expression 
profile observed in the “recovered from disease” GES was successful in identifying 
known insulin sensitising agents such as non-steroidal anti-inflammatory agents, β-
adrenergic antagonists, beta-lactams and sodium channel blockers [141]. In 
addition, a number of chemical families without previously known insulin-
sensitising actions were identified including β-lactams, sulfamide antifolates and 
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carbonic anhydrase inhibitors [141]. The carbonic anhydrase inhibitor 
methazolamide was identified in the original GES screen, and has since been 
characterised as a novel insulin sensitiser [149]. In DIO mice, methazolamide 
treatment lowered both plasma glucose and insulin during a GTT. In obese diabetic 
db/db mice, methazolamide lowered fasting blood glucose and HbA1c, and 
suppressed hepatic glucose production, and furthermore, enhanced the in vivo 
effects of metformin [149].  
 
Investigation of the GES genes and their role in insulin resistance has also yielded 
positive outcomes. We conducted a series of studies to assess what role (if any) the 
GES genes might play in the development of insulin resistance. Our investigation of 
the GES gene STEAP4 was mirrored by the results of data published at that time 
which showed that STEAP4 protects against inflammation and metabolic 
dysfunction [140]. This highlighted the utility of the GES in gene discovery related to 
the particular biological state being investigated, and was further proof of the 
power of this technique in investigating disease states. 
 
1.7.5. Identification of PA-derived GES from liver cells 
The PA-derived GES once identified can be used for the stratification of patient 
cohorts as described above. We propose that a PA-derived GES could identify an 
insulin resistant subpopulation from such a cohort. A key comparison with the 
different GES models will be the identity of the subgroups identified, and the 
degree of overlap (if any) observed in the groups. Drug screening, as well as 
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investigation of the GES genes will also be performed following development of a 
PA-derived GES.  
 
1.8. Summary 
The use of ‘omics’ style approaches to multifactorial disease states such as T2D are 
becoming increasingly accepted as one way research should investigate these 
diseases in the 21st century. The success of GES technology in the cancer field as 
both a diagnostic tool and a drug discovery tool is becoming increasingly apparent, 
and we have shown this technology is equally applicable to the study of T2D. As 
disease research is progressing towards the development of personalised medicine 
as the ‘holy grail’ for treatment regimes, we foresee a future where personalised 
medicine is seen as the gold standard for patient care. We believe GES technology 
will provide a platform for the development of novel, personalised treatments for 
patients with T2D. Further, the data collected via microarray analysis has additional 
utility via GSEA. By combining this approach with the model development described 
above, we can investigate regulated pathways at the transcriptional level in both 
the induction and reversal of lipid-induced dysregulated glucose production – such 
analysis has rarely been performed before, and has the potential for enhancing our 
understanding of the processes involved in the restoration of glucose homeostasis – 
which may be distinct from the processes involved in the induction of such a state. 
Such findings have significant implications on the methods used to identify novel 
targets for drug development.  
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1.9. Aims 
The overall aim of this project was to interrogate lipid-induced insulin resistance in 
a hepatic in vitro cell culture system via a global unbiased approach. The specific 
aims of this study were as follows: 
(i) To generate a model of PA-induced, and drug restored, insulin resistance in 
the liver using the rat-derived FAO hepatoma cell line, 
(ii) To generate a microarray-based expression profile of the model, 
(iii) To utilise DLDA to identify candidate genes for creation of a PA-based GES, 
(iv) To confirm the expression levels of the candidate genes using RT-PCR and in 
turn, in human lymphocyte tissue to determine whether the PA-based GES 
characterises individuals with markers of the metabolic syndrome, 
(v) To interrogate the gene expression profiles for regulated pathways, 
(vi) To generate a comprehensive mass-spectroscopy based lipid profile in order 
to characterise the effects of PA-induced, and drug restored, insulin resistance on 
lipid metabolism, 
(vii) To confirm the metabolic regulation observed in pathway analysis by 
measuring the effects of PA-induced, and drug restored, insulin resistance on 
cholesterol and bile acid levels. 
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Chapter 2 – In vitro model development of 
hyperlipidemia-induced dysregulation of glucose 
homeostasis 
 
2.1. Introduction 
 
2.1.1. Modelling dysregulated glucose homeostasis 
Induction of free fatty acid-induced insulin resistance in vitro has been commonly 
achieved using the saturated fatty acid PA [41, 152, 153]. Cellular insulin resistance 
can be defined as a reduction in the normal effects of insulin on any one or more of 
a range of cellular metabolic processes. The induction of PA-induced insulin 
resistance in muscle cells has highlighted the role of ceramides [152], DAGs [41] and 
PKC isoforms (such as PKCε) [154]. The induction of PA-induced insulin resistance in 
the liver has not been investigated to the same degree, however PKC activation 
(specifically PKCε) has been implicated in hepatic insulin resistance in in vivo 
modelling using PKCε-/- mice [94].  
Despite the success such approaches have had, a limitation in some early modelling 
attempts was the inference that measurement of decreased Ser473 
phosphorylation of Akt was sufficient to identify insulin resistance. It has since 
become clear that reduced phosphorylation of a single site on a single signalling 
intermediate such as Akt is insufficient to account for all of the observed 
intermediary and endpoint defects in insulin action in individuals with T2D [155]. 
The approach taken in this study was therefore to treat liver cells in vitro with PA to 
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induce insulin resistance, as determined by a key endpoint of insulin signalling – 
hepatic glucose production. This modelling approach allows for the in vitro 
measurement of defects in the same metabolic pathways that occur in individuals 
with T2D, and the reversal of which is required to successfully treat the human 
condition. 
 
2.1.2. Reversing dysregulated glucose homeostasis 
While there have been a number of studies investigating the mechanisms by which 
individual compounds are able to reverse insulin resistance, these changes are 
specific to the compound used, and as such it is hard to separate the direct effects 
of the compound on insulin action versus non-specific effects. Using a combination 
of multiple compounds, followed by a non-biased whole genome microarray 
approach, allows for the investigation of the global cellular responses to the 
reversal of lipid-induced dysregulation of glucose homeostasis. This may yield new 
information as to the cellular responses for both the induction and reversal of 
impaired glucose production. 
We attempt to reverse PA-induced dysregulation of glucose homeostasis using 
known anti-diabetic agents from a number of distinct classes. The salicylate class – 
including acetylsalicylic acid (aspirin) and sodium salicylate – act via inhibition of 
Ikkβ [156] to restore insulin signalling in models of inflammation (TNFα) induced 
insulin reisistance in liver and adipose tissue [42]. Both asprin and sodium salicylate 
have been shown in vitro to prevent NF-kB induced transcription when used at 2 
mM and above [156], and are equipotent in their inhibition of Ikkβ [157]. Aspirin 
also possesses potent-acetylation mediated cyclooxygenase (COX) inhibitory 
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properties, being 100 times more potent towards COX enzyme inhibiton than 
sodium salicylate [158] which lacks the required acetyl group. The contribution of 
COX activity in the induction of insulin resistance however has been refuted. 
Specific inhibition of both COX1 and COX2 by ibuprofen and naproxen was shown to 
be ineffective in restoring TNFα impaired IRS-2 tyrosine phosphorylation in FAO 
hepatoma cells [42], indicating that it is primarily the inhibition of NF-kB signalling 
which mediates the effects of aspirin and sodium salicylate on restoring insulin 
sensitivity. 
Although widely used for lowering hepatic glucose production [159], the 
mechanism of action for the biguanides (including metformin, buformin and 
phenformin) is still debatable, despite metformin and phenformin being identified 
as anti-hyperglycaemic agents first in 1957 [160, 161], and buformin the following 
year in 1958 [162]. Metformin is proposed to activate AMPK by the eNOS-
stimulated generation of reactive nitrogen species [163], as well as posessing 
AMPK-independent mechanisms [164]. In rat H4IIE hepatoma cells, 0.1 – 2 mM 
metformin-treatment for 18 h increased activation of AMPK, observed as increased 
Thr172 phosphorylation [165]. Whether this AMPK activation occurs via 
mitochondrial complex 1 inhibition and subsequent ATP depletion is controversial 
[165], however this mechanism has been extensively studied. Phenformin is the 
most potent inducer of ATP depletion, with an IC50 of 13 μM, with buformin having 
an IC50 of 47 μM and metformin the least potent at 2 mM [166]. The same potency 
rankings have also been shown for intact cell respiration, dissipation of 
mitochondrial membrane potential and depletion of reduced glutathione and ROS 
production in primary human hepatocytes [166]. Interestingly, despite having an 
IC50 for ATP depletion 150-fold that of metformin, 5 mM phenformin increases 
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AMPK kinase activity 3-fold higher than 2 mM metformin in H441 lung epithelial 
cells during the first hour of treatment, and after 24 h treatment remains 2 fold 
higher [167]. Given the 150-fold difference in ATP depletion, yet modest difference 
in AMPK activation, the current study will provide evidence as to whether the 
difference in effect of the biguanides on decreasing glucose production in 
hepatocytes are due to AMPK dependent or independent mechanisms. 
 
The thiazolidinedione (TZD) class of insulin sensitisers (including rosiglitazone, 
pioglitazone and troglitazone) are PPARγ agonists which act mainly in the adipose 
tissue (due to high PPARγ expression), but also in the muscle and liver [168]. 
Although the three members of this class have potent insulin sensitising effects, the 
association of serious complications with TZD therapy has resulted in these drugs 
being withdrawn from sale in many markets [169]. In addition to their PPARγ 
stimulating activity, both rosiglitazone and pioglitazone have been shown (using 
protein from rat liver cell lysate) to have binding affinities for numerous proteins 
regulating mitochondrial function, gluconeogenesis/glycolysis and lipid metabolism, 
including pyruvate dehydrogenase, glucose-6-phosphate isomerase and acyl-CoA 
dehydrogenase [170]. Pre-incubation of rosiglitazone (at 10, 30 and 100 μM), 
troglitazone (at 100 μM) and pioglitazone (at 100 μM) for 10 min inhibited 
mitochondrial complex 1 activity in rat liver homogenates [171]. Inhibition of 
mitochondrial complex 1 and subsequent energy dysregulation has been proposed 
to be one of the mechanism by which TZDs increase insulin-sensitivity. In H-2Kb 
transgenic mice myotubes (a conditionally immortal cell line derived from 
transgenic mice harboring a thermolabile simivan virus large tumor antigen 
regulated by the mouse major histocompatibility complex H-2Kb promoter [172]), 
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30 min incubation with rosiglitazone has been shown to dose-dependently activate 
AMPK up to a maximum at 100 – 200 μM [173]. Rosiglitazone has recently been 
associated with increased risk of cardiovascular disease [25, 174], however it is 
unclear whether there is a difference between rosiglitazone and pioglitazone on 
cardiovascular disease [175]. Further, pioglitazone has been recently linked to a 
small but significant increase to the risk of bladder cancers in adults with T2D [24]. 
In addition to its PPARγ activation, troglitazone treatment (4 weeks at 400 mg/day) 
has been shown in obese and diabetic individuals to reduce NF-kB binding activity in 
nuclear extracts of monocytes, as well as decreasing plasma C-reactive protein (a 
general marker of inflammation) – indicating troglitazone possesses anti-
inflammatory properties  [176]. Troglitazone has been associated with cases of 
drug-induced liver toxicity and hepatitis [177], and as such it is unsuitable for the 
reversal of insulin resistance in a hepatocyte model as used in this study. Given the 
increased potency for mitochondrial complex 1 inhibition by rosiglitazone over both 
pioglitazone and troglitazone, and the potential for fewer adverse cellular effects 
associated with bladder cancer and liver toxicity, rosiglitazone was chosen for use in 
this study.  
 
The traditional Chinese medicinal herb Rhizoma coptidis has been used for the 
treatment of diabetes for more than 1000 years [178], however the identification of 
the active hypoglycaemic agent in these herbs – berberine – was not discovered  
until the 1980s [179]. The effects of berberine on stimulating glucose uptake into 
3T3-L1 adipocytes have been shown to be independent of insulin signalling and 
involve activation of AMPK [180]. In both insulin sensitive and insulin resistant (24 h 
treatment with 25 mM glucose and 100 nM insulin) L6 myotubes, post-treatment 
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with 14 μM berberine for 1 h has been shown to activate AMPK, and improved 
impaired insulin signalling by increasing GLUT4 translocation to the plasma 
membrane via increasing insulin-stimulated IRS-1 tyrosine phosphorylation, 
recruitment of the p85 subunit of PI3K to IRS-1, and increasing Akt Ser473 
phosphorylation [181]. Berberine pre-treatment for 30 min at 1 and 10 μM has 
been shown to reduce IL-6 and TNFα  production in HepG2 hepatoma cells 
following 0.5 mM PA-treatment for 24 h, leading to increased insulin-stimulated 
glycogen production [182]. 
 
The aim of this study was to develop an in vitro cellular model of hyperlipidemia-
induced insulin resistance, followed by the restoration of the impairment in insulin 
action by trialling known anti-diabetic and/or insulin sensitising agents. The reversal 
of the hyperlipidemia-induced impaired glucose metabolism was optimised to use 
two different classes of anti-diabetic and/or insulin sensitising agents. The use of 
two different classes is a deliberate feature of the model, so that the regulatory 
changes in gene expression and metabolism (as measured in Chapters 3-5) 
represent the reversal of lipid-induced dysregulated glucose metabolism, rather 
than the effects of one specific compound. The induction of cellular insulin 
resistance using the fatty acid PA was investigated in both muscle and liver cell 
lines. While the model was unsuccessfully developed in muscle cell lines (see 
Appendix 1), PA was successfully used for model development in rat FAO hepatoma 
cells, as outlined in this chapter.  
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2.2. Methods 
 
2.2.1. Cell culture 
FAO rat hepatoma cells (FAO cells, [183]) were cultured in Roswell Park Memorial 
Institute (RPMI) 1640 medium (GIBCO Invitrogen, Melbourne, VIC, Australia) 
supplemented with 10% (v/v) Foetal Bovine Serum (FBS, GIBCO Invitrogen) at 37oC 
and 5% CO2. Media was replenished every 24 h. FAO hepatoma cells were seeded in 
48 well plates at 100,000 cells per well and treatments commenced 24 h post-
seeding as previously described [149]. 
 
2.2.2. Cell treatments 
FAO hepatoma cells were treated with vehicle (RPMI 1640 medium, pH 7.4, 
0.0285% (v/v) EtOH, 25μM BSA), 0.075, 0.15 or 0.3 mM PA or linoleate (LA) (RPMI 
1640 medium, pH 7.4, 0.0285% (v/v) EtOH, 25μM BSA) for either 24 or 48 h. To 
induce reversal of the dysregulation of glucose production, a series of ‘reversal 
agents’ were added in the final 24 h of the 48 h PA treatment. The ‘reversal agents’ 
were aspirin (1 – 10 mM), sodium salicylate (1 – 10 mM), metformin (0.1 – 1 mM), 
phenformin (10 – 100 μM), buformin (30 – 300 μM), rosiglitazone (1 – 100 μM) and 
berberine (1 – 100 μM). Treatment protocol is outlined in Figure 2.1. All treatments 
in the first 24 h of the 48 h incubation were in normal growth media as described 
above. In the final 24 h of the 48 h incubation, all treatments were in Glucose 
Production (GP) media which contained glucose- and serum-free RPMI 1640 media 
supplemented with 2 mM sodium pyruvate (GIBCO Invitrogen), 20 mM sodium L-
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lactate (Sigma-Aldrich, NSW, Australia) and 0.1% (w/v) BSA (USB Corporation) with 
and without 0.1 nM insulin (Humulin R, Eli Lilly, NSW, Australia). 
 
2.2.3. Measurement of glucose production in FAO hepatoma cells  
Glucose content within the conditioned media was measured using a Glucose (GO) 
assay kit (Sigma), as per manufacturer’s recommendations. Briefly, each sample was 
diluted 1:2 in dH2O, then 40 μL of each diluted sample was added to 80 μL of assay 
reagent in a 96-well plate and incubated at 37OC for 30 min. To stop the reaction, 50 
μL of 12 N H2SO4 was added to each well, which stabilised the coloration of the o-
dianisidine product. Absorbance was read at 540nm on a BioRad xMark Microplate 
Spectrophotometer using the Microplate Manager 6 software package (BioRad). 
Glucose production was corrected by the amount of cellular protein per well 
measured using the Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, 
USA). Briefly, following removal of conditioned media, cells were washed once in 
100 μL of 1 x Dulbecco’s Phosphate Buffered Saline, pH 7.4 (1 x PBS), then 
solubilised in 100 μL of 0.03% sodium-dodecyl sulfate (SDS) for 15 min at room 
temperature. Each well was mixed via pipetting, then 25 μL of each sample or BSA 
standard was added to 200 μL of assay reagent (supplied with kit) and incubated for 
30 min at 37OC. Absorbance was read at 562 nm as described above, and the 
absorbance of each sample was compared with the standards to determine protein 
concentration of each sample. 
Due to the high cost of the Glucose (GO) assay kit, the Trinder glucose oxidase 
method (as described previously [184]) was optimised for use with glucose 
standards made up in vehicle treatment media (0 – 60 μg/mL glucose) and a series 
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of volumes of standards were assayed. The maximum volume tested (40 μL from 
total 200 μL per well) was carried forward for use in the following assays as it 
showed the steepest trend line, and therefore had the greatest resolution between 
samples of differing concentrations (data not shown). Briefly, 40 μL conditioned 
media from each well was added to a 96-well plate and incubated at 37OC for 25 
min with 250 μL Assay Buffer (dH20, pH 7.0, 0.12 M NaH2PO4.2H2O (BDH Chemicals, 
Kilsyth, VIC, Australia), 0.1% (w/v) detached phenol crystals (Sigma-Aldrich), 0.5 
mg/ml 4-aminoantipyrine (MPBio), 1.6 U/ml peroxidise (Sigma) and 10 U/ml glucose 
oxidase (Sigma)). Absorbance was read at 490nm on a BioRad xMark Microplate 
Spectrophotometer using the Microplate Manager 6 software package (BioRad). 
Glucose production was corrected by the amount of cellular protein per well 
measured using the Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, 
USA). 
 
2.2.4. Cellular viability and cytotoxicity measurements in response 
to lipid and drug treatments 
Mitochondrial dehydrogenase function was determined using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma-Aldrich) 
colourmetric method as previously described [185]. This method measures 
mitochondrial oxidative capacity as a proxy measure of cellular viability [185].  
Briefly, 100 μL MTT assay buffer containing 0.5 mg/ml thiazolyl blue tetrazolium 
bromide (MTT, M2128 Sigma) in serum-free RPMI medium was added to each well 
of a 48-well plate containing treated cells as described above. Following incubation 
at 37OC for optimal colour development (for FAO hepatoma cells, 30 min), 500 μL 
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0.04 M HCl in isopropanol was added to each well to stop the reaction. The blue 
MTT formazan product was dissolved by mixing the contents of each well via 
pipetting repeatedly and 200 μL transferred to a 96-well plate for the absorbance to 
be read at 570nm with 630nm reference wavelength.  
Cellular cytotoxicity was measured using a CytoTox 96 ® Non-Radioactive kit (G1780 
Promega), as per manufacturer’s recommendation. Briefly, following cellular 
treatments, conditioned media was collected from each well (for released 
extracellular LDH measurement) and stored at 4OC until ready to use. To each well, 
200 μL of 1 x PBS pH 7.4 was added and cells were freeze thawed twice at -80OC for 
30 min to lyse cells and release intracellular LDH. Cell lysate was diluted 1:5 in 1 x 
PBS pH 7.4, and conditioned media was diluted 1:10 in 1 x PBS pH 7.4. 50 μL of 
diluted cell lysate or conditioned media was added to 50 μL of assay reagent 
(supplied with kit), covered to protect from light, and incubated for 30 min at room 
temperature. 50 μL of stop reagent (supplied with kit) was added to each reaction, 
then absorbance was measured at 490 nm. Cytotoxicity was determined as the ratio 
of conditioned media absorbance (extracellular LDH) to cell lysate absorbance 
(intracellular LDH), and expressed as percentage of vehicle-treated cells. 
 
2.2.5. Statistical analysis 
Statistical analysis was performed using Statistical Package for the Social Sciences 
(SPSS) version 20.0 (IBM). Data were first analysed for normality using a one-sample 
Kolmogorov-Smirnov test. All data was determined to be normally distributed. Data 
were then analysed using independent samples Students T-test, or a one-way 
ANOVA. Homogeneity of variance was determined using Levene’s Test, and post-
  Chapter 2: In vitro model development 
56 
 
hoc analysis of ANOVA used either Fisher’s least significant difference (LSD, for 
homogeneous variance) or Games-Howell (for non-homogeneous variance). Data 
were considered significant at p<0.05. All data presented as mean ± SEM unless 
otherwise stated. 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2.1: Schematic representation of the 48 h treatment regime for the 
induction and reversal of PA induced dysregulation of glucose production.  
Treatment regime for the induction and reversal of the dysregulation of glucose 
production in FAO hepatoma cells. PA treatment for 48 h induced 
dysregulated/elevated glucose production. Increased glucose production was 
reversed with the addition of a series of “reversal agents” in the final 24 h of PA 
treatment. 
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2.3. Results 
 
2.3.1. Effects of PA- and LA-treatment on glucose production in FAO 
hepatoma cells 
The effects of PA and LA on glucose production in FAO hepatoma cells were first 
assessed after 24 h incubation. Primary rat hepatocytes isolated from animals fed a 
high fat diet rich in canola oil (high in linoleate) for 3 weeks have previously been 
shown to exhibit increased glucose production and reduced insulin sensitivity 
compared with hepatocytes taken from animals on a control diet [186], making 
linoleate of potential use if PA-induced impairment of insulin action could not be 
successfully modelled (as observed in muscle cell experiments, see Appendix 1). Rat 
derived FAO hepatoma cells were selected for use in these experiments due to 
increased glucose production in basal and insulin stimulated conditions compared 
to alternative hepatic cell models such as the human HepG2 cells (N. 
Konstantopoulos unpublished in house data) or the FAO hepatoma genetic 
precursor cell line H4IIE cells [183]. Because FAO hepatoma cells exhibit relatively 
high glucose production, which can me modulated by fatty acids and drug 
treatments, they are commonly used for in vitro modelling of hepatic insulin 
resistant states [42].  
 
Glucose production was measured after 24 h treatment with 0.075, 0.15 and 0.3 
mM PA at 37OC in the presence or absence of 0.1 nM insulin. In vehicle-treated 
cells, insulin treatment suppressed glucose production by -34 ± 9% (p=0.00007, Fig. 
2.2 a). PA at 0.075 and 0.15 mM increased basal glucose production by 27 ± 2% and 
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34 ± 4% respectively (p=0.0005 and p=0.00006 versus basal vehicle-treated, Fig. 2.2 
a), but did not significantly alter insulin-suppressed glucose production. In contrast, 
0.3 mM PA did not affect basal glucose production nor insulin-suppressed glucose 
production. 
 
Glucose production was measured after 24 h treatment with 0.075, 0.15 and 0.3 
mM LA. In vehicle-treated cells, 0.1 nM insulin for 24 h suppressed glucose 
production by -28 ± 9% (p=0.0022, Fig. 2.2 b). LA-treatment at 0.075 mM did not 
alter either basal or insulin suppressed glucose production. LA-treatment at 0.15 
mM increased basal glucose production by 27 ± 8% (p=0.0027 versus basal vehicle-
treated, Fig. 2.2 b), however insulin-suppressed glucose production was not altered. 
In contrast, 0.3 mM LA did not alter basal or insulin-suppressed glucose production, 
similar to the observation in PA-treated cells. As observed for the 24 h PA-
incubation, the data show that LA treatment for 24 h did not affect insulin 
sensitivity, despite increasing basal glucose production at 0.15 mM, therefore the 
treatment duration was extended to 48 h (see below). 
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FIGURE 2.2: Dysregulation of glucose production by 24 h treatment with 
PA or linoleate in FAO hepatoma cells. 
(a) Basal (black bars) and insulin suppressed (0.1 nM insulin, white bars) glucose 
production following 24 h treatment with PA. The average amount of vehicle-
treated, basal glucose production was 37.54 ± 1.01 μg glucose / mg protein. (b) 
Basal (black bars) and insulin suppressed (0.1 nM insulin, white bars) glucose 
production following 24 h treatment with linoleate. Vehicle-treated, basal glucose 
production was 52.36 ± 2.58 μg glucose / mg protein. Data are expressed as mean ± 
SEM. *p<0.05 when compared with basal, vehicle-treated cells. †p<0.05 when 
compared with each individual treatment’s basal-treated cells. Each experiment 
was performed once in triplicate. 
a 
b 
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After 48 h vehicle treatment, 0.1 nM insulin (added in the final 24 h of treatment) 
suppressed glucose production by -46 ± 6% (p=0.0002 versus basal vehicle-treated, 
Fig. 2.3 a). PA-treatment at 0.075 and 0.15 mM for 48 h did not affect basal glucose 
production, while the effects of 0.1 nM insulin were ablated (Fig. 2.3 a). This was 
observed with a slight but significant decrease in cellular viability of -6 ± 1% 
(p=0.0066) and -5 ± 1% (p=0.0074) respectively compared with vehicle-treated cells, 
as measured by cleavage of MTT in the mitochondria (Fig. 2.3 c). 
 
Due to variability in glucose production following LA-treatment, the 0.1 nM insulin-
suppressed glucose production of -36 ± 7% observed in the vehicle-treated cells was 
not significant (p=0.14, Fig. 2.3 b). Glucose production was not altered by either 
0.15 or 0.3 mM LA-treatment for 48 h compared to vehicle-treated cells. This was 
observed with an increase in MTT cleavage in the mitochondria at both 0.15 mM 
(+56 ± 2%, p=3.47x10-8) and 0.3 mM (+55 ± 2%, p=3.66x10-8, Fig. 2.3 d), indicating an 
up-regulation of mitochondrial metabolism. LA-treatment therefore did not alter 
insulin sensitivity in these cells, but did have a significant impact upon 
mitochondrial oxidative capacity. Hence, PA rather than LA in FAO cells effectively 
impaired insulin’s ability to reduce glucose production with minimal impairment of 
cellular viability.  
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FIGURE 2.3: Dysregulation of glucose production and cellular viability by 
48 h treatment with PA or linoleate in FAO hepatoma cells. 
(a) Basal (black bars), 0.01 nM (dark grey bars), 0.05 nM (light grey bars) and 0.1 nM 
insulin stimulated (white bars) glucose production following 48 h treatment with 
PA. Vehicle-treated, basal glucose production was 20.32 ± 1.24 μg glucose / mg 
protein. (b) Basal (black bars), 0.01 nM (dark grey bars), 0.05 nM (light grey bars) 
and 0.1 nM insulin stimulated (white bars) glucose production following 48 h 
treatment with LA. Vehicle-treated, basal glucose production was 20.76 ± 1.07 μg 
glucose / mg protein. (c) Effect of PA on cellular viability (mitochondrial oxidative 
capacity) after 48 h treatment. (d) Effect of LA on cellular viability (mitochondrial 
oxidative capacity) after 48 h treatment. Data are expressed as mean ± SEM. 
*p<0.05 when compared with basal, vehicle treated cells. †p<0.05 when compared 
with the relevant basal treated cells. Each experiment was performed three times in 
triplicate.
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FIGURE 2.4: Increased cytotoxicity by 48 h treatment with 0.3 mM PA in 
FAO hepatoma cells. 
Effects of 0.075 - 3 mM PA on LDH ratio after 48 h treatment, expressed as a 
percentage of the ratio in vehicle-treated cells. The average LDH ratio 
(extracellular:intracellular) for basal, vehicle treated cells was 0.088 ± 0.003. Data 
are expressed as mean ± SEM. *p<0.05 when compared with basal, vehicle-treated 
cells. The experiment was performed once and each treatment measured in 
triplicate. 
 
 
LDH release was measured as a marker for cytotoxicity in PA-treated FAO cells. 
Release of LDH was not significantly increased by either 0.075 or 0.15 mM PA 
compared with vehicle-treated cells at 48 h (Fig. 2.4). In contrast, 0.3 mM PA for 48 
h increased the ratio of LDH release by 148 ± 21% (p=0.00003, Fig. 2.4). 
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PA-treatment for 48 h at 0.075 mM was selected as the optimal treatment, due to 
its ability to dysregulate glucose production, while having minimal effects on 
cellular viability. While 0.15 mM PA treatment was similar in its ability to 
dysregulate glucose production, the lower concentration of 0.075 mM was chosen 
in order to mimic the pathological levels of circulating lipids in individuals. Basu et 
al. have shown that arterial plasma PA concentrations in type 2 diabetic patients 
range from 175 ± 15 μM after overnight fasting to 75 ± 17 μM following 0.25 
mU/kg/min insulin infusion for 3 h, and 38 ± 11 μM following 0.5 mU/kg/min insulin 
infusion for 3 h [187]. The selected PA concentration of 75 μM falls within this 
range. 
 
2.3.2. Reversing PA dysregulation of glucose production in FAO 
hepatoma cells 
Compounds with known insulin sensitising and/or anti-diabetes properties were 
trialled to reverse/restore the PA-induced dysregulation of glucose production in 
this model. All compounds were assessed for their effects on glucose production 
when added in the final 24 h of 48 h PA-treatment, and their impact on cellular 
viability and cytotoxicity was also assessed. The panel of compounds tested 
included salicylates (aspirin and sodium salicylate), biguanides (metformin, 
phenformin and buformin), thiazolidinediones (rosiglitazone) and berberine (see 
Introduction). The data for each experiment is shown in Fig. 2.5, and for ease of 
comparison has also been summarised in Table 2.1. 
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TABLE 2.1: Effects of anti-diabetic agents on glucose production, cellular 
viability (MTT) and cellular cytotoxicity (LDH release)  in PA treated FAO 
cells. 
Viability, MTT, % change from PA-treated cells; Cytotoxicity, LDH , % change from 
PA-treated cells. Data are expressed as mean ± SEM. †p>0.05 versus relevant PA-
treated cells. Each experiment was performed three times, in triplicate.  
 
 Anti-diabetic Agent Glucose production  
(% change from PA-treated 
cells ) 
Viability 
(MTT)  
Cytotoxicity 
(LDH)  
Basal Insulin-
stimulated 
Sa
lic
yl
at
es
 
Aspirin 1 mM -3 ± 5% -18 ± 4% 4 ± 2% -1 ± 5% 
 5 mM -46 ± 4%† -54 ± 4%† 6 ± 1% 54 ± 11%† 
 10 mM -86 ± 1%† -86 ± 1%† -7 ± 1%† 297 ± 52%† 
      
Sodium  1 mM -2 ± 5% -5 ± 5% 2 ± 1% 5 ± 13% 
Salicylate 5 mM -60 ± 2%† -66 ± 1%† 5 ± 1% 73 ± 13%† 
 10 mM -83 ± 2%† -85 ± 1%† -5 ± 3% 322 ± 25%† 
      
Bi
gu
an
id
es
 
Metformin 0.1 mM -5 ± 4% -9 ± 4% -2 ± 2 % -5 ± 4% 
 0.5 mM -38 ± 2%† -39 ± 1%† -1 ± 2% -15 ± 2%† 
 1 mM -67 ± 1%† -69 ± 3%† -2 ± 3% -20 ± 5%† 
      
Phenformin 10 μM -33 ± 2%† -51 ± 1%† -4 ± 1% -10 ± 6% 
 30 μM -82 ± 1%† -89 ± 3%† -2 ± 1% -17 ± 11% 
 100 μM -99 ± 1%† -97 ± 1%† -14 ± 1%† 41 ± 28% 
      
Buformin 30 μM -37 ± 1%† -49 ± 2%† -3 ± 1% -1 ± 9% 
 100 μM -97 ± 1%† -98 ± 1%† 7 ± 1%† -10 ± 12% 
 300 μM -98 ± 1%† -97 ± 1%† -19 ± 1%† 71 ± 44% 
      
TZ
D 
Rosiglitazone 1 μM -3 ± 4% -3 ± 5% -3 ± 2% -1 ± 7% 
 10 μM -9 ± 4% -14 ± 7% -3 ± 2% 1 ± 7% 
 100 μM -69 ± 1%† -81 ± 2%† 17 ± 3%† -1 ± 7% 
      
O
th
er
 Berberine 1 μM -3 ± 3% -11 ± 5% 3 ± 2% -2 ± 7% 
 10 μM -22 ± 3%† -30 ± 5% 18 ± 3%† -9 ± 8% 
 100 μM -81 ± 2%† -78 ± 1%† 30 ± 5%† 42 ± 10%† 
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FIGURE 2.5: Reversal of PA-induced glucose dysregulation by 
anti-diabetic agents in FAO hepatoma cells. Basal (black) and 0.1 
nM insulin stimulated (white) glucose production following 48 h PA-
treatment. (a) Aspirin, (b) sodium salicylate, (c) metformin, (d) 
phenformin, (e) buformin, (f) rosiglitazone, and (g) berberine were added 
in the final 24 h of treatment. Basal vehicle-treated glucose production 
was (a) 33.88 ± 6.13, (b-c) 35.76 ± 1.42, (d-e) 39.62 ± 1.84, and (f-g) 40.95 
± 3.95 μg glucose / mg protein. Data are expressed as mean ± SEM. 
*p<0.05 for basal PA-treated cells when compared with basal vehicle-
treated cells. †p<0.05 for basal PA- and anti-diabetic-treated cells when 
compared with relevant basal PA-treated cells. ††p<0.05 for insulin 
stimulated cells when compared with relevant basal treatment. Each 
experiment was performed three times, in triplicate. 
e 
f 
g 
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The effects on insulin sensitivity of each anti-diabetic compound were assessed. 
None of the compounds showed a consistent ability to enhance insulin suppression 
of glucose production in FAO hepatoma cells treated with 0.075 mM PA for 48 h 
(Fig. 2.5). Rather, the main effect of each of the seven compounds tested was on 
basal glucose production. Therefore selection of compounds for the reversal of PA-
induced elevated glucose production was determined on their ability to lower basal 
glucose production to the same level as insulin-suppressed glucose production in 
vehicle-treated cells. 
 
2.3.2.1. Salicylates 
Aspirin was used at 1, 5 and 10 mM in the final 24 h of the 48 h PA-treatment (Table 
2.1, Fig. 2.5 a). Aspirin at 5 and 10 mM decreased basal glucose production by -46 ± 
4% (p=0.00001) and -86 ± 1% (p=0.0000002) respectively compared with basal, PA-
treated cells. Both of these concentrations led to increased cytotoxicity, increasing 
the LDH ratio by 54 ± 11 % (p=0.0229) and 297 ± 52% (p=0.0150) respectively when 
compared with PA-treated cells (Table 2.1). The higher concentration of 10 mM also 
decreased cellular viability by -7 ± 1%, (p=0.0119 compared with PA-treated, Table 
2.1). The effects of aspirin were therefore observed in parallel with decreased 
cellular viability at 10 mM, and increased cytotoxicity at 5 and 10 mM. 
 
Sodium salicylate was used at 1, 5 and 10 mM in the final 24 h of 48 h PA-treatment 
(Table 2.2, Fig. 2.5 b). Compared with aspirin, sodium salicylate showed increased 
potency at 5 mM, decreasing basal glucose production by -60 ± 2% (p=0.000001 
compared with basal PA-treated cells). Sodium salicylate at this concentration did 
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not affect cellular viability (Table 2.1). At 5 mM, sodium salicylate increased the LDH 
ratio by 73 ± 13 % (p=0.0236) compared with PA-treated cells (Table 2.1). The 
effects of sodium salicylate at 5 mM were more potent than aspirin, and could be 
reduced to minimise effects on cytotoxicity. Sodium salicylate was therefore chosen 
over aspirin as a potential reversal compound. 
 
2.3.2.2. Biguanides 
Metformin was used at 0.1, 0.5 and 1 mM in the final 24 h of 48 h PA-treatment 
(Table 2.1, Fig. 2.5 c). Metformin at both 0.5 and 1 mM reduced basal glucose 
production without altering cellular viability. In addition, metformin at 0.5 and 1 
mM improved the LDH ratio, thereby improving the measure of cytotoxicity (Table 
2.1). Metformin at 0.5 and 1 mM therefore reduced glucose production in the 
absence of changes to cellular viability and decreased (improved) cytotoxicity. Due 
to its current widespread utility in patients, these results confirmed metformin as a 
candidate reversal compound for PA-induced dysregulation of glucose production. 
 
Phenformin was used at 10, 30 and 100 μM in the final 24 h of 48 h PA-treatment 
(Table 2.1, Fig. 2.5 d). As previously reported, phenformin showed increased 
potency over metformin despite being used at a ten-fold lower dose, and also did 
not affect cellular viability at 10 or 30 μM. However, the improvement to 
cytotoxicity was not significant with phenformin, and at 100 μM showed a trend for 
increased cytotoxicity.  Buformin was used at 30, 100 and 300 μM in the final 24 h 
of 48 h PA-treatment and showed similar increased potency for reducing glucose 
production compared with metformin (Table 2.1, Fig. 2.5 e). Similarly to 
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phenformin, buformin did not significantly improve cytotoxicity, and also showed a 
trend for increased cytotoxicity at the higher dose of 300 μM (Table 2.1). 
Metformin was chosen as a reversal agent for further testing over phenformin and 
buformin despite the increased potency of phenformin and buformin on lowering 
glucose production. This was due to the discontinued use of buformin and 
phenformin in human patients due to concerns over possible association with the 
induction of lactic acidosis [188, 189], with the aim of making the combination 
treatment as physiologically relevant as possible. 
 
2.3.2.3. Thiazolidinediones 
Rosiglitazone was used at 1, 10 and 100 μM in the final 24 h of 48 h PA-treatment 
(Table 2.1, Fig. 2.5 f). At 1 and 10 μM, rosiglitazone had no effect on glucose 
production, cellular viability or cytotoxicity. Rosiglitazone at 100 μM decreased 
basal glucose production by -69 ± 1% (p=2.5x10-10 compared with basal PA-treated 
cells). The decrease in basal glucose production at 100 μM was observed with an 
increase in cellular viability of 17 ± 3% (p=0.00002 compared with PA treated cells, 
Table 2.1). Only at the highest dose tested was rosiglitazone able to lower glucose 
production in PA-treated FAO hepatoma cells, and this occurred with positive 
effects on cellular viability, however it remains to be observed if this effect would 
remain at lower concentrations. 
 
2.3.2.4. Berberine 
Berberine was used at 1, 10 and 100 μM in the final 24 h of 48 h PA-treatment 
(Table 2.1, Fig. 2.5 g). Berberine at 10 and 100 μM decreased basal glucose 
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production by -22 ± 3% and -81 ± 2% (p=0.0002 and p=4.4x10-12 respectively 
compared with basal PA-treated). At both 10 and 100 μM, berberine improved 
cellular viability by 18 ± 3% and 130 ± 5% respectively (p=0.0060 and p=0.0020 
compared with PA-treated cells, Table 2.1). Berberine had no effect on cytotoxicity 
at 1 or 10 μM, however 100 μM increased the LDH ratio by 42 ± 10 % (p=0.0021 
compared with PA-treated) indicating increased LDH release due to a decrease in 
plasma membrane integrity (Table 2.1). 
 
Based upon the results gained in the single compound experiments, metformin and 
sodium salicylate were chosen for use in combined therapy. Briefly to summarise 
their effects, both metformin and sodium salicylate reduced basal glucose 
production, coupled with minimal effects on cellular viability and cytotoxicity at the 
lowest (1 mM sodium salicylate and 0.1 mM metformin) and intermediate (5 mM 
sodium salicylate and 0.5 mM metformin) concentrations tested. Sodium salicylate 
was selected in preference over aspirin due to increased potency for lowering 
glucose production at 5 mM. Metformin was used in preference over buformin and 
phenformin (which were both more potent at lower concentrations) due to 
metformin’s ongoing utility in human patients [188, 189] – with the aim of making 
the treatments relevant to the human condition. Given the recent removal of 
rosiglitazone from sale in multiple countries [190], alongside stringent restrictions 
on use in the United States of America [191], it was also not utilised for further 
experimentation.  Berberine was able to reduce basal glucose production at the 
higher concentration tested, however this occurred with large changes to cellular 
viability and cytotoxicity, and as such berberine was not carried forward for further 
use. 
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2.3.4. Optimising combination treatment to reverse PA 
dysregulation of glucose production in FAO hepatoma cells  
For combination treatment, metformin was used at 0.1 - 0.5 mM and sodium 
salicylate at 1 - 5 mM in the final 24 h of 48 h PA-treatment. As no insulin sensitising 
effect was observed with either of these compounds on their own, the focus of the 
reversal shifted away from attempting to improve insulin action, to lowering basal 
glucose production in PA-treated cells to the same level observed in insulin-
stimulated, vehicle-treated cells. In addition to the ability to reduce glucose 
production, it was also determined whether any cumulative effect could be 
achieved with combination therapy, or whether there was a dominant glucose 
lowering effect by a single agent. The results of the reversal experiment which 
successfully reduced the PA-induced increase in glucose production to the same 
level as insulin-stimulated, vehicle-treated cells is summarised in Table 2.3 below. 
For the complete dataset for each combination reversal experiment, see Appendix 
2. 
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TABLE 2.3: Reversal of the PA-induced increase in basal glucose 
production using co-treatment with metformin and sodium salicylate. 
Effects of metformin and sodium salicylate on glucose production, cellular viability 
(MTT) and cellular cytotoxicity (LDH release) in PA-treated FAO cells. †p>0.05 versus 
PA-treated cells. M p>0.05 versus metformin-alone treated cells. N p>0.05 versus 
sodium salicylate alone treated cells. Data are represented as mean ± SEM of three 
independent experiments performed in triplicate. 
 
Insulin suppressed glucose production in vehicle-treated cells by -38 ± 4% (p=0.0002 
compared with basal vehicle-treated cells), consistent with previous results, while 
PA-treatment raised basal glucose production by 28 ± 3% (p=0.0014) compared with 
basal vehicle-treated cells (see Appendix 2, Appendix Fig. a2.2). The optimal 
combination therapy was required to reduce basal glucose production to the same 
level as observed in insulin-stimulated, vehicle-treated cells. For comparative 
purposes, this equates to a reduction of 51% from basal PA-treated cells. The 
combination which best achieved this was 0.25 mM metformin and 2 mM sodium 
salicylate, at -47 ± 3% (p=1.8x10-7 compared with basal, PA-treated cells), and was 
not significantly different to insulin-suppressed, vehicle-treated cells (p=0.999). 
 Basal Glucose production  
(% change from PA-
treated cells ) 
Viability (MTT, % change 
from PA-treated cells)  
Cytotoxicity (LDH , % 
change from PA-treated 
cells) 
  Metformin 
So
di
um
 S
al
ic
yl
at
e 
 0 mM  0.25 mM  0 mM  0.25 mM  0 mM  0.25 mM  
0 mM - -21 ± 4%† - -13 ± 1%† - -7 ± 4% 
       
1 mM -22 ± 5%† -31 ± 3%† -4 ± 1%† -9 ± 1%†MN -4 ± 2% -2 ± 3% 
       
2 mM -42 ± 4%† -47 ± 3%†M +3 ± 1%† -7 ± 1%†MN +5 ± 3% +3 ± 4% 
       
3 mM -54 ± 2%† -56 ± 3%†M -2 ± 1% +8 ± 1%†MN +15 ± 4% +22 ± 7% 
       
4 mM -65 ± 2%† -66 ± 3%†M -1 ± 1% +10 ± 1%†MN +34 ± 8% +35 ± 6%†M 
       
5 mM -58 ± 2%† -69 ± 2%†M +6 ± 1%† +11 ± 1%†MN +47 ± 13% +81 ± 6%†M 
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Combination treatment with 0.25 mM metformin and 2 mM sodium salicylate 
caused a decrease in cellular viability of -7 ± 1% compared with PA-alone treated 
cells (p=0.00001, Table 2.3). The combination treatment had no effect on 
cytotoxicity as measured by LDH ratio compared with PA-alone treated cells (Table 
2.3).  
 
Metformin at 0.25 mM and sodium salicylate at 2 mM therefore successfully 
reversed the PA-induced dysregulation of glucose production. Although an additive 
effect was not observed with these concentrations, both metformin at 0.25 mM 
and sodium salicylate at 2 mM lowered glucose production independently, and the 
combination reduced glucose production to the same level as observed in insulin-
stimulated, vehicle-treated cells.  
 
2.3.5. Metformin and sodium salicylate reverse PA dysregulation of 
glucose production in FAO hepatoma cells 
In order to fully characterise the effects of metformin and sodium salicylate on PA 
induced dysregulation of glucose production, the selected concentrations of 0.25 
mM metformin and 2 mM sodium salicylate were repeated eight independent times 
to set stringent criteria for the selection of samples to be used in microarray 
analysis (see Chapter 3). Insulin suppressed glucose production in vehicle-treated 
cells by -34 ± 1% (p=6.6x10-13, Fig. 2.6 a). PA-treatment for 48 h raised basal glucose 
production by 25 ± 2% (p=0.00002 compared with basal, vehicle-treated cells), 
while the insulin effect on glucose production in PA-treated cells was completely 
ablated. Combination treatment using 0.25 mM metformin and 2 mM sodium 
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salicylate (PAMN) lowered basal glucose production by -45 ± 2% compared with 
basal, PA-treated cells (p=7.1x10-13, Fig. 2.6 a). Insulin suppressed glucose 
production in PAMN-treated cells was significantly lowered by -8 ± 2% (p=0.018, Fig. 
2.6 a). Insulin suppressed glucose production in vehicle-treated cells was not 
significantly different to either basal (p=0.5269) or insulin suppressed (p=0.2988) 
glucose production in PAMN-treated cells (Fig. 2.6 a). 
 
PA-treatment for 48 h lowered cellular viability by -15 ± 1% compared with vehicle-
treated cells (p=1.3x10-17, Fig. 2.6 b). PAMN-treatment did not significantly alter 
cellular viability compared with PA-treated cells (p=0.10; Fig. 2.6 b). Similarly, PA-
treatment increased the LDH ratio by 15 ± 4% compared with vehicle-treated cells 
(p=0.021, Fig. 2.6 c), however PAMN-treatment did not further change LDH ratio 
compared with PA-treated cells (p=0.25, Fig. 2.6 c). As the PAMN-treatment did not 
further impair cellular viability or cytotoxicity, it was concluded that the reduction in 
basal glucose production observed with PAMN treatment is a glucose lowering 
effect, and not due to a side effect of impaired cellular function with the 
combination treatment. 
 
   Chapter 2: In vitro model development 
76 
 
 
a 
b 
c 
   Chapter 2: In vitro model development 
77 
 
 
 
 
 
 
 
FIGURE 2.6: Combination reversal of PA-induced glucose dysregulation 
using 0.25 mM metformin and 2 mM sodium salicylate in FAO hepatoma 
cells. 
(a) Basal (black bars) and 0.1 nM insulin stimulated (white bars) glucose production 
following 48 h treatment with PA, with metformin and sodium salicylate added in 
the final 24 h of treatment. The level of glucose produced by basal, vehicle-treated 
cells was equal to 50.03 ± 3.86 μg glucose / mg protein. (b) Effect of PA, metformin 
and sodium salicylate on cellular viability after 48 h treatment, with metformin and 
sodium salicylate added in the final 24 h of the 48 h PA-treatment. (c) Effects of PA, 
metformin and sodium salicylate on LDH ratio after 48 h treatment, with metformin 
and sodium salicylate added in the final 24 h of the 48 h PA-treatment. Average LDH 
ratio (extracellular:intracellular) for basal, vehicle-treated cells was 0.110 ± 0.009. 
Data are expressed as mean ± SEM. *p<0.05 for basal PA-treated cells when 
compared with basal, vehicle-treated cells. †p<0.05 for basal PAMN-treated cells 
when compared with basal PA-treated cells. ††p<0.05 for insulin stimulated cells 
when compared with each individual treatment’s basal treated cells. (a) Average of 
8 independent experiments performed in triplicate; (b-c) average of six experiments 
in triplicate. 
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2.4. Discussion 
In contrast to the in vitro muscle cell models (see Appendix 1), the liver cell model 
was superior in its ability to demonstrate the induction and reversal of PA-induced 
dysregulation to a key endpoint of insulin action. Firstly, 0.1 nM insulin suppression 
of glucose production for 24 h in FAO hepatoma cells was consistently greater than 
30%. This contrasts favourably over the muscle cell models whereby the maximum 
insulin effect was observed to be 27 ± 1% in HA-GLUT4 translocation in stable 
transfected L6 cells, and was lower in the L6 and C2C12 cell lines used to measure 2-
deoxyglucose (2-DOG) uptake and glycogen synthesis respectively. Secondly, the 
induction of cellular insulin resistance was demonstrated with 75 – 150 μM PA for 
48 h, after which insulin suppression of glucose production was ablated. Again, this 
contrasts to the muscle cell models, where complete ablation of the insulin 
response was frequently observed in parallel with significant decreases in basal 
measurements – suggestive of reduced cellular viability (although this was not 
measured in the muscle cell models). Finally, the induction of dysregulated glucose 
production in FAO hepatoma cells with PA-treatment occurred in parallel with mild 
changes to both cellular viability and cytotoxicity, which were not further affected 
in the reversal with PAMN-treatment. Therefore, the observed regulation of glucose 
production with PA, metformin and sodium salicylate were due to the effects of the 
lipid or compound on glucose metabolism, rather than off-target effects due to 
compromised cellular integrity. In addition, there is currently less understood about 
the induction of PA-induced insulin resistance in the liver than in muscle tissue, and 
as such this model has greater potential to provide novel information.  
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All seven of the compounds tested were able to reduce basal glucose production to 
varying degrees (Table 2.2). The ability of each compound to reverse the PA-
induced increase in basal glucose production yields potential mechanisms of action 
for the effects of PA in these cells. The ability of both sodium salicylate and aspirin 
to lower basal glucose production may indicate a potential for an underlying 
inflammatory mechanism of action with PA-treatment [156]. The induction of 
insulin resistance by PA in hepatocytes has previously been shown to involve 
activation of the NF-kB pathway [192], and therefore the inhibition of this signalling 
pathway by the salicylates is consistent with the effects observed on glucose 
production in this model. Berberine is also a suppressor of inflammation, and has 
been shown in 3T3-L1 adipocytes to suppress the gene expression levels of TNFα 
and IL-6 [193]. In human HepG2 hepatoma cells, berberine was demonstrated to 
lower PA-induced increases in the excreted protein level of these 2 inflammatory 
cytokines in conditioned media [182], alongside restoration of PA-inhibited insulin-
stimulated glycogen synthesis. Both aspirin and sodium salicylate lowered basal 
glucose production only at a concentration greater than 1 mM, keeping with the 
established inhibition of NF-kB signalling and cytokine production at 2 mM and 
above [156]. Aspirin, but not sodium salicylate, increased insulin sensitivity at the 
lower concentration of 1 mM (Fig. 2.5 a), and given the increased potency for COX 
inhibition by aspirin [158], this finding may indicate that COX inhibition is an 
effective mechanism for the restoration of insulin sensitivity in this model. This 
effect however was not observed at 5 and 10 mM, indicating the dominant effect of 
NF-kB inhibition in lowering basal glucose production at these concentrations. 
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The reduction in glucose production by metformin does not suggest a mechanism 
for the effects of PA on glucose production. There are multiple proposed 
mechanisms of action for metformin in the liver. The main proposed mechanisms of 
action for metformin involves AMPK activation via the generation of reactive 
nitrogen species [163], and may involve downstream induction of Sirt1 activity 
[194]. It has also been reported however that metformin can act independently of 
AMPK to reduce glucose production, although the mechanisms by which this is 
achieved are not completely understood [164]. PA-treatment does not affect the 
activation of AMPK [195], and thus the actions of metformin do not restore a PA-
induced defect. Interestingly, phenformin and buformin showed a greater than ten-
fold potency for lowering glucose production than metformin. Given the relative 
similarity in AMPK activation that others have reported for metformin and 
phenformin [167], it is likely that the difference in potency observed between 
phenformin, buformin and metformin are due to AMPK independent mechanisms. 
 
The main actions of rosiglitazone on glucose production in the liver, similarly to 
metformin, are likely to be independent of the PA-induced defects – although 
rosiglitazone has been shown to reduce mononuclear blood cell NF-kB activation 
and plasma TNFα levels in patients [196]. Activation of PPARγ in adipose tissue is 
thought to lead to increased expression of adiponectin, an adipokine which 
activates AMPK. It has been reported that troglitazone (another TZD) induces rapid 
AMPK activation in muscle, liver and adipose tissue independently of adiponectin 
expression [197]. The concentrations of rosiglitazone used here correlate with its 
ability to inhibit mitochondrial complex 1 [171] and activate AMPK [173]. It is 
   Chapter 2: In vitro model development 
81 
 
therefore likely that rosiglitazone is acting independently of the mechanisms by 
which PA-induces dysregulated glucose production in the current study. 
 
Any conclusions as to the mechanism of action in this model based on the 
compounds used however has to consider the inability of any of the compounds to 
reverse the PA-induced cellular insulin resistance. It is therefore likely that the 
effects of PA on inducing insulin resistance and elevated glucose production occur 
by independent mechanisms to which the lowering of basal glucose production is 
achieved by treatment with the compounds. This will be further investigated in 
Chapter 4, where the effects of PA treatment on the alteration of whole genome 
gene expression will be compared with the effects of metformin and sodium 
salicylate treatment on whole genome gene expression. Of course, this finding has 
significant implications for the main aims of the project. Therefore, this study does 
not model the induction and reversal of PA-induced insulin-resistance. The updated 
aim for the project is to model the PA-induced dysregulation of glucose production 
in the liver (which includes the induction of insulin resistance and increased basal 
glucose production) and the reversal of such a state (which involves the lowering of 
basal glucose production, but not necessarily the restoration of insulin sensitivity). 
 
Therefore, a key finding described in this chapter is the inability of any of the 
compounds tested to improve insulin sensitivity in PA-treated FAO hepatoma cells. 
This is in contrast with the effects of these compounds in other cell types, or against 
other insults, where they have been shown to improve insulin sensitivity. For 
example, aspirin has been shown in vivo to improve whole body insulin sensitivity in 
Zuckerfa/fa rats and leptinob/ob mice [42], both models of obesity and insulin 
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resistance. The same study also showed that pre-treatment of both aspirin and 
sodium salicylate can protect from insulin-responsive IRS-2 tyrosine 
phosphorylation defects induced by TNFα treatment in FAO cells. Aspirin also 
protected against TNFα-induced IRS-1 tyrosine phosphorylation defects in 3T3-L1 
adipocytes [42]. However it was not described if these changes at the insulin 
signalling level resulted in a rescue of altered glucose metabolism in these cells. 
 
Metformin has been previously reported to improve hepatic insulin sensitivity in 
T2D patients [143, 198], as well as lowering basal glucose production [199]. 
Contrasting this, other studies have reported that metformin acts mainly by 
lowering basal glucose production alone [200]. Regardless, the lowering of basal 
glucose production is a common finding amongst all human studies with metformin 
in diabetic patients, and is consistent with the findings presented here. It is perhaps 
possible that by lowering basal hepatic glucose production, and subsequently 
lowering plasma glucose levels, a reduction in the secretion of insulin from 
pancreatic β-cells is achieved – preventing β-cell exhaustion and improving insulin 
sensitivity due to lower plasma insulin levels maintaining glycaemic control.  
 
Rosiglitazone has been shown to improve whole body insulin sensitivity in C57BL/6 
mice fed a corn oil-based high-fat diet [201]. Although rosiglitazone’s major target 
organ is the enriched PPARγ-expressing adipose tissue, rosiglitazone has been 
shown to reduce basal glucose production and increase hepatic insulin sensitivity in 
human type 2 diabetic patients [202]. This is in contrast with the results obtained in 
this study, however it is possible that the systemic effects of whole body 
rosiglitazone treatment may elicit responses not seen in individual cellular 
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experiments as reported in this study (as with metformin). For example, activation 
of PPARγ has an inhibitory effect on the expression of pro-inflammatory cytokines 
such as TNFα [203]. By activating PPARγ with rosiglitazone, a reduction in circulating 
proinflammatory cytokines would reduce systemic inflammation – thereby reducing 
inflammation-based insulin resistance if present in the liver. 
 
Experiments performed in human HepG2 hepatoma cells showed that pre-
treatment with 1 and 10 μM berberine for 30 min could prevent PA-induced insulin 
resistance developing over 24 h, measured using insulin-stimulated glycogen 
synthesis [182]. Glycogen synthesis in FAO hepatocytes was difficult to measure 
directly due to very low levels of intracellular glycogen (unpublished in-house data), 
thus making a direct comparison across the different cell lines difficult. At the same 
concentrations however, berberine did not enhance insulin sensitivity in FAO 
hepatocytes in the presence of PA in this study. Berberine (0.01 – 100 μM for 24 h) 
has also been shown to increase glucose transport in 3T3-L1 adipocytes in an 
insulin-independent manner [180]. This is consistent with the effects of berberine 
reported in this chapter, where the reduction in glucose production was 
independent of insulin sensitivity. 
 
The main effect of all compounds tested in this study was on basal glucose 
production. Whether this is a reflection of the unique insulin signalling 
intermediates of the liver (IRS-1 is the main receptor substrate in the muscle, while 
IRS-2 is the main receptor substrate in the liver), or lack of systemic factors 
operating in in vivo models is unclear. While this finding was surprising, the model 
still remains a valid in vitro version of the human condition, where lowering hepatic 
   Chapter 2: In vitro model development 
84 
 
glucose production (with compounds such as metformin) is an important remedy 
for elevated blood glucose levels.  
 
In summary, we developed an in vitro cellular model of hyperlipidemia-induced 
insulin resistance using the fatty acid PA. While the specific restoration of insulin 
action in rat FAO hepatoma cells using metformin and sodium salicylate was 
unsuccessful, the combination treatment was able to reverse the increase in 
glucose production observed with PA treatment. The remainder of this thesis 
therefore investigated the induction and reversal of elevated fatty acid induced 
glucose production, rather than the specific inhibition and restoration of insulin 
action. Although this avenue of investigation diverged from the original aim, the 
lowering of hepatic glucose production in the presence of elevated lipids remains 
clinically relevant to obesity-induced T2D. 
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Chapter 3 – Identification of a GES that 
discriminates between dysregulated hepatic glucose 
production (PA-treated) and restored, healthy 
hepatic glucose production (PAMN-treated) 
 
3.1. Introduction 
Developed nearly two decades ago for the measurement of the expression of 
multiple genes in parallel [124], microarray technology can now be used to assess 
the expression of tens of thousands of genes in a sample simultaneously. This 
provides a powerful tool to assess genome wide transcriptional events for any given 
cell or tissue, in any biological state. Microarray technology has a range of 
applications including identifying disease-causing genes, identifying targets for new 
therapies and prediction of drug responsiveness [125]. The major applications for 
microarray technologies include identification of differentially expressed genes – 
the focus of this chapter, and the identification of co-ordinately regulated signalling 
or metabolic pathways – the focus of Chapter 4. 
 
Initially applied to the study of cancer malignancy, early genomic scale microarray 
studies allowed for the identification of large profiles consisting of hundreds of 
differentially expressed genes [204]. While such expression profiles are robust in 
their ability to characterise different cellular states, the sheer number of genes 
involved presents a technical challenge in the application of such profiles to 
characterise patients in a clinical setting. Therefore, the statistical selection of a 
small subset of genes (termed Gene Expression Signature, GES) that robustly 
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discriminates between two biological states enhances the utility of such 
information: through multiplex RT-PCR analysis, the measurement of the selected 
genes can be quickly, and more cost effectively, determined in patient samples. This 
can be achieved by minimising the extensive redundancy that exists in such large 
datasets by using only a relatively small subset of discriminating genes, which can 
approach equivalence in predictive power to the whole dataset when properly 
identified [132]. 
 
The challenge for the application of a discriminating GES is the availability of 
relevant patient tissues for ex vivo measurement of the relevant genes. While the 
GES being developed in this study was generated in hepatoma cells, it would be 
unrealistic to expect all diabetic patients to undertake liver biopsies for 
characterisation of their disease. An attractive alternative is the measurement of 
gene expression in the relatively non-invasive white blood cell population, 
undertaken as a proxy for hepatic gene expression. Disease specific alterations to 
gene expression profiles of lymphocytes have been shown previously [205]. The 
application of lymphocyte gene expression as a marker for disturbed disease states 
in other tissues has been shown for numerous diseases including Alzheimer’s 
disease [206], first-episode psychosis [207], rheumatoid arthritis [208] and coronary 
artery disease [209]. However, the expression profiles from these studies were 
identified in the lymphocyte tissue – while in this study we are developing the GES 
in the relevant biological tissue in vitro. The relationship between lymphocyte and 
liver gene expression in a pre-diabetic animal model has been previously described 
[148]. In pre-diabetic Otuka Long-Evans Tokushima Fatty rats, 1080 genes were 
found to be regulated in either lymphocytes or liver tissue compared with control 
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animals. Of those 1080 genes, 57 were found to be regulated in both lymphocytes 
and liver tissue. Therefore, while not all gene expression changes in the face of a 
disease state are likely to change in both tissues, there is at least a subset of genes 
that shows a common expression profile across the liver and lymphocyte tissues. 
 
The early application of GES in the cancer field was for the characterisation of 
malignancy in various cancer cell types [131, 210], allowing for better prediction of 
disease and treatment outcomes in cancer patients [132, 133]. This has recently 
been applied to the setting of insulin resistance, where a TNFα-based GES was able 
to identify a subset of individuals with more severe insulin resistance from a larger 
cohort [141]. In addition, the use of GES in high-throughput screening platforms for 
the identification of novel therapies from chemical libraries has also been applied to 
such disease states as cancer [139, 211] and insulin resistance [141, 149]. 
 
Therefore, the initial aim of this chapter was to perform microarray analysis of 
vehicle-, PA- and PAMN-treated FAO mRNA, for further use in interrogating the 
gene expression changes to signalling and metabolic pathways in Chapter 4. The 
secondary aim of this chapter was to interrogate the microarray data in an unbiased 
manner to develop a GES-based screening platform. This involved the identification 
of the set of genes that is the most discriminating between the PA-treated 
(dysregulated glucose production) and PAMN-treated (restored glucose production) 
states. This GES will then have two potential applications: first, to screen a library of 
compounds to identify new anti-diabetic agents, and second, to stratify a cohort of 
individuals with varying degrees of insulin resistance to attempt to identify an 
insulin resistant cohort of patients [141]. Once identified, putative GES genes need 
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to be validated in two ways. First, the microarray-determined mRNA levels will be 
confirmed using an alternative technology such as RT-PCR analysis. Secondly, as the 
genes were identified in an in vitro cell line, the biological relevance of the genes 
will be determined by measuring their expression in human lymphocytes. The 
tertiary aim of this chapter, once the biological relevance of the GES genes has been 
established by assessing their expression in a human lymphocyte gene expression 
data set (from the San Antonio Family Heart Study (SAFHS) [150] in collaboration 
with Professor John Blangero and Dr. Tom Dyer at Texas Biomedical Research 
Institute, San Antonio), is to mine the cohort data to determine if any of the GES 
genes are associated with metabolic syndrome phenotypes. 
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3.2. Methods 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.1: Flowchart for GES development. 
Flowchart of methodology from collection of RNA samples for microarrays and data 
normalisation through to Diagonal Linear Discriminate Analysis (DLDA) and gene 
validation. 
 
3.2.1. Selection of samples for microarray analysis  
Selection of samples for microarray analysis was based upon statistical confirmation 
for the following three criteria: (i) a robust reduction in glucose production in 
vehicle-treated cells by 0.1 nM insulin, (ii) a reduced insulin effect in 0.075 mM PA-
treated cells, and (iii) a lowering of basal glucose production in the presence of 
0.075 mM PA, 0.25 mM metformin and 2 mM sodium salicylate (PAMN) to within 
20% of the levels observed in insulin-stimulated vehicle-treated cells. The average 
values were as follows: (i) in vehicle-treated cells, insulin resulted in a -34% ± 3% 
decrease in glucose production (p=1.21x10-9 compared with basal vehicle-treated 
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cells) , (ii) PA-treatment increased basal glucose production by +32 ± 3% (p=5.08x10-
8 compared with basal vehicle-treated cells) and completely ablated the effects of 
insulin on glucose production, and (iii) PAMN-treatment lowered basal glucose 
production to the same level as observed in insulin suppressed vehicle-treated cells 
(p=0.1308). These findings are summarised below in Fig. 3.2. 
 
 
FIGURE 3.2: Glucose production for selected microarray samples. 
Basal (black bars) and 0.1 nM insulin stimulated (white bars) glucose production 
following vehicle-, PA- or PAMN-treatment for 48 h. Vehicle treated, basal glucose 
production was equal to 33.05 ± 2.52 μg glucose / mg protein. Data are expressed 
as mean ± SEM. *p<0.05 for basal PA-treated cells when compared with basal 
vehicle-treated cells. †p<0.05 for basal PAMN-treated cells when compared with 
basal PA-treated cells. ††p<0.05 for insulin stimulated cells when compared with 
each individual treatments basal treated cells. Average of 5 experiments performed 
in triplicate. 
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3.2.2. RNA extractions and microarrays 
Total RNA was extracted from FAO cells treated with VEH (n=8), PA (n=20) or PAMN 
(n=20) using TRIzol reagent (Invitrogen), and purified using RNeasy Mini Kit columns 
(Qiagen, Mannhiem, Germany) as per manufacturer’s instructions. Quality and 
quantity of the purified RNA was determined using the Agilent 2100 Bioanalyser 
(Agilent Technologies, Palo Alto, CA, USA) and RNA 6000 Nano Assay Kit (Agilent, 
Melbourne, Australia). Fluorescently labelled cDNA was prepared from 800 ng of 
total RNA using Agilent Quick Amp Labeling Kit (5190-0424) and Agilent One Color 
RNA Spike-In Kit (5188-5282), as per manufacturer’s instructions. The cyanine 3-CTP 
labelled cDNA was hybridised for 17 h to Agilent Whole Rat Genome (4x44k) Oligo 
Microarray Slides (G4131F) using Agilent Gene Expression Hybridisation Kit (5188-
5242) as per manufacturer’s instructions. Fluorescent images of microarrays were 
acquired using GenePix 4000B scanner, with data extraction performed via GenePix 
5.1 software (Molecular Devices, Melbourne). 
 
Normalisation and primary analysis of microarray data was performed using Acuity 
4 software (Molecular Devices) as previously described [212]. Briefly, the 
fluorescent reading for all duplicate genes were averaged, leaving 37,047 unique 
array gene identification numbers. Of those, 14,098 genes were detected in each 
sample (n=20 for PA and PAMN, n=8 for vehicle). Each array dataset sample was 
normalised so that the median expression value in each array was 1.0. The average 
%CV for vehicle-treated cells was 39%, for PA-treated cells was 34% and for PAMN-
treated cells was 31%. The %CV values for the internal Agilent SpikeIn controls in 
the linear range for long(signal) against log(relative concentration) were 10% for 
vehicle, 8% for palmitate and 7% for PAMN. The low relative %CV values for the 
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internal controls indicates technical proficiency with the microarray 
experimentation, and the variation observed in sample data is mostly due to inter-
sample biological variation, rather than lack of technical proficiency. Genes were 
selected for further analysis if they were detected in at least 5 vehicle, 15 PA and 15 
PAMN samples, of which 16,276 genes fulfilled the selection criteria. 
 
3.2.3. Diagonal Linear Discriminate Analysis (DLDA) for  
identification of GES genes 
To identify a small subset of genes that best discriminate between PA- and PAMN-
treated cells, DLDA was performed using Acuity 4 software [138, 141]. DLDA was 
performed on the entire normalised data set to select the subset of genes that best 
discriminated between PA- and PAMN-treated cells. The selected genes best 
characterised the reversal of the effect of PA-treatment on glucose production, 
rather than any unrelated effects of the metformin and sodium salicylate treatment 
alone. Therefore, the DLDA algorithm required genes which were significantly 
different between vehicle- and PA-treated cells (nominal p<0.05), while also being 
significantly different between PA- and PAMN-treated cells (nominal p<0.05). There 
was no requirement for difference in gene expression levels between vehicle and 
PAMN-treated cells. Of the 450 genes that showed evidence for significant 
difference between vehicle- and PA-treated cells, only 75 of these genes were also 
significantly different between PA- and PAMN-treated cells. The DLDA algorithm 
then utilised a forward step-wise variable selection process to identify the minimum 
subset of genes that had the most power to distinguish between both vehicle- and 
PA-treated, and also between PA- and PAMN-treated cells in the microarray data. 
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Fourteen genes were identified via the DLDA algorithm, of which 7 were able to be 
mapped to known genes using BLAST database analysis. 
 
3.2.4. RNA extractions and RT-PCR validation of GES genes 
Total RNA was extracted and quantified from a randomly selected subset of 
samples used in microarray analysis treated with vehicle (n=4), PA (n=4) or PAMN 
(n=4) (technical replicates) and an alternative set of vehicle- (n=6), PA- (n=6) and 
PAMN- (n=6) treated FAO cells (biological replicates). 1 μg of sample RNA in 10 μL 
nuclease free water (NFW) was added to 1 μL dNTP mix (10 mM) and 1 μL oligo(dT) 
primer (0.5 μg/μL), then incubated at 65OC for 5 min, placed on ice for 2 min and 
briefly centrifuged. To each sample was added 5 μL of 5 x reverse transcription 
buffer, 2 μL DTT (0.1 M), 1 μL RnaseOUT (40 U/μL), 0.25 μL Superscript III reverse 
transcription enzyme (200 U/μL) and 0.75 μL NFW. Samples were then heated to 
50OC for 50 min, followed by 5 min at 85OC and finally cooled to 4OC. Samples were 
diluted 1:10 in NFW and stored at -80 prior to use. 
 
Gene expression was analyzed by semiquantitative real-time PCR (RT-PCR) using 
Brilliant SYBR Master Mix (Stratagene, La Jolla, CA) on the MX3005P QPCR system 
(Stratagene). Validation was performed on the same RNA used for microarray 
(technical replication) as well as alternative sets of treated samples (biological 
replication). The RT-PCR conditions were 95°C for 10 min and 40 cycles of 95°C for 
30 s and 60°C for 1 min. Relative gene expression was calculated as 2-ΔCt, where Ct is 
threshold cycle. RT-PCR results were normalised to cDNA concentration, measured 
using Quant-iT Oligreen ssDNA Assay Kit (Invitrogen), as per manufacturer’s 
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instructions. Table 3.1 displays the list of primer sequences. All primers were 
designed using Beacon Designer 7.2 (Premier Biosoft International, CA, USA).  
 
TABLE 3.1: Primer sequences for RT-PCR analysis of the seven target 
genes identified through DLDA. 
Gene 
Name 
NCBI Ref. No. Forward Primer Reverse Primer 
Anxa3 NM_012823 GGAGGAGATGATTGAAGAAGATG CATTCGCTTGCCCATTGC 
Slc2a2 NM_012879 CTGGTCTCTGTCTGTGTC TCCTGATACGCTTCTTCC 
Gstm3 NM_020540 GACACTTTGGAGAACCAG GACTTCAAGAACTCTGGC 
Pla2g1b NM_031585 GAGGGAGTACAACAACTACG CTGATTGTAGCAGTGGTC 
Rab33a NM_001108257 GAGACATCAGCCAAGGAC GCATCACGGTACAAGAGG 
Serpina5 NM_022957 TGCTCCAAGGTCCTATCAC CAGAATCTCAGTCCAATGTCC 
Snn NM_001034083 CTGGCTTGGATGTGTTAG GTCAGTGGATGGTAGAGG 
Anxa3, annexin a3/LC3, lipocortin 3; Slc2a2, solute carrier family 2 (facilitated 
glucose transporter), member 2/GLUT2, Glucose transporter 2; Gstm3, glutathione 
S-transferase mu 3; Pla2g1b, phospholipase A2, group IB; Rab33a, RAB33A, member 
RAS oncogene family; Serpina5, serpin peptidase inhibitor, clade A, member 5; Snn, 
stannin. 
 
3.2.5. Statistical analysis 
Statistical analysis was performed using Statistical Package for the Social Sciences 
(SPSS) version 20.0 (IBM). Data were first analysed for normality of distribution 
using a one-sample Kolmogorov-Smirnov test. Data were then either analysed using 
independent samples Students T-test, or a one-way ANOVA. Homogeneity of 
variance was determined using Levene’s Test, and post-hoc analysis of ANOVA used 
either Fisher’s least significant difference (LSD, for homogeneous variance) or 
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Games-Howell (for non-homogeneous variance). Preliminary correlations between 
gene expression data and human phenotype data [141] were determined via 
Pearson correlation for normally distributed data, or Spearman for non-normally 
distributed data sets. Where a preliminary correlation was found, Liner Regression 
analysis was performed to confirm whether an association was independent of age, 
sex and BMI. Data were considered significant at p<0.05. 
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3.3. Results 
 
3.3.1. DLDA identified the most discriminating genes between PA- 
and PAMN-treated cells 
From the 450 genes that were identified in the microarray data as differentially 
expressed between vehicle- and PA-treated cells, 75 of these were also 
differentially expressed between PA- and PAMN-treated cells. DLDA identified 14 
genes from the microarray data that best discriminated between PA- and PAMN-
treated cells (Table 3.2). Of the 14 genes, only the genes that could be mapped to 
the rat genome were chosen for further analysis. This was achieved via the Basic 
Local Alignment Search Tool (BLAST: http://blast.ncbi.nlm.nih.gov/) as two separate 
searches: against all Rattus norvegicus genes and against all reference RNA 
sequences optimized for highly similar sequences. There were 6 sequences from the 
microarray data identified with 60mer microarray sequences which could not be 
mapped to known Rattus norvegicus genes - AA998612, DY472907, TC628671, 
TC641785, TC612212, TC603506. Of the remaining 8 genes, one was a predicted 
sequence duplicate of Pla2g1b, RDG1560824_predicted phospholipase A2 
precursor, which was not carried forward, due to there being no sequence 
homology to any Rattus norvegicus gene for the 60mer sequence from the 
microarray. The 60mer sequences from the Agilent 4x44k microarray chips for all 14 
identified genes are detailed in Appendix 3. 
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TABLE 3.2: Genes identified via DLDA as discriminating between PA- and PAMN-treated cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anxa3, annexin a3/LC3, lipocortin 3; Gstm3, glutathione S-transferase mu 3; Pla2g1b, phospholipase A2, group IB; Rab33a, RAB33A, member RAS 
oncogene family; Serpina5, serpin peptidase inhibitor, clade A, member 5/PCI, protein c inhibitor; Slc2a2, solute carrier family 2 (facilitated glucose 
transporter), member 2/GLUT2, Glucose transporter 2; Snn, stannin. 
Gene Name Reference Gene ID Description 
Anxa3 NM_012823 Annexin A3 
Gstm3 NM_020540 Glutathione S-transferase M3 
Pla2g1b NM_031585 Phospholipase A2, group IB 
Rab33a NM_001108257 Member of RAS oncogene family 
RGD1560824_predicted XR_007343 PREDICTED: Rattus norvegicus similar to 
Phospholipase A2 precursor 
Serpina5 NM_022957 Serine peptidase inhibitor A5 
Slc2a2 NM_012879 Solute carrier family 2 (facilitated glucose 
 transporter), member 2 (GLUT2) 
Snn NM_001034083 Stannin 
AA998612 TC590201 Rattus norvegicus cDNA clone 
DY472907 FQ217834 RVL24274 Wackym-Soares normalized rat 
vestibular cDNA library Rattus norvegicus cDNA 5' 
TC603506 TC603506 Q4TA41_TETNG (Q4TA41) Chromosome undetermined SCAF7452, whole genome shotgun 
sequence.(Fragment), partial (4%) 
TC612212 TC612212 Unknown 
TC628671 TC628671 Unknown 
TC641785 TC641785 Q5PR95_BRARE (Q5PR95) Zgc:101855, partial (5%) 
   Chapter 3: Identification of candidate GES genes 
98 
 
Following the removal of duplicate genes and genes that were non-homologous to 
any currently identified Rattus norvegicus genes (as described above), the 7 
remaining genes were Rab33a, Serpina5, Anxa3, Pla2g1b, Slc2a2 (GLUT2), Snn and 
Gstm3. The relative expression levels for each of these genes as determined in the 
microarray dataset are shown in Fig. 3.3. 
 
 
FIGURE 3.3: Candidate gene expression levels as measured via microarray 
analysis. 
Relative gene expression levels as measured via microarray analysis between 
vehicle- (black), PA- (grey) and PAMN- (white) treated cells for the seven genes 
identified via DLDA. The expression levels of all seven genes were altered with PA-
treatment, while PAMN-treatment reversed this change. Data are expressed as 
mean ± SEM, n=8 for vehicle, n=20 for PA and PAMN, *p<0.05 versus vehicle-
treated, †p<0.05 versus PA-treated gene expression levels.  
 
Out of the seven genes, the mRNA levels of five genes were decreased with PA-
treatment and restored, or in some instances further enhanced compared with 
vehicle-treated cells, by PAMN-treatment. Serpina5 is a serine protease inhibitor 
that can inactivate multiple anti-coagulant and fibrinolytic enzymes [213]. Serpina5 
   Chapter 3: Identification of candidate GES genes 
99 
 
gene expression levels were decreased with PA-treatment by -41 ± 5% (p=0.0054 
compared with vehicle), and increased with PAMN-treatment by +15 ± 4% 
(p=0.0226 compared with PA-treated), but remained lower than vehicle-treated 
cells (p=0.0477). Pla2g1b catalyses the breakdown of glycero-3-phosphocholines to 
individual fatty acids, and Pla2g1b inactivation has been shown to be protective 
against diet-induced obesity, hyperglycaemia and hyperlipidaemia in mice [214]. 
Pla2g1b gene expression levels were decreased with PA-treatment by -14 ± 2 % 
(p=0.0142 compared with vehicle), and this change in expression was reversed with 
PAMN-treatment by +33 ± 2% (p=1.1x10-9 compared with PA-treated), which 
elevated gene expression levels higher than vehicle-treated cells (p=0.0026). 
 
Slc2a2, also known as GLUT2, is a low affinity glucose transport protein enriched in 
the liver and kidney [215]. Slc2a2 mRNA levels were decreased by -19 ± 2% by PA 
(p=0.0149 compared with vehicle), and increased by +17 ± 3% following PAMN-
treatment (p=0.0035 compared with PA-treated). Treatment with PAMN returned 
Slc2a2 mRNA levels to the same level as measured in vehicle-treated cells. Snn is a 
transmembrane protein that binds trimethyltin and activates apoptotic cascades, 
and has been demonstrated to mediate tissue specific sensitivity to organotins 
[216]. Snn mRNA levels following PA-treatment were decreased by -28 ± 5% 
(p=0.0206 compared with vehicle), and following PAMN-treatment increased by +23 
± 5% (p=0.0022), returning to the same level as in vehicle-treated cells. Gstm3 is a 
cytoplasmic glutathione-s-transferase subunit, which interacts with glutathione to 
detoxify numerous toxins, and has been shown to be decreased in rodent models of 
hyperglycaemia [217]. Gstm3 gene expression levels following PA-treatment were 
decreased by -29 ± 5% (p=0.0159 compared with vehicle), and following PAMN-
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treatment were increased by +81 ± 4% (p=3.3x10-7 compared with PA-treated), 
increasing gene expression levels above vehicle-treated cells (p=0.0004). 
 
Two out of the potential seven GES genes increased with PA-treatment and in turn 
were decreased following PAMN-treatment. Rab33a is a member of the small GTP-
binding protein family which play a role in intracellular vesicular transport [218]. 
The mRNA levels of Rab33a increased by +18 ± 4% with PA-treatment (p=0.0413 
compared with vehicle), while following PAMN-treatment, Rab33a decreased by -33 
± 4% (p=1.0x10-6 compared with PA-treated) to similar levels as measured in the 
vehicle-treated cells. Anxa3 is a member of a calcium-dependant phospholipid-
binding protein family, which inhibits the action of phospholipase A2 family 
members [219]. Anxa3 mRNA levels increased with PA-treatment by +91 ± 14% 
(p=0.0099 compared with vehicle). Following PAMN-treatment, Anxa3 expression 
decreased by -48 ± 12% (p=0.0115 compared with PA-treated), restoring gene 
expression to the same levels as measured in the vehicle-treated cells. 
 
3.3.2. Validation of the potential PA-based GES genes using RT-PCR 
The potential GES genes were validated using RT-PCR in technical replicates to 
confirm the microarray results with an alternative technology, as well as in 
biological replicates to establish the reproducibility of the microarray results (Fig. 
3.4). Of the genes that decreased with PA-treatment in the microarray data, and 
were increased (restored) with PAMN-treatment (Serpina5, Pla2g1b, Slc2a2, Snn 
and Gstm3), none were validated in either the technical replicates or biological 
replicates via RT-PCR analysis (Fig. 3.4 a). PA-treatment did not significantly alter the 
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expression levels of any of these genes. The only genes to show a similar expression 
profile to the microarray data were Serpina5 and Pla2g1b, however these changes 
were not significant across both validation experiments. In contrast to the 
microarray data, the gene expression of Gstm3 following PAMN-treatment was 
decreased (-55 ± 9%, p=0.0331) compared with PA-treated cells (Fig. 3.4 b). 
 
Similarly, of the genes which were increased with PA-treatment and lowered 
(restored) with PAMN-treatment (Rab33a and Anxa3), neither were validated in 
either the technical or biological replicate samples. Rab33a gene expression 
changed in direct contrast to the observed trends measured in the microarray data, 
while the expression changes to Anxa3 in response to PA-treatment were only 
observed in the technical replicates and were not reproduced in the biological 
replicate samples (Fig. 3.4 a-b). 
 
In summary, the gene expression levels of Rab33a and Gstm3 in both RT-PCR 
validation experiments were opposite to the gene expression levels observed in the 
original microarray data, and as such they were not carried forward for further 
experimentation. The gene expression levels of Slc2a2 and Snn were not 
significantly altered in the validation experiments in response to either PA- or 
PAMN-treatment. Therefore, Slc2a2 and Snn were not validated, and not carried 
forward for further experimentation. The trends for gene expression changes for 
Serpina5, Anxa3 and Pla2g1b were consistent with the changes observed in the 
original microarray data, however one or more of the statistical differences 
observed in the original analysis were not replicated by RT-PCR. This may have been 
due to the larger sample size in the original microarray experiments (n= 8 for 
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vehicle, and n=20 for PA and PAMN) compared with the validation experiments 
(n=4 for the microarray samples, n=6 for the biological replicate samples). In the 
absence of genes with full validation in both the technical and biological replicates, 
the generation of a GES in this model was unsuccessful using DLDA. Further analysis 
of the microarray dataset is currently ongoing using a Bayesian modelling approach 
to identify an increased number of candidate genes to be validated. This modelling 
has been recently completed by our collaborators (Professor John Blangero, Dr. 
Tom Dyer, Dr Marcio Almeida and Dr. Joanne Curran at Texas Biomedical Research 
Institute, San Antonio), and validation of these genes is a future direction for this 
study. 
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FIGURE 3.4: Candidate GES gene expression levels as measured via RT-
PCR. 
Relative gene expression levels measured via RT-PCR of either a random subset of 
samples used for microarray analysis (technical replicates) (a) or a separate set of 
biological replicate samples (b). Gene expression levels shown between vehicle- 
(black), PA- (grey) and PAMN- (white) treated cells for the seven genes identified via 
DLDA. Data are expressed as mean ± SEM, (a) n=4 or (b) n=6, *p<0.05 versus vehicle 
gene expression levels, †p<0.05 versus PA-treated gene expression levels.  
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3.3.3. Human phenotypic profiling of the candidate gene Anxa3 
In the absence of any fully validated genes from the GES candidates identified 
through DLDA, the genes Serpina5, Anxa3 and Pla2g1b were considered as potential 
candidates for phenotype analysis in a human dataset, as they showed similar 
trends for gene expression between RT-PCR and microarray data, however this was 
not consistently different in all data sets. Data from the San Antonio Family Heart 
Study (SAFHS, [150]) was mined for each of the three candidate genes Serpina5, 
Anxa3 and Pla2g1b as proof of principle to determine whether any correlations 
between human gene expression data and a series of phenotypes relevant to the 
metabolic syndrome could be determined. Of the three candidate genes, only 
Anxa3 was detected in the human lymphocyte expression data from the SAFHS. The 
correlation data is summarised in Table 3.3 below. 
 
TABLE 3.3: Correlations between Anxa3 gene expression levels and 
phenotypes linked with the metabolic syndrome in the SAHFS (n = 1240).  
Phenotype Correlation 
Coefficient 
(r) 
Significance 
(2-tailed) 
N 
HOMA-β -0.008 0.791 1223 
HOMA-IR -0.015 0.603 1223 
Total Serum Cholesterol (mM) 0.035 0.225 1237 
HDL Cholesterol (mM) -0.020 0.492 1236 
Total Serum Triglyceride 0.069 0.015* 1237 
Fasting Glucose (mM) -0.066 0.033* 1051 
Fasting Insulin -0.007 0.818 1035 
BMI (kg/m2) 0.026 0.368 1224 
Waist Circumference -0.002 0.950 706 
Anxa3, annexin a3/LC3, lipocortin 3; HOMA-β, homeostatic model assessment – 
beta cell function; HOMA-IR, homeostatic model assessment – insulin resistance; 
HDL, high-density lipoprotein; BMI, body mass index. *p<0.05. 
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No correlation was found between Anxa3 gene expression levels and either of the 
HOMA scores for insulin and glucose homeostasis, HOMA-β and HOMA-IR. Related 
to this, there was no correlation between Anxa3 mRNA levels and fasting circulating 
insulin levels. However, there was a significant negative correlation (-0.066, 
p=0.033, Table 3.3) between fasting plasma glucose levels and Anxa3 mRNA levels. 
There was also a positive correlation (0.069, p=0.015, Table 5.3) between total 
serum triglyceride and Anxa3 gene expression levels. This correlation is in 
agreement with the significant increase in triglyceride levels observed in PA-treated 
FAO cells (Chapter 5). Linear regression analysis was performed, and when adjusted 
for age, sex and BMI, Anxa3 was not an independent predictor of either fasting 
plasma glucose or total serum triglyceride (data not shown). 
 
 
 
 
 
   Chapter 3: Identification of candidate GES genes 
106 
 
3.4. Discussion 
The initial aim of this chapter was the collection of a global gene expression profile 
for PA-induced insulin resistance and dysregulation of glucose production, alongside 
the reversal of the high glucose production with PAMN treatment. There were 
16,276 genes that passed quality control measures following normalisation of the 
data. The gene expression data will be used for further analysis in Chapter 4 (of 
regulated signalling and metabolic gene networks). Therefore the first aim of this 
chapter has been successfully completed - the measurement of whole genome 
transcriptional changes between vehicle, PA and PAMN-treated cells. 
 
While many studies have investigated in vitro and in vivo gene expression in 
response to elevated fatty acids or obesity (see Chapter 4 for further discussion), 
our laboratory is unaware of any studies using this data for the generation of a GES 
as performed in this study. Unfortunately, the putative GES genes identified in this 
study were unable to be validated in vitro, and as such the identity of a PA-based 
hepatic GES remains unresolved at this stage. 
 
Due to the identification of only 14 genes via DLDA, and the inability to validate any 
of those gene expression changes in the technical and biological replicate samples, 
the secondary aim of this chapter to identify a GES has not been successfully 
completed. Despite this outcome, there remains significant utility for the 
microarray dataset detailed in this thesis for future study. Firstly, the use of 
Bayesian statistical modelling to compare the discriminating power of all possible 
gene combinations from the microarray data [147] will lead to the identification of a 
greater number of candidate GES genes. This approach will therefore maximise the 
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chances of identification of a subset of GES genes that are able to be validated in 
both the technical and biological replicate samples, as well as being expressed in 
human lymphocytes (analysis currently in progress). This approach has been utilised 
previously in the successful development of a TNFα-induced insulin resistance GES 
by our laboratory [141]. In this previous study, Bayesian modelling identified 20 
different GESs, comprising a total of 20 genes. The low validation rate described in 
this chapter may be due to a number of factors. Numerous studies have reported 
significant variation between microarray and RT-PCR data when the measured gene 
expression changes are less than 2-fold [220-222], as was the case for all of the 
microarray data in this study. Studies have also found that increased distance 
between the PCR primer location and microarray probe location lead to a reduction 
in correlation between the two data sets [221]. Therefore, designing RT-PCR 
primers closer to the microarray oligonucleotide sequences may improve the 
correlation between the two techniques. A number of studies have also noted 
higher correlation between microarray and RT-PCR datasets for up-regulated genes, 
as a consequence of increased variability in the lower-intensity array spots for 
down-regulated genes [223, 224]. Given that five of the seven candidate genes in 
this study were down-regulated with PA-treatment, this may in part explain the 
poor correlation between the microarray and RT-PCR data. 
 
As an alternative to the gene expression based signatures, lipidomic, metabolomic 
and proteomic-based approaches have been successfully employed for other 
diseases. A metabolic signature for Alzheimer’s disease has been developed in 
human plasma from a subset of known signalling proteins [225]. One recent study 
has described plasma amino acid based signatures which alter with both age and 
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progression of a prediabetic state in dominant-negative glucose-dependant 
insulinotropic polypeptide receptor (GIPRdn) transgenic pigs [226]. The same study 
also profiled plasma lipids and described altered plasma concentrations for a 
number of lipid species which correlated with glucose tolerance, insulin secretion 
and total β-cell volume [226]. Given that the lipidomic profiling of FAO hepatoma 
cells has already been completed in this study (see Chapter 5), it would be possible 
to generate a lipid-based signature with the current data. This approach poses 
increased technical challenges in patient or compound screening due to the 
increased complexity for sample preparation and analysis. Despite this limitation, 
future technical advances in the measurement of these metabolites via mass 
spectroscopy or alternative technologies such as nuclear magnetic resonance 
(NMR) spectroscopy may make this approach viable.  
 
The first aim of this chapter – to utilise microarray analysis to identify the whole 
genome expression profile of FAO hepatoma cells in response to PA and PAMN 
treatment was successfully completed, and this dataset will be further utilised in 
Chapter 4. The second aim of Chapter 3 – the identification and validation of 
putative GES genes was only partially completed. Seven candidate GES genes were 
identified using DLDA, however none of the putative GES genes were validated in 
the technical or biological replicates. As a consequence of this, the tertiary aim of 
the chapter was completed as proof of principle, using the one gene (Anxa3) which 
followed the same trends in the technical and biological replicate data and was 
present in the SAFHS human lymphocyte dataset. The gene expression of Anxa3 
was confirmed in the human lymphocytes, and found to be negatively correlated 
with fasting glucose, however this was not an independent association when 
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adjusted for age, sex or BMI. Neither BMI or waist circumference were found to be 
correlated with Anxa3 expression, an interesting observation given that the gene 
was identified in a model of hyperlipidemia-induced glucose dysregulation. 
 
Given the changes in gene expression levels associated with metabolism of 
cholesterol discussed in Chapter 4, it was of particular interest to determine 
whether Anxa3 gene expression was correlated with both total serum cholesterol 
and HDL-cholesterol. However, there was no significant correlation between Anxa3 
gene expression and either total serum cholesterol or HDL-cholesterol in the SAFHS 
cohort. A weak positive correlation between total serum triglyceride and Anxa3 
gene expression was found, however this association was not independent of age, 
sex and BMI. 
 
The role of Anxa3 gene expression in insulin resistance and obesity can be 
established via its interaction with another of the candidate genes – Pla2g1b. Anxa3 
has been shown to inhibit the activity of phospholipase proteins [219]. 
Phospholipases, specifically Pla2g1b, have been implicated in obesity-related insulin 
resistance in numerous animal models. In addition, studies in human patients have 
shown evidence of an association between SNPs in PLA2G1B and central fat mass 
[227]. Pla2g1b-/- mice, have been shown to have lower postprandial glycaemia 
compared with wild type controls. This is due to increased postprandial glucose 
uptake in the liver, heart and muscle tissues. It was shown that Pla2g1b-mediated 
lysophospholipid absorption contributes to this postprandial hyperglycaemia [228], 
as intraperitoneal injections of lysophosholipids ablated the increased glucose 
uptake effects observed in Pla2g1b-/- mice. Lysophospholipid species have been 
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shown to suppress hepatic fatty acid oxidation [229], and have been shown to 
suppress insulin-stimulated hepatic glycogen synthesis in vitro. In contrast, Pla2g1b-
/- mice exhibit increased postprandial hepatic fat oxidation, through increased gene 
expression levels of PPARα, PPARδ, PPARγ and mitochondrial uncoupling protein 2 
(Ucp2) [229]. Protection against diet-induced hyperlipidemia [214], obesity and 
obesity-driven insulin resistance [230] in Pla2g1b-/- mice have all been described. It 
is therefore the effects of Pla2g1b on downstream control of hepatic fatty acid 
oxidation that are responsible for its effects on glucose metabolism in these mice. 
 
Further, Pla2g1b has been successfully pharmacologically targeted. High-fat fed 
mice treated with the Pla2g1b inhibitor methyl indoxam were protected from 
developing diet-induced obesity and glucose intolerance, and this was correlated 
with a decrease in postprandial lysophospholipid absorption [231]. The effects of 
Pla2g1b appear to be closely related to its role in the digestive tract, as 
overexpression of Pla2g1b in pancreatic acinar cells has been shown to exacerbate 
diet-induced obesity and insulin resistance in rodent models [232]. Therefore, it 
may be that reducing Pla2g1b activity proximal to the digestive tract is a viable 
mediator for its role in lysophospholipid absorption. 
 
In summary, the development of a PA-based GES was unsuccessful in this study. 
However, despite a non-biased approach to find candidate genes, two mediators of 
hepatic lipid oxidation and glucose metabolism were identified (Anxa3 and Pla2g1b) 
proved the value of this approach. It is therefore possible that with further study 
this approach could be successful in identifying additional novel mediators of 
glucose metabolism. 
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Chapter 4 – Global gene expression profiling of PA-
induced dysregulation of hepatic glucose 
production, and restoration with metformin and 
sodium salicylate 
 
4.1. Introduction 
Gene set enrichment analysis (GSEA) is a computational software package which 
can be used to determine whether specific gene sets (grouped on functional 
similarity), are overrepresented in a given set of differentially expressed genes 
between two biological states or tissues. GSEA can therefore be used to indicate 
whether a correlation exists between differential expression of a specific set of 
genes (pathway), and the phenotype being investigated [127, 128]. The main 
advantage of the GSEA approach is that it simplifies often highly complex data sets 
into more biologically relevant information [127]. By grouping genes according to 
their biological function, gene expression changes which may appear minimal at the 
level of a single gene can become significant when viewed as part of the wider 
regulation of a larger signalling or metabolic network. Further, it is now becoming 
apparent that another advantage of the GSEA approach to classifying disease 
includes improved reproducibility across samples sets compared with individual 
markers of disease [233]. This approach has been successfully applied to the 
classification of tumour subtypes, and therefore has the potential to accurately 
guide treatment selection compared with single marker identification. 
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There have been relatively few studies investigating changes to whole genome 
expression in the face of hyperlipidaemia-induced dysregulation of glucose 
production in the liver [234, 235], and there are no published studies to date 
reporting on both the induction and reversal of such a state. This study will 
therefore provide a novel insight into the transcriptional changes accompanying 
dysregulated glucose production, as well as successful treatment of such a 
phenotype. Therefore, the aim of this chapter was to perform GSEA on the 
microarray data collected in Chapter 3 to determine the regulation of metabolic 
and signalling pathways at the whole genome level. 
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4.2. Methods 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4.1: Flowchart for identification of regulated pathway using 
DAVID.  
Flowchart of methodology from collection of RNA samples for microarrays, through 
to data analysis and GSEA using Database for Annotation, Visualization and 
Integrated Discovery (DAVID) software package. 
 
 
4.2.1. Gene Set Enrichment Analysis (GSEA) using DAVID  
Selection criteria for samples to undergo microarray analysis, RNA extraction and 
microarray analysis was performed as described in Chapter 3. Paired t-tests were 
used to identify genes, from the normalised microarray data, with evidence of 
differential expression between vehicle- and PA-treated cells (450 genes with 
nominal p<0.05), as well as between PA- and PAMN-treated cells (1434 genes with 
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nominal p<0.05). The complete gene lists of putative differentially expressed genes 
were then imported into the online Database for Annotation, Visualization and 
Integrated Discovery (DAVID) software package v6.7 [236, 237]. Using the 
functional annotation tools, the data was analysed to determine enrichment values 
for defined Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways. 
Pathways were selected based on significant enrichment using Fisher exact 
statistical analysis (p<0.05). Pathway data was expressed as a percentage change 
from vehicle- to PA-treated cells, or from PA- to PAMN-treated cells. All data was 
expressed as mean ± SEM. 
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4.3. Results 
 
4.3.1. Gene pathways induced with PA-mediated dysregulation of 
glucose production 
Microarray analysis identified 450 genes with evidence for differential expression 
between vehicle- and PA-treated cells (nominal p<0.05). This set of 450 genes were 
assessed by DAVID to provide an unbiased approach to rank the global gene 
expression data into pathways of biological significance by identifying groups of 
genes that are enriched and functionally related. The GSEA analysis of vehicle- 
versus PA-treated cells identified 17 pathways (nominal p<0.05) involved in a range 
of processes including cell cycle regulation, cancer progression, and inositol 
phosphate metabolism (Table 4.1). All gene expression levels in this section are 
reported as the percentage change in PA-treated cells compared with vehicle-
treated cells. All pathways identified as being differentially expressed between 
vehicle- and PA-treated cells are represented alongside relevant changes in gene 
expression in Appendix 4. 
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TABLE 4.1:  Pathways identified as significantly overrepresented in the list 
of differentially expressed genes between vehicle- and PA-treated cells. 
 Number of differentially expressed genes in pathway expressed as: number of 
differentially expressed genes from KEGG pathway identified in array data/total 
number of genes in defined KEGG pathway; Fold enrichment quantifies the 
overrepresentation of a specific KEGG pathway in the differentially expressed genes 
identified in microarray data. GnRH, gonadotropin-releasing hormone; NOD, 
Nucleotide-oligomerization domain. These pathways are represented along with 
changes in gene expression in Appendix 4. 
 
 
Defined KEGG Pathway Number of 
differentially 
expressed 
genes in 
pathway 
Fold 
Enrichment 
Fisher 
Exact 
p-value 
Cell cycle 8 / 126 4.9 1.9E-4 
Oocyte meiosis 6 / 111 4.2 2.9E-3 
Toll-like receptor signalling pathway 5 / 90 4.3 5.8E-3 
Renal cell carcinoma 4 / 69 4.5 1.2E-2 
Leukocyte transendothelial migration 5 / 115 3.4 1.6E-2 
Colorectal cancer 4 / 81 3.8 2.0E-2 
Neutrophin signalling pathway 5 / 126 3.1 2.3E-2 
Progesterone-mediated oocyte  maturation 4 / 87 3.6 2.5E-2 
Antigen processing and presentation 4 / 88 3.5 2.6E-2 
Prostate cancer 4 / 90 3.5 2.8E-2 
Inositol phosphate metabolism 3 / 52 4.5 2.9E-2 
Melanogenesis 4 / 92 3.4 3.0E-2 
GnRH signalling pathway 4 / 94 3.3 3.2E-2 
RNA degradation 3 / 57 4.1 3.7E-2 
Wnt signalling pathway 5 / 145 2.7 3.8E-2 
Focal adhesion 6 / 195 2.4 3.9E-2 
NOD-like receptor signalling pathway 3 / 62 3.8 4.5E-2 
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4.3.1.1. Gene set enrichment analysis between vehicle- and PA-
treated FAO cells identified multiple regulatory pathways in cell cycle 
regulation 
Common to nine of the 17 pathways regulated with PA-treatment is the theme of 
cell cycle, proliferation and cancer progression. Pathways involved in cell cycle 
regulation include cell cycle, oocyte meiosis, neutrophin signalling pathway, 
progesterone mediated oocyte maturation, Wnt signalling pathway and focal 
adhesion. Overall, there was a consistent down-regulation of genes involved in the 
progression of the cell cycle pathway (see Appendix 4). 
 
In addition to direct control of the cell cycle, growth and proliferative signalling was 
a common theme amongst the above pathways. The neutrophin signalling pathway, 
focal adhesion pathway, toll-like receptor signalling pathway, renal cell carcinoma, 
leukocyte transendothelial migration, colorectal cancer and prostate cancer all 
contained a central signalling network including members of proliferative (and 
insulin-induced) signalling cascades such as phosphoinositide-3-kinase regulatory 
subunit 3 gamma (Pik3r3, -35 ± 3%, nominal p=0.0382) and its downstream target 
catenin beta 1 (Ctnnb1, -21 ± 5%, nominal p=0.0404) which together regulate cell 
growth, and cellular adhesion through anchoring the cytoskeleton [238, 239].  
 
The largest increase in gene expression common to these pathways were both Fos 
(+124 ± 52%, nominal p=0.0389) and Jun (+119 ± 27%, nominal p=0.0007), 
downstream of the stress kinase JNK, which form the transcription complex AP-1 – a 
regulator of both cell cycle and apoptotic signalling genes. The decrease in Jun 
expression was also common to the gonadotropin-releasing hormone signalling 
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pathway, which contains genes regulating the synthesis and release of glycoprotein 
hormones from the pituitary, as well as the toll-like receptor signalling pathway. 
 
In summary, both the cell cycle and cancer pathways were negatively regulated in 
their control of normal cell proliferative mechanisms following PA-treatment, and 
positively regulated in their control of apoptotic signalling. This may in part explain 
the decrease observed in cellular viability and the increased cellular cytotoxicity 
(see Chapter 2) observed with PA-treatment. The negative regulation of normal cell 
proliferative signalling along with the increased apoptotic signalling support this 
conclusion, however as neither of these factors have been directly measured it is 
currently unclear whether this was due to decreased proliferation or increased 
apoptosis, or a combination of the two factors. 
  
4.3.1.2. Gene set enrichment analysis between vehicle and PA-
treated FAO cells identified multiple regulatory pathways in immune 
function and inflammation 
Four pathways with defined roles in immune function and inflammation were 
identified as being significantly regulated following PA-treatment - the toll-like 
receptor signalling pathway, leukocyte transendothelial migration, antigen 
processing and presentation and nucleotide-oligomerization domain (NOD) -like 
receptor signalling pathway. Common to these pathways are inducers of 
inflammatory cytokines including signalling members Fos and Jun (see above) as 
well as inflammasome mediators cytosolic heat shock protein of 90 kDa alpha class 
B, member 1 (Hspcb, -17 ± 4%, nominal p=0.0484), and Erbb2 interacting protein 
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(Ebin, -30 ± 4%, nominal p=0.0361), which is upstream of a number of mediators of 
apoptosis (incuding Caspase 8) and proinflammatory cytokine production (JNK and 
NF-kB). The combined data from these pathways indicates an inflammatory 
response to PA-treatment in these cells. 
 
4.3.1.3. Gene set enrichment analysis between vehicle and PA-
treated FAO cells identified regulation of inositol phosphate 
metabolic pathways 
Due to their roles as key molecules in the insulin signal transduction pathway, 
regulation of phosphatidyl inositols through the inositol phosphate metabolism 
pathway is of specific interest and relevance to the observed dysregulation of the 
insulin endpoint action of glucose production in this model. The mRNA levels of the 
PIP3 generating inositolphosphate multikinase (Ipmk [240]) was decreased with PA-
treatment (-29 ± 5%, nominal p=0.0197). Additionally the gene expression levels of 
the enzyme responsible for the removal of 1,2-diacylglycerols from the inositol 
phosphate metabolic pathway (Plcb1) were also decreased (-32 ± 5%, nominal 
p=0.0273).  Given the importance of phosphatidylinositols in signal transduction in 
the insulin signalling cascade, the identification of the regulation of this pathway by 
PA-treatment was significant and warrants further investigation (see Chapter 5). 
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4.3.2. Regulated gene pathways induced with PAMN-mediated 
reversal of PA-induced dysregulation of glucose production 
Microarray analysis identified 1434 genes as being differentially expressed between 
PA- and PAMN-treated cells (nominal p<0.05). GSEA of the microarray data resulted 
in the identification of 24 pathways (nominal p<0.05) that were reported as 
significantly regulated by PAMN-treatment according to DAVID analysis (Table 4.2). 
The pathways involved biological processes such as fatty acid synthesis and 
metabolism, sphingolipid metabolism, PPAR signalling and glutathione metabolism. 
In contrast to the pathways identified above by DAVID as being significantly 
regulated when comparing vehicle- with PA-treated cells, no identical pathways 
were identified when comparing PA- with PAMN-treated cells. Some similar 
functions were identified however, with pathway regulation of immune response 
and mediators of inflammation occurring in both GSEA comparisons (see below). 
This largely disparate transcriptional response implies mostly different mechanisms 
for the induction of an insulin resistant, increased glucose production phenotype 
with PA-treatment compared with the lower glucose production phenotype 
observed with PAMN-treatment. All pathways identified as being differentially 
expressed between PA- and PAMN-treated cells are represented alongside relevant 
changes in gene expression in Appendix 5. 
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TABLE 4.2: Pathways identified as significantly overrepresented in the list 
of differentially expressed genes between PA- and PAMN-treated cells. 
 
Number of differentially expressed genes in pathway expressed as: number of 
differentially expressed genes from KEGG pathway identified in array data/total 
number of genes in defined KEGG pathway; Fold enrichment quantifies the 
overrepresentation of a specific KEGG pathway in the differentially expressed genes 
identified in microarray data. CYT., cytochrome. These pathways are represented 
along with changes in gene expression in Appendix 5. 
Defined KEGG Pathway Number of 
differentially 
expressed genes 
in pathway 
Fold 
Enrichment 
Fisher 
Exact p-
value 
Steroid biosynthesis  11 / 17 12.6 4.9E-11 
Terpenoid backbone biosynthesis  9 / 14 12.6 3.4E-9 
Metabolism of xenobiotics by CYT. P450  16 / 60 5.2 2.8E-8 
Drug metabolism – CYT. p450  17 / 72 4.6 7.4E-8 
PPAR signalling pathway  16 / 71 4.4 3.6E-7 
Complement and coagulation cascades  15 / 70 4.2 1.7E-6 
Porphyrin and chlorophyll metabolism  8 / 31 5.0 1.2E-4 
Biosynthesis of unsaturated fatty acids  7 / 24 5.7 1.4E-4 
Steroid hormone biosynthesis  9 / 43 4.1 2.6E-4 
Retinol metabolism  10 / 59 3.3 7.1E-4 
Drug Metabolism – Other Enzymes  8 / 44 3.6 1.5E-3 
Arachidonic acid metabolism  10 / 70 2.8 2.7E-3 
Glutathione metabolism  8 / 50 3.1 3.5E-3 
Systemic lupus erythematosus  11 / 90 2.4 5.8E-3 
Butanoate metabolism  6 / 33 3.6 5.8E-3 
Synthesis and degradation of ketone bodies  3 / 9 6.5 8.8E-3 
Fatty acid metabolism  6 / 42 2.8 1.9E-2 
Sphingolipid metabolism  6 / 42 2.8 1.9E-2 
Linoleic acid metabolism  5 / 33 3.0 2.5E-2 
Nicotinate and nicotinamide metabolism  4 / 23 3.4 2.8E-2 
Valine, leucine, and isoleucine degradation  6 / 46 2.5 2.8E-2 
RIG-1-like receptor signalling pathway  7 / 60 2.3 3.2E-2 
Pentose and glucuronate interconversions  3 / 15 3.9 3.8E-2 
Primary bile acid synthesis  3 / 15 3.9 3.8E-2 
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4.3.2.1. Gene set enrichment analysis between PA-and PAMN-
treated FAO cells identified multiple regulatory pathways of both the 
fatty acid and amino acid biosynthetic pathways 
The GSEA analysis identified 5 pathways regulating fatty acid and amino acid 
biosynthesis, which all produce acetyl-CoA as an intermediary: biosynthesis of 
unsaturated fatty acids, fatty acid metabolism, synthesis and degradation of ketone 
bodies, butanoate metabolism and valine, leucine and isoleucine degradation (Fig. 
4.2).  
 
In the biosynthesis of unsaturated fatty acids pathway, short and medium chain 
fatty acid elongase (Elovl6, -19 ± 6%, nominal p=0.0265) and desaturase (Fads2, -25 
± 6%, nominal p=0.0239) were  decreased in PAMN-treated cells compared with PA- 
treated cells, alongside increased acyl-CoA acyltransferase 1 (Acaa1, +15 ± 5%, 
nominal p=0.0356) and thioesterase (Acot1, Acot2, Acot4, and Acot5) enzymes. 
These changes indicate a shift away from medium chain fatty acid metabolism and 
an increased ability to generate acetyl-CoA and free fatty acids from fatty acyl-CoA 
molecules. 
 
In the fatty acid metabolism pathway, the very long chain acyl-CoA dehydrogenase 
(Acadvl) was decreased with PAMN-treatment (-21 ± 4%, nominal p=0.0078), 
however there was an increase to enoyl-CoA hydratase/3-hydroxyacyl CoA 
dehydrogenase (Ehhadh, +108 ± 24%, nominal p=0.0004) as well as hydroxyacyl-
CoA dehydrogenase short chain (Hadhsc, +9 ± 3%, nominal p=0.036). The increased 
expression levels of these genes may be an indicator of increased conversion of 
medium and short chain fatty acids to acetyl-CoA. 
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The synthesis and degradation of ketone bodies pathway also regulates metabolism 
of acetoacetate and acetyl-CoA. The genes acetyl-CoA acyltransferase 2 (Acat2, -37 
± 4%, nominal p=8.8x10-8), the soluble 3-hydroxy-3-methylglutaryl-CoA synthase 1 
(Hmgcs1, -23 ± 4%, nominal p=0.0055) and mitochondrial 3-hydroxy-3-
methylglutaryl-CoA synthase 2 (Hmgcs2, -27 ± 6%, nominal p=0.0193) were all 
decreased in this pathway. These genes all metabolise acetyl-CoA into either 
acetoacetyl-CoA or acetoacetate, therefore, the observed decrease in mRNA levels 
may indicate decreased utilisation of acetyl-CoA by this metabolic pathway. 
 
The butanoate metabolism pathway also identified many of the same genes that 
metabolise acetyl-CoA, including decreased expression of genes that irreversibly 
metabolise acetyl-CoA (Hmgcs1 and Hmgcs2, as noted above), and both decreased 
(acetoacetyl-CoA synthetase, Aacs, -22 ± 6%, nominal p=0.0304) and increased 
(Ehhadh and Hadhsc, as noted above) expression of genes feeding into acetyl-CoA 
production. The direction of acetyl-CoA synthesis is therefore less clear in this 
pathway. With the exception of Aacs, these same genes were also identified in the 
branch chain amino-acid metabolism pathway valine, leucine and isoleucine 
degradation, further highlighting the regulation of metabolic pathways involving 
acetyl-CoA metabolism following PAMN-treatment. The enzymes leading to acetyl-
CoA synthesis in this pathway however were both increased and decreased, with no 
clear pattern observed. The relationship between these pathways and acetyl-CoA 
metabolism is summarised in Fig. 4.2. 
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FIGURE 4.2: PAMN-induced changes in metabolic pathways regulating 
acetyl-CoA metabolism. 
Biosynthesis pathways that include acetyl-CoA as an intermediate were identified as 
being regulated at the transcriptional level between PA-and PAMN-treated cells via 
DAVID analysis. The thickness and direction of the arrows indicate the effect the 
observed gene expression changes would have on the ability of the cell to 
metabolise acetyl-CoA. The transcriptional regulation observed with PAMN 
treatment indicates a potential for increased acetyl-CoA production through the 
fatty acid metabolism and biosynthesis of unsaturated fatty acid pathways, as well 
as a decreased utilisation of acetyl-CoA by the synthesis and degradation of ketone 
bodies pathway. These factors combined indicate an increased availability of acetyl-
CoA as a metabolite of downstream metabolic pathways such as terpenoid 
backbone biosynthesis. 
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4.3.2.2. Gene set enrichment analysis between PA-and PAMN- 
treated FAO cells identified changes in the cholesterol and bile acid  
synthetic pathways 
There were four key pathways that were induced between PA-and PAMN-
treatment which followed directly from acetyl-CoA synthesis (as described above) 
through to steroid hormone and bile acid production. These pathways follow the 
conversion of acetyl-CoA to farnesyl-PP (Terpenoid Backbone Biosynthesis pathway, 
fold enrichment 12.6, p=3.4x10-9, Fig. 4.3 a), farnesyl-PP to cholesterol (Steroid 
Biosynthesis pathway, fold enrichment 12.6, p=4.9x10-11, Fig. 4.3 b) and Cholesterol 
to c18-, c19- and c21-steroid hormones (Steroid Hormone Biosynthesis pathway, 
fold enrichment 4.1, p=2.6x10-4, Fig. 4.3 c) or cholesterol to primary bile acids 
(Primary bile acid synthesis, fold enrichment 3.9, p=3.8x10-2). The metabolic link 
between these pathways is detailed in figure 4.3 d. All 20 enzymes in the metabolic 
pathway regulating the conversion of acetyl-CoA to cholesterol were reduced in the 
PAMN-treated group compared with PA-alone treated cells, suggesting a decreased 
ability of the cells to synthesise cholesterol, and therefore any downstream 
metabolic products such as steroid hormones or bile acids. These pathways are 
discussed in further detail below. 
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FIGURE 4.3: Biosynthesis pathways identified as being regulated at the 
transcriptional level between PA-and PAMN-treated cells via GSEA. 
(a) Downregulation of all nine enzymes of the terpenoid backbone biosynthesis 
pathway, following the continuous conversion of acetyl-CoA to farnesyl-PP. (b) 
Downregulation of all 11 enzymes of the steroid biosynthesis pathway, following 
the continuous conversion of farnesyl-PP to cholesterol. (c) Regulation of 9 enzymes 
of the steroid hormone biosynthesis pathway, following the conversion of 
cholesterol to steroid hormones. The direct linkage of these three pathways, as well 
as primary bile acid biosynthesis, is highlighted in (d). Relative amounts of each 
transcript reported as percentage change from PA to PAMN and represented as 
mean ± SEM. All expression changes detailed were significant at nominal p<0.05. 
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For the first of these linked pathways, Terpenoid backbone biosynthesis, all 9 
members showed decreased expression in PAMN-treated cells compared with PA-
treated cells (Fig. 4.3 a), including the enzyme mevalonate kinase (Mvk, -19 ± 5%, 
nominal p=0.043). Similarly in the second pathway, Steroid Biosynthesis, all eleven 
members showed decreased expression in PAMN-treated cells compared with PA-
treated cells (Fig. 4.3 b). The third pathway in this group, Steroid Hormone 
Biosynthesis, did not follow this trend, with both increased and decreased gene 
expression in PAMN-treatment compared with PA-treated cells (Fig. 4.3 c). Both up 
and downregulation was observed in the synthetic pathways leading to C21-
steroids, as well as the branches of the pathway leading to C18/C19-steroids. These 
three pathways form a direct and continuous metabolic link from acetyl-CoA to 
cholesterol, and then diverge to C18-, C19- and C21 steroid hormones (Fig. 4.3 d). 
 
In addition, the associated pathway of Primary Bile Acid Biosynthesis follows the 
conversion of cholesterol, through to the two primary bile acids cholate and 
chenodeoxycholate. There was decreased expression in three of the genes encoding 
the intermediate enzymes Cyp8b1 (-43 ± 6%, nominal p=0.0028), Amacr (-31 ± 3%, 
nominal p=0.043) and Acox2 (-44 ± 9%, nominal p=0.0228), however no change in 
expression was observed for Cyp7a1, the rate-limiting enzyme in bile acid 
production. The metabolic links between these four pathways is highlighted in Fig. 
4.3d. The data suggests a downregulation of the metabolic pathways leading to 
cholesterol, as well as downregulation of the cholesterol utilisation pathways 
leading to both steroid hormone and bile acid production. This finding may in part 
explain the regulation of glucose production observed following PAMN-treatment. 
The production of bile acid in the liver, and downstream signalling through the 
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farnesoid x receptor (Fxr) has been shown to regulate the expression of genes 
involved in glucose production including glucose-6-phosphatase (G6Pase) [241] and 
Pepck [242, 243], thereby lowering hepatic glucose production. 
 
4.3.2.3. Gene set enrichment analysis between PA-and PAMN-
treated FAO cells identified regulation of multiple lipid metabolic 
pathways 
In the sphingolipid metabolism pathway, there was an increase in PAMN-treated 
cells compared with PA-treated cells in the expression of one of the genes that 
converts ceramide to sphingosine (alkaline ceramidase 2, Acer2, +36 ± 10%, nominal 
p=0.0086), which can then be further converted to sphingosine-1-P. The enzyme 
that dephosphorylates sphingosine-1-P to sphingosine (and also dephosphorylates 
ceramide-P to ceramide) was decreased with PAMN-treatment (phosphatidic acid 
phosphatase type 2B, Ppap2b, -36 ± 6%, nominal p=0.0014). These transcriptional 
changes indicate a possible shift towards sphingosine-1-P metabolism away from 
ceramide production. The sphingosine-1-phosphate receptor SIP2 has been shown 
to activate Erk1/2 [244] regulated phosphorylation and stabilisation of the small 
heterodimer partner (SHP) [245], a transcriptional repressor that supresses hepatic 
gluconeogenetic gene expression [246]. 
 
The linoleic acid metabolism pathway and arachidonic acid pathways identified 
increased expression of phospholipase group 2 1b (Pla2g1b) – which was 
significantly decreased with PA-treatment (-31 ± 4%, nominal p=0.0120) and 
increased with PAMN-treatment (+135 ± 13%, nominal p=1.0x10-9). In contrast to 
   Chapter 4: Gene set enrichment analysis 
130 
 
my findings, Pla2g1b-/- mice show resistance to diet induced obesity [230] and 
reduced postprandial hyperglycaemia [228]. The Pla2g1b decrease observed with 
PA-treatment may therefore act as a cellular defence mechanism to reduce fatty-
acid uptake and avoid lipid toxicity. Following PAMN-treatment, it is possible that 
this defence is no longer required, and therefore Pla2g1b expression increased. The 
cytochrome P450 2e1 was reduced following PAMN-treatment (Cyp2e1, -36 ± 9%, 
nominal p=0.0480). This enzyme has been found to display increased activity in the 
liver of type 2 diabetic patients [247], and Cyp2e1-/- mice  have been shown to be 
resistant to diet-induced obesity and insulin resistance [248], consistent with the 
decrease in the mRNA levels of this enzyme in PAMN-treated cells. 
 
The regulation of the retinol metabolic pathway also shows direct links to glucose 
production, as all-trans-retinoic acid (a vitamin A derivative) has been shown to 
activate transcription of Pepck through activating transcription factor-2 (Atf2) [249]. 
The key regulator of retinoic-acid, Cyp26a1, was increased with PAMN-treatment 
(+72 ± 15%, nominal p=0.0003) and therefore may act to reduce availability of 
retinoic acid with PAMN treatment and lower Pepck expression and subsequently 
reduce glucose production. However, when Pepck (and G6Pase) mRNA expression 
levels were measured via RT-PCR (see Chapter 5), there was no difference between 
PA- and PAMN-treated cells.  
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4.3.2.4. Gene set enrichment analysis between PA-and PAMN-
treated FAO cells identified transcriptional regulation of PPAR 
signalling 
Gene expression levels of the PPAR signalling pathway was regulated with the 
addition of metformin and sodium salicylate to the PA-treated cells (Fig. 4.4). The 
intestinal fatty acid binding protein Fabp2 and brain fatty acid transport protein 
Fabp7 were decreased (-25 ± 5%, nominal p=0.0220; -63 ± 3%, nominal p<0.0001) 
with PAMN-treatment compared with PA-alone-treated cells, while the main 
adipocyte fatty acid binding protein Fabp4 was increased (+70 ± 11%, nominal 
p=0.0003). The main liver fatty acid binding protein in the liver however is Fabp1, 
which was not altered with either treatment, so the impact of the changes of the 
additional lower expressed proteins on fatty acid transport in the liver is not clear. 
The mRNA expression level of PPARδ itself was decreased (-24 ± 5%, nominal 
p=0.0240) following PAMN-treatment. 
 
The downstream transcriptional targets of all three PPARs were altered (see data in 
Fig. 4.4), with down-regulation of genes with diverse roles in ketogenesis 
(Hmgcrs2), lipid transport (Apoa5), lipogenesis (Fads2), cholesterol metabolism 
(Cyp8b1), and gluconeogenesis (Pepck, -23 ± 6%, nominal p=0.0193), which 
correlates with the lowering of glucose production following PAMN-treatment. 
Genes with roles in fatty acid oxidation were both up- (Ehhadh, Acaa1) and down-
regulated (Cyp4a2). Signalling through this pathway could play a role in inducing the 
changes observed in the fatty acid metabolic pathways discussed above, as well as 
explaining the observed reduction in glucose production with PAMN-treated cells 
due to the decreased Pepck expression observed in the microarray data. 
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FIGURE 4.4: Transcriptional regulation of the PPAR signalling pathway 
between PA-and PAMN-treated cells. 
Relative amounts of each transcript reported as percentage change from PA to 
PAMN, represented as mean ± SEM. All expression changes detailed were 
significant at nominal p<0.05. 
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4.3.2.5. Gene set enrichment analysis between PA-and PAMN-
treated FAO cells identified transcriptional regulation of multiple 
pathways involving immune function 
When comparing vehicle versus PA-treated cells, GSEA identified regulation of the 
toll-like receptor signalling pathway, leukocyte transendothelial migration, antigen 
processing and presentation and the NOD-like receptor signalling pathways. These 
pathways regulate the production of pro-inflammatory cytokines and activate 
lymphocyte chemotactic effects. In contrast, the comparison of PA- versus PAMN-
treated expression levels identified regulation of RIG-1 like receptor signalling 
pathway, systemic lupus erythematosus and the compliment and coagulation 
cascade pathways. 
 
RIG-1-like receptor signalling pathways lead to the production of inflammatory 
cytokines following viral RNA detection by the cell. Similarly to the reduction in the 
complement factors in the complement and coagulation cascade pathway (see 
Appendix 5), there was a decrease in multiple genes involved in the innate immune 
response including DEAD box polypeptide 58 (Ddx58, -22 ± 6%, nominal p=0.0159) 
and interferon regulatory factor 7 (Irf7, -25 ± 5%, nominal p=0.0061), which 
normally activate the downstream induction of cytokine expression of interleukin 6 
(IL-6) [250]and interferon-β (IFN-β) [251]. Due to the decreased levels of these pro-
inflammatory genes, there may be potential for reduced type 1 interferon and 
inflammatory cytokine production with PAMN-treatment in this model – consistent 
with the main role of sodium salicylate in reducing cellular inflammation. 
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4.3.2.6. Gene set enrichment analysis between PA-and PAMN-
treated FAO cells identified transcriptional regulation of mediators of 
oxidative stress   
Glutathione metabolism tightly controls one of the key oxidative stress response 
molecules - glutathione. Glutathione interacts with glutathione peroxidase (Gpx1) 
to detoxify hydrogen peroxide [252]. Gpx1 expression was decreased (-37 ± 4%, 
nominal p<0.0001) with PAMN-treatment, indicating a reduced capacity to counter 
radical species, suggesting a possible reduction in oxidative stress with PAMN-
treatment. 
 
Nicotinate and nicotinamide metabolism regulates the production and recycling of 
NADP+, which itself is a by-product of glutathione cycling back to its antioxidant 
form [253]. The rate limiting enzyme for NAD+ biosynthesis, nicotinamide 
phosphoribosyltransferase (Nampt), was significantly increased with metformin and 
sodium salicylate treatment by +20 ± 7% (nominal p=0.0312). The increased 
availability of NAD+ via Nampt upregulation has been proposed as an alternative 
mechanism of action for the inhibitory effect of metformin on glucose production 
([194], reviewed in [254]). 
 
Related to these pathways is porphoryn and chlorophyll metabolism, which leads to 
the production of heme and bilirubin – a component of bile acid and potent 
antioxidant. The expression levels of four genes identified in this pathway, which 
lead to bilirubin production, were all decreased – Alas1 (-28 ± 3%, nominal 
p=1.6x10-5), Alad (-13 ± 4%, nominal p=0.0250), Uros (-16 ± 4%, nominal p=0.0437) 
and Blvra (-17 ± 5%, nominal p=0.0372). Further to a potential decreased capacity 
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for bilirubin production, the three glucuronosyltransferase genes which metabolise 
bilirubin into bilirubin β-diglucuronide (the water soluble form) were increased – 
Ugt2b1 (-25 ± 7%, nominal p=0.0193), Ugt2b10 (-29 ± 8%, nominal p=0.0317) and 
Ugt2b4 (-25 ± 8%, nominal p=0.0463). Therefore, the availability of bilirubin may be 
decreased following PAMN-treatment in this model. 
 
These three pathways taken together appear to indicate a selective shift away from 
an oxidative stress- response in this model following metformin and sodium 
salicylate treatment. The role of sodium salicylate in reducing fatty acid-induced 
inflammation [91] and oxidative stress [255] in the liver has been established, and 
one possible explanation may be that treatment with sodium salicylate reduces the 
need for such antioxidant responses by reducing the source of inflammation.  
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4.4. Discussion 
The most convincing evidence for impairment of a metabolic pathway was found for 
acetyl-CoA to cholesterol metabolism. The identification of the terpenoid backbone, 
steroid, steroid hormone and primary bile acid biosynthesis pathways as being 
regulated following PAMN-treatment correlates with the known role of metabolites 
of these pathways in insulin action and hepatic glucose production. There was a 
general decrease in the expression levels of all members of the metabolic pathways 
regulating the synthesis of cholesterol from acetyl-CoA with PAMN-treatment. In 
addition, the transcriptional changes associated with multiple lipid and amino acid 
metabolic pathways with PAMN-treatment indicates a potential for increased 
generation of acetyl-CoA. Further, the metabolic pathway regulating the 
metabolism of primary bile acids from cholesterol was identified as being regulated 
following PAMN-treatment. 
 
The role of acetyl-CoA in increasing hepatic glucose production via activation of 
pyruvate carboxylase has been detailed in Chapter 1. This mechanism may in part 
explain the increase in glucose production observed following PA-treatment in the 
current study. It is therefore curious that the changes in gene expression for the 
regulatory pathways leading to the generation of free acetyl-CoA suggest an 
increased ability for synthesis following PAMN-treatment. If this were the case, then 
there exists at least the following explanations as to why glucose production falls in 
PAMN-treated cells with the potential for increased acetyl-CoA production: (i) the 
generation of acetyl-CoA has already reached its maximum, limited by substrate 
availability, or (ii) the levels of acetyl-CoA do increase with PAMN-treatment, 
however the effects of PAMN-treatment are sufficient to overcome the acetyl-CoA 
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induced increase in pyruvate carboxylase activity in order to lower hepatic glucose 
production. In order to fully investigate this hypothesis, the levels of intracellular 
acetyl-CoA would have to be determined. 
 
The comprehensive decrease in gene expression in the metabolic pathways 
regulating the conversion of cholesterol from acetyl-CoA suggests a decreased 
ability to synthesise cholesterol in PAMN-treated cells. Cholesterol has been shown 
to play a key role in the regulated uptake of long chain fatty acids across multiple 
cell types [256, 257]. The long chain fatty acid transport protein cluster of 
differentiation 36 (CD36/FAT) resides within the plasma membrane, and its 
association with cholesterol rich lipid rafts are required for activation of fatty acid 
transport [258]. This process has been shown to be cholesterol dependant in human 
HepG2 hepatoma cells, in which the cholesterol binding agent filipin III (which 
preferentially removes cholesterol from the plasma membrane, thus depleting 
caveolae lipid rafts [259]) reduced the uptake of 3H-oleic acid following 30 mins of 
pre-treatment [256]. This regulation by cholesterol of fatty acid transport may play 
a role in the decreased glucose production observed in PAMN-treated cells in the 
current study. By inhibiting the uptake of PA, the acetyl-CoA mediated increase in 
glucose production could be prevented. Further investigation into the regulation of 
cholesterol metabolism is therefore required to determine whether this mechanism 
may be playing a role in the regulation of glucose production in PAMN-treated cells. 
This will be further analysed in Chapter 5. 
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The role of bile acids and cholesterol metabolism in the regulation of glucose and 
lipid metabolism has been widely reported in recent years. A recent study by 
Meissner et al found that sequestration of bile acids in db/db mice using 
Colesevelam HCl for two weeks led to increased glucose clearance in the peripheral 
tissues by ≈37%, but there was no effect on total hepatic glucose production [260]. 
Alternatively, in Zuckerfa/fa rats it has been reported that activation of the nuclear 
bile acid Farnesoid X Receptor (Fxr), via the Fxr ligand 6α-ethyl-chenodeoxycholic 
acid, leads to a reduction in blood glucose levels through reduced hepatic Pepck and 
G6Pase gene expression levels [243]. Likewise, synthetic agonists of Fxr, as well as 
hepatic overexpression of Fxr, have also been shown to reduce blood glucose levels, 
although this was reported with an increase in PEPCK expression alongside 
decreased G6Pase expression [242]. In vivo transgenic overexpression of cholesterol 
7α-hydroxylase in the liver – the rate limiting step in cholesterol to bile acid 
synthesis – has been shown to lead to an increased bile acid pool and subsequent 
decrease in blood glucose levels, correlating with decreased hepatic G6Pase 
expression, and no change in PEPCK expression [241].  The regulation of glucose 
homeostasis by bile acids therefore appears to be tissue specific, with sequestration 
away from peripheral tissues leading to improved glucose clearance, however direct 
effects of bile acids on the liver through its effects mediated by Fxr signalling lower 
glucose production. Investigation into the metabolism and synthesis of cholesterol 
and bile acids by PA- and PAMN-treatment in FAO cells is required to determine 
whether they are contributing to glucose homeostasis in this model. This will be 
further analysed in Chapter 5. 
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There have been relatively few studies looking into the genome wide effects of PA 
in hepatic cell or tissue models.  Swagell et al. [235] found differential regulation of 
162 of 18,000 genes using cDNA microarrays in the human hepatic Huh-7 cells 
following 48 h treatment with 0.15 mM PA. The total number of regulated genes 
was far fewer than identified in the current study, most likely due to a smaller 
number of replicate samples; n=4 in both control and PA treated cells. While the 
Swagell study did not perform GSEA, differentially expressed genes were grouped 
according to function and described. Amongst their key findings were increased 
expression of mediators of lipid and cholesterol transport, fatty acid metabolism 
and oxidative stress. Given that multiple pathways with similar functions in fatty 
acid and cholesterol metabolism were down-regulated in the current study 
following PAMN-treatment, these pathways appear to be correlated with PA-
induced increases to glucose production. Additionally, expression of many 
mediators of cellular proliferation were found in both the Swagell [235] and this 
study to be decreased in response to PA-treatment. Swagell [235] observed a 
correlation between these changes in gene expression and decreased cellular 
number following PA treatment for 48 h. Further complicating the correlation 
between reduced proliferation and glucose production however is the finding that 
reduced glucose production by metformin is also associated with decreased protein 
synthesis and cellular proliferation through AMPK activation ([261], reviewed in 
[262]). It is therefore unclear whether the reduction in cellular proliferation plays a 
role in the increased production of glucose by PA treatment as observed in this 
model. 
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Using human HepG2 hepatoma cells treated with 50 μM PA for 24 h, Vock et al. 
[234] performed cDNA microarray analysis and found only 11 of 38,500 array 
probes to be regulated by PA-treatment. This is strikingly lower than the number of 
regulated genes in the current study, however given the reduced PA concentration, 
time of exposure and number of samples (n= 3 independent experiments, each in 
triplicate), a reduced number of regulated genes with increased sensitivity to PA-
treatment might be expected. The main regulated genes identified were increased 
expression of the inhibitor of fibrinolysis Serine peptidase inhibitor E1 (Serpine1) 
and increased expression of insulin-like growth factor II (Igf-II), which has been 
linked to the induction of type 2 diabetes in mouse models of Igf-II overexpression 
[263].  
 
In contrast to these in vitro based microarray studies, this study has identified 
pathway regulation of inositol phosphate signalling with PA-treatment, with 
reduced Impk expression potentially reducing insulin signalling through Akt and 
thus supressing the effects of insulin on repression of glucose production [240].  The 
effects of regulation of this pathway on phosphorylation of PIP2 – PIP3 generation, 
coupled with the widespread changes to many lipid metabolic genes with PAMN 
treatment warrants further investigation. 
 
Regulation of signalling pathways controlling cellular inflammation were induced by 
both PA- and PAMN-treatments, and included regulation of the JNK signalling 
pathway and increased expression of Fos and Jun – mediators of inflammatory 
cytokine release and recruitment of lymphocytes. Given the role of macrophage 
infiltration and subsequent inflammatory cytokine release compounding pre-
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existing insulin resistance in peripheral tissues [63, 264, 265], the control of 
inflammatory pathways is important in the restoration of altered glucose 
metabolism. A reduction in the expression of key upstream mediators of NF-kB 
signalling (Ddx58 and Irf7) was observed. Alongside this reduction in gene 
expression is the established inhibition of Ikkβ by sodium salicylate, which has been 
shown in animal models of diet-induced insulin resistance to improve abnormal 
liver Irs-1 (increase tyrosine phosphorylation, reduce Ser 307 phosphorylation), Irs-2 
(increase tyrosine phosphorylation, reduce Ser 233 phosphorylation)  and Akt 
(increase Ser 473) phosphorylation [91] and lower hepatic glucose production, 
fasting blood glucose and fasting insulin levels [255]. It is therefore likely that the 
regulation of inflammatory signalling pathways is playing a role in the effects of PA- 
and PAMN-treatment on glucose production in this model. 
 
The regulation of oxidative stress pathways observed in response to PAMN 
treatment has been previously linked to the hepatic glucose production lowering 
mechanisms of both metformin and sodium salicylate. Sodium salicylate has been 
shown to reverse lipid-induced increases in release of plasma malondialdehyde 
(MDH) a marker of whole body oxidative stress, as well as increased liver 
glutathione peroxidase (Gpx) activity in a rat model of intralipid induced whole body 
insulin resistance [255]. In contrast to these findings, this study observed a decrease 
in Gpx1 gene expression levels in response to PAMN treatment. Whether these 
differences are due to PAMN-treatment reducing the stimulus for Gpx1 
transcription in the in vitro model versus the more complex in vivo model is unclear. 
Metformin has also been shown to induce transcription of oxidative stress response 
genes, specifically through AMPK-induced transcription of Nampt, Gcn5 and Sirt1 
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[194]. The proposed mechanism involves a metformin-induced increase in NAD+-
dependant Sirt1 inhibition of Torc2-mediated glucose production, while 
simultaneously increasing Gcn5 inhibition of Pgc1α-stimulated glucose production. 
In the current study, although no changes to Sirt1 or Gcn5 expression was observed, 
Nampt expression was increased by 20 ± 7% with PAMN-treatment (p=0.0312 
compared with PA-treated) which remains consistent with the published study. 
 
The regulation of the PPAR signalling pathway, as identified in the GSEA analysis, 
may explain the regulation of the numerous fatty acid signalling pathways observed 
in our model. Activation of PPARs α and γ have been attributed to both saturated 
and unsaturated fatty acids [266]. Activation of the PPARα with the glucocorticoid 
dexamethasone or the agonist WY14,643 has been shown to lead to dysregulation 
of glucose production in the liver, increasing both Pepck and PPARα expression in 
primary human hepatocytes [267]. Further downstream targets of PPARα identified 
in the current study include Fads2, Acox2, and Fabp4. The identification of 
transcriptional regulation of the 9 pathways via GSEA involving fatty acid and acetyl-
CoA metabolism may be explained, in part, by this interaction. 
 
Despite the wealth of biologically relevant information that can be obtained via 
microarray and GSEA approaches, the main drawback to this technology is the distal 
nature of gene expression to metabolic outputs. Multiple factors including 
regulation of translational processes, post-translational modifications, protein 
turnover, availability of co-factors and signalling initiation all confound the 
interpretation of gene expression data. Therefore, there is a need for further 
analysis in order to confirm any pathway regulatory changes, which can be 
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confirmed by measuring relevant key metabolites. This will be further investigated 
in Chapter 5. 
 
In summary, a GSEA approach was used to investigate the regulation of metabolic 
and signalling pathways in both the PA-induced dysregulation of glucose 
production, as well as its restoration with PAMN-treatment. The findings of this 
chapter, including regulation of multiple lipid metabolic pathways including 
phosphatidylinositol and cholesterol metabolism, however have not yet been 
confirmed beyond the level of gene expression changes. Therefore, Chapter 5 will 
investigate the changes to the global lipid profile in vehicle-, PA- and PAMN- treated 
FAO cells in order to further investigate this question. 
 
   Chapter 5: Lipidomic profiling 
144 
 
Chapter 5 – PA-induced alterations to the global 
lipidomic profile in FAO hepatoma cells 
 
5.1. Introduction 
In Chapter 4, the reversal of PA-induced high glucose production in the liver by 
PAMN-treatment was characterised by transcriptional regulation of a number of 
metabolic pathways regulating fatty acid metabolism. In addition, a comprehensive 
decrease in the gene expression levels of all of the metabolic enzymes regulating 
the synthesis of cholesterol from acetyl-CoA was observed. Given the accepted role 
of many lipid metabolites in the pathogenesis of T2D – most predominately DAGs 
[268] and ceramides [152] -  further analysis at the level of the individual lipid 
metabolites was warranted to observe the effect of these transcriptional changes at 
the level of lipid metabolism. This approach may identify potential mediators of 
dysregulated glucose production in this model. Global lipidomic approaches, made 
possible with current generation chromatographic and mass spectroscopic 
technology, provide the means to analyse these changes and track the metabolism 
of specific intermediates of interest [122]. These new approaches to metabolomics 
investigation are proving as revolutionary to the field as microarray technology has 
been in the study of transcriptional regulation. By allowing the study of nearly the 
entire cellular lipid content, improved analysis on the regulation of multiple 
pathways can be performed. Given the complex nature of T2D, the ability to 
separate out multiple dysregulated metabolic pathways will prove critical in 
furthering understanding of the disease. 
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Global lipidomic approaches to dissecting the mechanisms of T2D are becoming 
more widespread as the identity of specific lipid species in the regulation of glucose 
metabolism are being recognised rather than whole classes. For example, the 
activation of total PKC in HepG2 hepatoma cells following acute (1 – 12 h) fatty acid 
treatment was found to be proportional to the degree of unsaturation of the fatty 
acid [269]. Activation of total PKC in lipid vesicles in vitro by DAG species has been 
shown to be greater for DAGs containing PUFA side chains such as 18:0/22:6 and 
18:0/20:4 than the saturated DAG 18:0/18:0 [270]. Further, DAG activation of 
conventional (α, βI and βII) and novel (δ, ε, η and θ) PKC isoforms is structure-
specific, requiring sn-1,2-DAG species, and is unaffected by sn-1,3-DAG and sn-2,3-
DAG [271]. In muscle cells, the ceramide class of lipids have been shown to play a 
key role in the induction of insulin resistance [152], however levels of total 
ceramides have been shown to remain relatively constant between healthy insulin 
sensitive patients and obese insulin resistant patients [272]. One study has even 
described a positive correlation between skeletal muscle total ceramide content 
and insulin sensitivity in individuals [272]. It is therefore likely that this discrepancy 
can be explained by the role of individual lipids on insulin action and glucose 
metabolism, rather than the class as a whole. Determining the individual lipid 
species within those classes that are responsible for these toxic effects is the next 
challenge in determining new targets for therapeutic intervention. 
 
Much of the published work on utilising lipidomic approaches has been on profiling 
the plasma lipids of obese cohorts and comparing with lean healthy control subjects 
to identify novel markers of insulin resistance and obesity ([273], reviewed in [122]). 
However, since not all obese individuals are insulin resistant, or develop T2D, 
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careful analysis of such markers is required to determine whether an association 
with insulin resistance can be made. There have been studies attempting to answer 
this problem, for example identifying TAG species in varying lipoprotein fractions to 
identify species which correlate with insulin resistance [274]. Common criticisms of 
such studies have been a failure to perform adjustments for obesity and as such it is 
not clear if some of the associations made with insulin resistance or obesity are 
truly independent of one another. Associations with a number of plasma markers 
including saturated TAG species [274] and ceramides [273] have been described, 
however similar studies on patient intra-hepatic lipid metabolism are less common. 
 
The key finding of Chapter 4 was that the gene expression levels of every enzyme 
involved in the synthesis of cholesterol from acetyl-CoA were decreased in PAMN-
treated cells compared with PA-treated cells. In addition, numerous lipid 
metabolism pathways were identified as being differentially regulated in PAMN- 
compared with PA-treated cells. Finally, the regulation of phosphatidylinositol (PI) 
metabolism as being differentially expressed between vehicle- and PA-treated cells 
was a novel finding. Therefore, the primary aim of this chapter was to complete a 
mass-spectroscopic based lipidomic analysis of vehicle, PA- and PAMN-treated cells 
in order to determine if the changes observed in transcriptional regulation as 
outlined in Chapter 4 are related to an altered lipid profile in these cells (a “whole 
lipidome” approach). The secondary aim of this chapter was to investigate specific 
aspects of lipid metabolism (a “targeted lipidome” approach) highlighted in the 
findings of Chapter 4 including cholesterol and bile acid metabolism in order to 
further characterise the mechanisms involved in the dysregulation of glucose 
metabolism. 
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5.2. Methods 
 
5.2.1. Lipidomic profiling of FAO cells following PA- and PAMN-
treatment 
Cell lysate for lipidomic profiling was collected from vehicle- (n=6), PA- (n=6) or 
PAMN- (n=6) treated FAO hepatoma cells, in 10 cm dishes with a media volume of 
10 mL. Treated cells (as detailed in Chapter 2) were trypsinised, and centrifuged at 
200 x g for 5 min at room temperature then resuspended in RPMI 1640 media 
(Invitrogen), then centrifuged at 200 x g for 5 min at room temperature, washed 
twice in 500 μL 1 x PBS pH 7.4 and transferred to a 1.5 mL tube pre-chilled to 4oC. 
On ice, cells were lysed using a sonicator probe at 20% amplitude (model 250 
Branson Sonifier®, with model 102c sonicator probe) twice for 15 seconds, put back 
on ice for 1 min following each sonication. Samples were centrifuged at 14,000 x g 
for 5 min at 4OC, and supernatant (cell lysate) was collected and stored at -80OC. 
Protein concentrations for each sample were determined using the Pierce BCA 
Protein Assay Kit, and each sample was diluted in 1 x PBS pH 7.4 to achieve 
equivalent protein concentration for all samples (2.0 mg/mL). 
 
The following lipid extraction technique and mass-spectroscopic analysis were 
performed at Professor Peter Meikle’s Metabolomics laboratory (BakerIDI, 
Melbourne, AUS) following established protocols developed for comprehensive lipid 
analysis in human plasma samples [275]. Lipid extraction from cell lysates were 
performed using a modified Folch extraction [276]. 10 μL of cell lysate was used, 
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and an internal standard (ISTD) mix (15 μL, consisting of 28-lipid species standards 
mix) were added into the samples. 2 mL of 2:1 chloroform:methanol solution was 
added and samples were placed on a rotary mixer for 10 min at room temperature 
followed by sonication for 30 min and incubation at room temperature for 20 min. 
Samples were centrifuged at 16,000 x g for 10 min at room temperature and the 
supernatant dried down under nitrogen at 40 °C. Samples were resuspended in 50 
μL saturated butanol and sonicated for 10 min. 50μl MeOH containing 10 mM 
ammonium formate was then added and centrifuged again at 2000 x g for 5 min at 
room temperature. The supernatant was transferred to 0.2 mL micro-inserts in 
32x11.6 mm glass vials with Teflon insert caps. 
 
Liquid chromatography, electrospray ionisation-tandem mass spectrometry (LC ESI-
MS/MS) analysis was performed by Ms Jacqui Weir at Professor Peter Meikle’s 
Metabolomics laboratory (BakerIDI, Melbourne, AUS).  Separation was achieved 
using a HP1200 liquid chromatography system with a Zorbax C18 column (1.8 μm, 
50 x 2.1 mm column, Agilent technologies, USA).  The mobile phase was 
tetrahydrofuran:methanol:water in a 30:20:50 ratio (A) and 75:20:5 (B) both 
containing 10 mM NH4COOH. The following gradients were used for all lipids except 
for DAGs and TAGs; 100% A/0% B reducing to 0%A/100%B over eight min followed 
by 2 min at 0% A/100% B, a return to 100% A/0% B over 0.5 min then held for 3.5 
min at 100% A/0% B prior to the next injection. DAGs and TAGs were separated 
using the same system with an isocratic flow at 15%A/85% for 6 min between 
injections. Electrospray ionisation-tandem mass spectrometry was then performed 
using an Applied Biosystems 4000 Q/TRAP mass spectrometer with turbo-ionisation 
source (350oC) using Analyst 1.5 software.  Quantification of individual lipid species 
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was performed using scheduled multiple-reaction monitoring (MRM) in positive ion 
mode. Lipid concentrations were calculated by measuring the peak area of each 
lipid species (using Multiquant 1.2 software) and relating it to the peak area of the 
corresponding internal standard. Total lipids of each class were determined by 
summing the individual lipid species. Data is presented as an average of all sample 
measurements ± SEM.  
 
A series of product ion scans in negative ion mode were performed to determine 
the side chains of PI 38:5 (see Appendix 5). Based upon previous characterisation 
work undertaken in Professor Peter Meikle’s Metabolomics laboratory at the Baker 
IDI, PI 38:5 has a known retention time of approximately 5.4 min for their mass 
spectroscopic platform. Following fragmentation of the sample at this specific 
retention time, each fragment of the lipid loses one hydrogen atom and becomes 
negatively charged. The charged fragments were then compared with standard 
fragment sizes for the identification of the side chains of interest (resolution is 
measured with an error of ± 0.4 mass units). 
 
5.2.2. Analysis of excreted cholesterol levels in conditioned media  
Conditioned media was collected from vehicle- (n=3), PA- (n=3) or PAMN- (n=3) 
treated FAO hepatoma cells in 10 cm dishes with a media volume of 10 mL. Total 
cholesterol were measured via HDL and LDL/VLDL Cholesterol Assay Kit (Abcam, 
Cambridge, UK), following the manufacturer’s instructions. Briefly, in a 1.5 mL tube, 
100 μL conditioned media was mixed with 100 μL precipitation buffer (kit supplied 
reagent), incubated for 10 min at room temperature, then centrifuged at 2000 x g 
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for 10 min at room temperature. The supernatant (HDL fraction) was transferred to 
a fresh 1.5 mL microfuge tube, while the precipitate (LDL/VLDL) was resuspended in 
200 μL of 1 x PBS pH 7.4. 20 μL of the HDL, LDL/VLDL fractions, and unfractionated 
conditioned media (for total cholesterol measurement) was added to 80 μL of 
reaction buffer (kit supplied reagent, containing cholesterol oxidase and a H2O2 
sensitive probe) in the presence or absence of cholesterol esterase to measure total 
(with cholesterol esterase) and free (without cholesterol esterase) cholesterol. The 
reaction was incubated for 60 min at 37OC and protected from light. Absorbance 
was read at 570 nm and compared with a series of known standards prepared in 
cholesterol assay buffer using 0.25 μg/μL cholesterol standard supplied with the 
assay kit. The subtraction of free from total cholesterol levels yields measurement 
of cholesterol esters. 
 
5.2.3. Measurement of excreted and intracellular total bile acids  
Cell lysate for total bile acid analysis were extracted from FAO cells treated with 
vehicle (n=3), PA (n=3) or PAMN (n=3) as described above for lipidomic cell lysate 
preparation. Conditioned media was also collected to measure extracellular total 
bile acids as described above for analysis of excreted cholesterol levels. Total bile 
acids were measured via Total Bile Acid Assay kit (enzyme cycling method, DZ042A-
K, Diazyme Labs, USA), following the manufacturer’s instructions. Briefly, 8 μL of 
sample conditioned media or cell lysate was incubated with 270 μL assay reagent 1 
(kit supplied reagent) for 5 min at 37OC, followed by the addition of 90 μL of assay 
reagent 2 (kit supplied reagent). Absorbance was then immediately measured at 
405 nm for two min at 37OC. The rate of change for the reaction was measured 
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from 60 – 120 seconds. The rate of change is directly proportional to the level of 
total bile acids present, and was compared with a series of known standards 
prepared in 1 x PBS pH 7.4 using 50 μM total bile acid standard supplied with the 
assay kit. 
 
5.2.4. RNA extractions and RT-PCR analysis of gluconeogenetic genes 
Total RNA was extracted and quantified from vehicle- (n=4), PA- (n=4) or PAMN- 
(n=4) treated FAO hepatoma cells as described in Chapter 3 (technical replicates), in 
addition to vehicle- (n=4), PA- (n=4) or PAMN- (n=4) treated FAO hepatoma cells 
(biological replicates). RT-PCR was performed as described in Chapter 3. Data is 
presented as the average of n=8 samples. Primer sequences are detailed in Table 
5.1 below. All primers were designed using Beacon Designer 7.2 (Premier Biosoft 
International, CA, USA). 
 
TABLE 5.1: Primer sequences for RT-PCR experiments. 
Gene Forward primer sequence Reverse primer sequence 
Pepck AGCCATGTGCAACTCATGCA CTCGGTGCCACCTGAAACA 
G6Pase ACGCCTTCTATGTCCTCTTTCCC TGTTGCTGTAGTAGTCGGTGTCC 
Pepck, phosphoenolpyruvate carboxykinase, NM_198780; G6Pase, glucose-6-
phosphatase, NM_013098. 
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5.2.5. Statistical analysis 
Statistical analysis was performed using Statistical Package for the Social Sciences 
(SPSS) version 20.0 (IBM). Data were first analysed for normality using a one-sample 
Kolmogorov-Smirnov test. All data was determined to be normally distributed. Data 
were then either analysed using independent samples Students T-test, or a one-way 
ANOVA. Homogeneity of variance was determined using Levene’s Test, and post-
hoc analysis of ANOVA used either Fisher’s least significant difference (LSD, for 
homogeneous variance) or Games-Howell (for non-homogeneous variance). Data 
were considered significant at p<0.05. All data reported as mean values ± SEM. 
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5.3. Results 
 
As outlined in Chapter 4, GSEA of regulated expression between PA- and PAMN-
treated cells highlighted widespread transcriptional regulation of pathways involved 
in lipid metabolism. The most prominent of these regulatory pathways linked 
acetyl-CoA metabolism through to cholesterol metabolism, in which the majority of 
genes were down-regulated (from terpenoid backbone biosynthesis, hormone 
biosynthesis and steroid hormone biosynthetic pathways). Linked to this was the 
observed down-regulation in the primary bile acid biosynthetic pathway. Mass 
spectroscopic analysis of common lipid species was therefore performed to assess 
whether the observed changes at the transcriptional level may be having an effect 
on lipid metabolism, and therefore affecting specific lipid species. 
 
The following mass-spectroscopy derived results have been provided in pmol/mg 
protein for each lipid class. In order to directly compare between lipid classes, a 
complete set of standards is required for each individual lipid species measured. It 
should be noted that there were only 1-3 internal standards used for each lipid class 
in this study. Therefore, as advised by Prof Peter Meikle of the Metabolomics 
Laboratory at the Baker IDI, the comparisons of relative lipid levels have been 
restricted to within a single class of lipid. 
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5.3.1. Regulation of the TAG lipid profile by palmitate, metformin 
and sodium salicylate 
Following PA treatment, the levels of total TAG species were increased by +175 ± 
52% compared with vehicle-treated cells (nominal p=0.0360), and remained 
unchanged following PAMN-treatment (compared with PA-treated cells, Fig. 5.1 a). 
Palmitate treatment led to increased levels of 21 different TAG species, all with side 
chains ranging from 14C-18C, and zero to two double bonds (Fig. 5.1 b). Only 9 of 
these lipids contained a PA side chain, indicating that PA-treatment is driving 
metabolism into other medium or long chain species that are stored as TAGs. 
Following PAMN-treatment, only two TAG species were reduced (Fig. 5.1 b) – 18:0 
18:1 18:1 (-65 ± 22%, nominal p=0.0431), and 18:0 18:0 18:1 (-75 ± 16%, nominal 
p=0.0288) when compared with PA-treated cells. A further ten TAG species were 
detected which did not significantly change following either PA- or PAMN-
treatment (Fig. 4.1 c). 
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FIGURE 5.1: Regulation of intracellular TAG species with PA- and PAMN-
treatment in FAO hepatoma cells. 
Intracellular TAG levels in vehicle- (black), PA- (grey) or PAMN- (white) treated cells. 
(a) Increased total intracellular DAGs are observed with PA. (b) Individual TAG 
species with changed levels following treatment with either PA or PAMN. (c) 
Individual TAG species which did not change after treatment with either PA or 
PAMN. Data are expressed as mean ± SEM, n=3, *p<0.05 versus vehicle-treated lipid 
levels, †p<0.05 versus PA-treated lipid levels. 
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5.3.2. Regulation of the DAG lipid profile by palmitate, metformin 
and sodium salicylate 
Intrahepatic DAG species have been previously linked to dysregulation of hepatic 
glucose production in obese patients [268], therefore making DAGs a metabolite of 
interest in this study. Total DAG levels increased following PA-treatment by +36 ± 
11% (nominal p=0.0433) compared with vehicle-treatment. Similar to TAG levels, 
the increase in DAG levels was not changed with PAMN-treatment when compared 
with PA-treated levels (Fig. 5.2 a). 
 
Of all the DAG species detected, four had increased levels following PA-treatment 
(Fig. 5.2 b) – 16:1 18:1 (+64 ± 17%, nominal p=0.0350), 18:1 18:2 (+57 ± 16%, 
nominal p=0.0315), 18:1 18:1 (+50 ± 4%, nominal p=0.0019), and 18:0 18:1 (+44 ± 
13%, nominal p=0.0406) compared with vehicle. Two of these DAG species, 18:1 
18:1 and 18:0 18:1 were in turn decreased following PAMN- treatment (-18 ± 7%, 
nominal p=0.0320, and 36 ± 7%, nominal p=0.0304 respectively compared with PA-
treated cells), making them of specific interest as the increased lipid levels were 
reversed in parallel with the reversal of  dysregulated glucose production. One 
species – 18:1 20:0 – was unchanged with PA-treatment when compared with 
vehicle-treatment, but was decreased following PAMN-treatment (-49 ± 4%, 
nominal p=0.0216 compared with PA-treatment). The common inclusion of the side 
chain 18:1 (oleate) in all of these DAG species indicates a shift towards 18:1 DAG 
incorporation. Given the proposed role of DAGs in PKC activation and impairment of 
downstream insulin signalling, the increase in 18:1 containing DAGs may be a key 
regulator of glucose production in this model. A further 17 DAG species were 
measured which did not change following either PA or PAMN-treatment (Fig. 5.2 c).
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FIGURE 5.2: Regulation of intracellular DAG species with PA- and PAMN-
treatment in FAO hepatoma cells. 
Intracellular DAG levels in vehicle- (black), PA- (grey) or PAMN- (white) treated cells. 
(a) Increased total intracellular DAGs were observed with palmitate treatment. (b) 
Individual DAG species with changed levels following treatment with PA or PAMN. 
(c) Individual DAG species which did not change following treatment with either PA 
or PAMN. Data are expressed as mean ± SEM, n=3, *p<0.05 versus vehicle-treated 
lipid levels, †p<0.05 versus PA-treated lipid levels. 
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5.3.3. Regulation of the cholesterol lipid profile by palmitate, 
metformin and sodium salicylate 
Due to the transcriptional regulation of lipid metabolic pathways leading to 
cholesterol synthesis following PAMN-treatment (see Chapter 4), the levels of 
cholesterol and cholesterol esters were measured to determine whether regulation 
of the levels of these lipid species occurs in parallel with the regulation of hepatic 
glucose production. There was no significant difference in total intracellular 
cholesterol levels with either PA- (compared with vehicle-treated cells) or PAMN-
treatment (compared with PA-treated cells; Fig. 5.3 a). PA-treatment for 48 h 
increased total cholesterol esters (+92 ± 26%, nominal p=0.0092 compared with 
vehicle-treated cells), and while there was a trend for reduction in the levels of 
cholesterol esters following PAMN-treatment this did not reach significance (-31 ± 
16%, nominal p=0.0830, Fig. 5.3 b). As single species, only the levels of cholesterol 
ester 16:1 was significantly increased with PA-treatment (+180 ± 57, nominal 
p=0.0127, Fig. 5.3 c). There was a general trend for an increase across eight of the 
nine measured cholesterol esters (Fig. 5.3 c – d) – which was reflected in the 
observed increase to total cholesterol esters with PA-treatment. Only cholesterol 
ester 18:1 was altered with PAMN-treatment (-58 ± 13%, nominal p=0.0225, Fig. 5.3 
c). 
 
The lack of widespread changes to intracellular cholesterol species appears to be 
inconsistent with the regulatory changes observed in the transcriptional study in 
Chapter 4 in response to PAMN-treatment. However, because only total levels have 
been measured at this stage, alterations to metabolic flux through this pathway 
cannot be discounted. 
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FIGURE 5.3: Regulation of intracellular cholesterol and cholesterol ester 
levels in PA- and PAMN-treated FAO hepatoma cells. 
Intracellular cholesterol levels vehicle- (black), PA- (grey) or PAMN- (white) treated 
cells. (a) Total intracellular cholesterol levels were unchanged with either PA- or 
PAMN-treatment. (b) Total intracellular cholesterol esters were increased following 
PA-treatment. (c) Individual cholesterol ester species with changed levels following 
treatment with either PA or PAMN. (d) Individual cholesterol ester species that did 
not change after treatment with either PA or PAMN. Data are expressed as mean ± 
SEM, (a) n=3, (b-d) n=6, *p<0.05 versus vehicle-treated lipid levels, †p<0.05 versus 
PA-treated lipid levels. 
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5.3.4.1. Excreted cholesterol was detected at very low levels and 
was not regulated by either PA- or PAMN-treatment 
As there was no observed changes to cholesterol metabolism in response to PAMN-
treatment, levels of excreted cholesterol were measured to determine whether 
PAMN-treatment resulted in increased cholesterol release from the cells.  Levels of 
HDL and LDL/VLDL cholesterol, as free cholesterol, esterified cholesterol or total 
cholesterol forms were measured. No significant differences were observed 
between any of the treatment groups (vehicle-, PA- or PAMN-treated; Fig. 5.4). In 
addition, despite a modest average %CV (19%), the data was at the low end of the 
assay’s detection limit, as the LDL/VLDL results cross the x-axis. The standards used 
for the assay ranged from 0.25 – 7 μg/well cholesterol, which yielded a standard 
curve with an R2=0.9983. The highest concentration measured was 0.093 μg/well 
cholesterol in the vehicle total HDL group, approximately a third of the lowest 
standard. The reliability of the assay for the detection of excreted cholesterol in 
conditioned media was therefore difficult to interpret, however the standard 
deviation within each sample is modest and consistent. In light of the limitations 
reported here with regards to this assay, these results indicate no difference 
between excreted cholesterol levels in vehicle-, PA- or PAMN-treated cells. 
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FIGURE 5.4: Profile of excreted cholesterol following PA- and PAMN-
treatment in FAO hepatoma cells. 
Excreted HDL, LDL/VLDL and total cholesterol fractions in vehicle- (black), PA- (grey) 
and PAMN- (white) treated conditioned media. Data are expressed as mean ± SEM, 
n=3 *p<0.05 versus vehicle-treated cholesterol levels, †p<0.05 versus PA-treated 
cholesterol levels. 
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5.3.5. Total bile acids were not regulated by PA- or PAMN-treatment 
in FAO hepatoma cells 
As there was no detectable difference in either intracellular or excreted cholesterol, 
bile acids were next measured to determine if changes in cholesterol pathway 
regulation might result in altered bile acid production. This arm of the cholesterol 
biosynthetic pathway was also identified via GSEA (see Chapter 4), and in addition 
the role of bile acids in regulating glucose metabolism through the Fxr receptor has 
been described previously [242, 243], therefore making the determination of both 
intracellular and excreted bile acid levels important in identifying potential 
mediators of glucose production in this model. 
 
Both total intracellular and excreted bile acids were measured in cell lysate and 
conditioned media respectively. No differences were observed in the total 
intracellular or excreted levels of bile acids between vehicle-, PA- or PAMN-treated 
cells (Fig. 5.5). However the methodology used in this study for detection of total 
bile acids is only capable of measuring the total level of bile acid, and is unable to 
determine the rate of flux through cholesterol to bile acids. Therefore, the role of 
bile acids in regulating glucose production requires further investigation at this 
stage. 
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FIGURE 5.5: Regulation of intracellular and excreted total bile acids in PA- 
and PAMN-treated FAO hepatoma cells. 
Intracellular and excreted total bile acids from vehicle- (black), PA- (grey) or PAMN- 
(white) treated cells. Data are expressed as mean ± SEM, n=3 *p<0.05 versus 
vehicle-treated total bile acid levels, †p<0.05 versus PA-treated total bile acid levels. 
 
 
5.3.6. Modest regulation of the ceramide lipid profile by PA- and 
PAMN-treatment 
Although ceramides have been shown to play a key role in the regulation of insulin 
resistance and glucose metabolism in muscle cells, their role in the liver is not as 
well defined (see Introduction). Therefore, characterisation of ceramide 
metabolism in this model was warranted. Total ceramide levels did not change with 
PA- or PAMN-treatment (Fig. 5.6 a). It is becoming increasingly clear however that 
specific species of ceramide have the ability to affect insulin signalling, not just total 
ceramide levels. There were four ceramide species that increased with PA-
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treatment compared with vehicle-treated cells; cer 18:0 (+34 ± 8%, nominal 
p=0.0110), cer 20:0 (+123 ± 19%, nominal p=0.0001), cer 22:0 (+54 ± 11%, nominal 
p=0.0011), mono-hexocyl-ceramide (MHC) 20:0 (+242 ± 60%, nominal p=0.0175) 
and MHC 22:0 (+107 ± 23%, nominal p=0.0041), however these were not further 
altered following PAMN-treatment (Fig. 5.6 b). Only MHC 24:0 was decreased with 
PA-treatment (-19 ± 6%, nominal p=0.0363) compared with vehicle-treatment. 
Further, only one ceramide, dihydro-ceramide (dhcer) 20:0 was lowered with 
PAMN-treatment (-41 ± 8%, nominal p=0.0386) compared with PA-treated cells (Fig. 
5.6 b). A further 15 ceramide species remained unchanged following both PA- and 
PAMN-treatment (Fig. 5.6 c). 
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FIGURE 5.6: Regulation of intracellular ceramide species with PA- and 
PAMN-treatment in FAO hepatoma cells. 
Intracellular ceramide levels in vehicle- (black), PA- (grey) or PAMN- (white) treated 
cells. (a) Total intracellular ceramide remained unchanged with PA- and PAMN-
treatment. (b) Individual ceramide species with changed levels following treatment 
with either PA or PAMN. (c) Individual ceramide species which did not change 
following treatment with PA or PAMN. Data are expressed as mean ± SEM, n=6, 
*p<0.05 versus vehicle-treated ceramide levels, †p<0.05 versus PA-treated 
ceramide levels.  
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5.3.7. Modest regulation of the sphingomyelin lipid profile by PA- 
and PAMN-treatment 
Structurally related to ceramides, the sphingomyelins (SM) are a class of membrane 
phospholipids usually located within the membrane of the myelin sheath of nerve 
cell axons. Sphingomyelins contain a ceramide backbone and polar head group, and 
can be interconverted to ceramides. Sphingomyelin synthase 2 (Sms2) knockout 
animals have been shown to have lower fasting blood glucose and insulin levels 
alongside a reduced SM content in plasma membrane lipid microdomains [277, 
278]. In vitro studies have shown the addition of SM inhibited insulin-stimulated Akt 
phosphorylation in HepG2 cells following acute (5 h) treatment [278]. In this study, 
total sphingomyelins were not altered between vehicle-, PA- or PAMN-treated cells 
(Fig. 5.7 a). 
Following PA-treatment, SM 18:1 and 20:0 both increased (by +385 ± 78%, nominal 
p=0.0386 and +94 ± 24%, nominal p=0.0278 respectively) compared with vehicle-
treated cells. In contrast to the effects of PAMN-treatment on the other lipid 
classes, two species of SM increased with PAMN-treatment compared with PA-
treated cells; 14:1 (+201 ± 47%, nominal p=0.0204) and 20:1 (+150 ± 38%, nominal 
p=0.0061, Fig. 5.7 b). Although there was no overall change to SM lipids with either 
PA- or PAMN-treatment, the alterations of individual species may play a role in the 
regulation of hepatic insulin sensitivity with PA-treatment. 
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FIGURE 5.7: Regulation of intracellular sphingomyelin species with PA- 
and PAMN-treatment in FAO hepatoma cells. 
Intracellular sphingomyelin levels in vehicle- (black), PA- (grey) or PAMN- (white) 
treated cells. (a) Total intracellular sphingomyelin remain unchanged with PA- and 
PAMN-treatment. (b) Individual sphingomyelin species with changed levels 
following treatment with either PA or PAMN. (c) Individual sphingomyelin species 
which did not change after treatment with either PA or PAMN. Data are expressed 
as mean ± SEM, n=6, *p<0.05 versus vehicle-treated lipid levels, †p<0.05 versus PA-
treated lipid levels. 
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5.3.8. Regulation of the phosphatidylinositol lipid profile by 
palmitate, metformin and sodium salicylate 
Given their role as signalling intermediates in the insulin signalling cascade, and the 
identification of the inositol phosphate metabolism pathway as being regulated 
with PA-treatment, the phosphatidylinositol (PI) class of lipids was investigated to 
observe if the changes in transcriptional regulation impacted upon the levels of 
intracellular metabolites of this class. Total PI levels were not significantly different 
following PA- or PAMN-treatment (Fig. 5.8 a). Phosphatidylinositol species were the 
only class of lipid where the majority of changes observed at the individual species 
level were due to PAMN- treatment compared with PA-treatment (Fig. 5.8 b). 
Treatment with PAMN lead to increased levels of PI 32:1 (+109 ± 38%, nominal 
p=0.0074) and PI 36:4 (+55 ± 14%, nominal p=0.0296), while also leading to 
decreased levels of PI 38:2 (-38 ± 9%, nominal p=0.0397) and PI 40:5 (-24 ± 5%, 
nominal p=0.0414), compared with PA-treated cells. PA-treatment increased levels 
of PI 36:1 (+49 ± 10%, nominal p=0.0013 compared with vehicle-treated cells), while 
levels of this species were decreased following PAMN-treatment (-35 ± 6%, nominal 
p=0.0010 compared with PA-treated cells). 
 
One species of specific interest identified through this analysis was PI 38:5. PA-
treatment lead to decreased levels of PI 38:5 (-34 ± 11%, nominal p=0.0283 
compared with vehicle-treated cells). There was a trend for an increase in PI 38:5 
following PAMN-treatment, although this did not reach significance (+36 ± 2%, 
nominal p=0.0691 compared with PA-treated cells). The regulation of PI 
phosphorylation by phosphoinositide-3-kinase (PI3K), and subsequent downstream 
activation of the insulin signalling cascade has been described for many years [279]. 
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Despite this, the identity of specific PI species and their side chains and what role 
the identity of the side chains has in signal transduction or glucose production, has 
yet to be described. The potential to identify a specific PI species, which might play 
a key role in signal transduction involved in glucose production, would be an 
important advance in our understanding of this signalling molecule and insulin 
action. For this reason, further investigation as to the identity of the side chains of 
PI 38:5 was warranted, and this is detailed below. 
 
Additionally, PI 40:4 decreased following PA-treatment (-32 ± 2%, nominal p=0.0047 
compared with vehicle-treated cells), and remained unchanged following PAMN-
treatment (mirroring the induction of insulin-resistance with PA-treatment, which 
was not restored with PAMN-treatment). However, reduction in levels of this lipid 
species only reached nominal significance upon repetition of the mass 
spectroscopic analysis (the addition of further 3 independent experiments bringing 
the total to 6), which occurred at the same time as the side chain determination of 
PI 38:5 was performed. Similarly the changes observed in the predominant PI 36:1 
only reached nominal significance upon repetition of the mass spectroscopic 
analysis. For this reason, the side chain determination of PI 40:4 and PI 36:1 in this 
model remains unresolved at this time, however this would be of future interest. 
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FIGURE 5.8: Regulation of intracellular PI species with PA- and PAMN-
treatment in FAO hepatoma cells. 
Intracellular phosphatidylinositol levels in vehicle- (black), PA- (grey) or PAMN- 
(white) treated cells. (a) Total intracellular phosphatidylinositol remain unchanged 
with palmitate, metformin and sodium salicylate treatment. (b) Individual 
phosphatidylinositol species with changed levels following treatment with 
palmitate, metformin and sodium salicylate. (c) Individual phosphatidylinositol 
species which did not change after treatment with palmitate, metformin and 
sodium salicylate. Data are expressed as mean ± SEM, n=6, *p<0.05 versus vehicle 
lipid levels, †p<0.05 versus palmitate lipid levels.  
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5.3.8.1. Characterisation of lipid side chains on 
phosphatidylinositol 38:5 
There is currently little information available indicating whether the identity of the 
PI signalling lipid is important for its ability to be involved in signal transduction. 
Therefore, determining the identity of PI 38:5 may for the first time provide the 
identity of a key signalling lipid. PI 38:5 is of interest as it decreased following PA-
treatment, making it a possible candidate for impaired insulin action observed with 
PA-treatment in these cells - correlating with the regulation of glucose production in 
this model. The mass and expected negative ion mass/charge ratio (m/z) of the 
likely species appears in Table 5.2. 
 
TABLE 5.2: Expected fragments from the product ion scans of PI 38:5. 
Expected Fragment Mass (g/mol) Mass of negative ion 
(m/z) 
C18:0 (stearic acid) 284.5 283.5 
C18:1 (oleic acid) 282.5 281.5 
C20:4 (arachidonic acid) 304.5 303.5 
Inositol Head Group 242 241 
 
 As proof of principle, a de-identified human plasma sample (provided by the Meikle 
lab, BakerIDI) was analysed. Retention time for the precursor ion was 5.4 validating 
the identity of the lipid. The main peaks of the product ion scan had m/z of 240.8, 
281.2 and 303.4, corresponding to the inositol head group, C18:1 and C20:4 
respectively (Table 5.3, Appendix 6). 
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One random sample from each of the vehicle-, PA- and PAMN-treated samples was 
then subjected to the product ion scan protocol. Retention time for the precursor 
ions fell within the predicted range (vehicle: 5.41 min; PA: 5.38 min; PAMN: 5.41 
min). After fragmentation, the inositol head group was also detected in each sample 
within the predicted m/z range (240.8 - 241.3 m/z). The predicted side chains of 
arachidonic acid and oleic acid were detected in each of the samples (Table 5.3, 
Appendix 6). In addition, smaller peaks at 255.0 m/z and 329.2 m/z were identified 
in the vehicle-treated sample, which correspond to the mass of C16:2 and C22:3. 
These side chains also add to 38:5, and may therefore represent a minor PI 38:5 
lipid, present at a lower concentration than oleic and arachidonic acid containing 
species (Appendix 6). The identification of the side chains of PI 38:5 may be the first 
characterisation of a specific PI species of importance in the insulin signalling 
cascade. Further experimentation will be required to confirm this finding (see 
Discussion). 
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TABLE 5.3: Identified peaks from the product ion scans of PI 38:5.  
Sample Mass of negative ion 
(m/z) 
Identified lipid side chain 
De-identified Human plasma 281.2 C18:1 (oleic acid) 
 303.4 C20:4 (arachidonic acid) 
 
 
240.8 Inositol Head Group 
Vehicle 281.3 C18:1 (oleic acid) 
 303.2 C20:4 (arachidonic acid) 
 
 
240.8 Inositol Head Group 
PA 281.1 C18:1 (oleic acid) 
 303.1 C20:4 (arachidonic acid) 
 
 
240.8 Inositol Head Group 
PAMN 281.3 C18:1 (oleic acid) 
 303.1 C20:4 (arachidonic acid) 
 241.3 Inositol Head Group 
 
5.3.9. Increased lipid levels for species containing palmitate side 
chains was not common to all measured species 
In order to assess how palmitate might be incorporated and metabolised by cells, 
only those species measured which had at least one PA chain were grouped 
together and assessed (Fig. 5.9). No changes in lipid levels were observed in any 
DAG species containing PA following either PA- or PAMN-treatment (Fig. 5.9 a). 
Given one of the more prevalent current hypotheses of lipid-induced glucose 
deregulation is via DAG-mediated activation of PKC isoforms (reviewed in [280]), 
this result highlights the necessity for the metabolism of PA to other lipids in order 
to up regulate DAG levels. In contrast, there was significant up regulation in the 
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levels of nine PA-containing TAG species (14:0 16:0 18:2, +224 ± 69%, nominal 
p=0.0331; 14:1 16:0 18:1, +222 ± 38%, nominal p=0.0061; 18:1 14:0 16:0, +165 ± 
39%, nominal p=0.0166; 16:0 16:0 16:0, +114 ± 27%, nominal p=0.0132; 16:0 16:0 
18:2, +184 ± 47%, nominal p=0.0263; 16:0 16:1 18:1, +188 ± 60%, nominal 
p=0.0427; 16:0 16:0 18:0, +177 ± 29%, nominal p=0.0044; 16:0 18:1 18:2, +354 ± 
107%, nominal p=0.0320; 16:0 18:0 18:1, +212 ± 71%, nominal p=0.0483), while 
only four PA-containing TAG species remained unchanged following PA-treatment 
compared with vehicle-treatment (Fig. 5.9 b). Of the remaining PA-containing lipids, 
there were four ceramides, one cholesterol ester, one phosphatidylglycerol and one 
sphingomyelin. None of these species were changed following PA-treatment 
compared with vehicle-treated cells. No PA-containing lipid species were altered 
following PAMN-treatment compared with PA-treatment. 
 
These results indicate that the changes observed for all lipid species described 
above are not only a result of direct PA incorporation, but rather result from 
widespread regulation of lipid metabolism leading to the conversion of PA to other 
long chain fatty acids and subsequent downstream fluctuations in global lipid 
metabolism. 
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FIGURE 5.9: Regulation of lipid species with PA side chains in PA- and 
PAMN-treated FAO hepatoma cells. 
Intracellular lipid species with palmitate side chains in vehicle- (black), PA- (grey) or 
PAMN- (white) treated cells. (a) All measured DAG species with PA side chains 
remain unchanged with PA- or PAMN-treatment. (b) All measured TAG species with 
PA side chains following PA- and PAMN-treatment. (c) All remaining lipid species 
with PA side chains following PA- and PAMN-treatment. Data are expressed as 
mean ± SEM, (a-b) n=3, (c) n=6, *p<0.05 versus vehicle-treated lipid levels, †p<0.05 
versus PA-treated lipid levels.  
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5.3.10. PA-treatment was not associated with changes to the 
gluconeogenetic genes Pepck or G6Pase 
Finally, to further investigate the changes in glucose production observed in this 
model, RT-PCR analysis of the gluconeogenetic genes Pepck and G6Pase was 
performed. PA-treatment did not significantly alter the gene expression levels of 
either Pepck or G6Pase (Fig. 5.10). Although there was a trend for a reduction in 
Pepck expression with PA-treatment this did not reach significance (p=0.1120). 
PAMN-treated cells had significantly lower expression of Pepck than vehicle-treated 
cells (p=0.0033), however this was not significant versus PA-treated cells. The lower 
Pepck expression observed here in PAMN-treated cells appears consistent with 
lower glucose production in these cells. In contrast however, the changes observed 
in Pepck expression with PA-treatment were in conflict with the increase in glucose 
production, indicating that expression of this gene may not be the predominant 
regulator of glucose production in this model. The expression of G6Pase was not 
altered with either PA- or PAMN- treatment (Fig. 5.10). 
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FIGURE 5.10: Regulation of the gluconeogenetic genes Pepck and G6Pase 
with PA and PAMN-treatment. 
Relative gene expression levels for (a) Pepck and (b) G6Pase in vehicle- (black), PA- 
(grey) and PAMN- (white) treated FAO hepatoma cells. Gene expression levels are 
normalised to cDNA concentration. Data are expressed as mean ± SEM, n=8, 
*p<0.05 versus vehicle-treated, †p<0.05 versus PA-treated.  
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5.4. Discussion 
The main hypothesis drawn from the results of Chapter 4 was that the 
transcriptional alterations in the pathways leading to cholesterol and bile acid 
metabolism may have impacted upon cellular levels of cholesterol and bile acids, 
and as such may be responsible for the regulation of glucose production in FAO 
cells. In this chapter, the levels of both intracellular and excreted cholesterol and 
bile acids were determined in order to test this hypothesis. There was no detected 
difference between either vehicle-, PA- or PAMN-treated cells for either total 
intracellular or excreted cholesterol or bile acids. The only difference observed was 
for cholesterol esters, which were increased with PA-treatment compared with 
vehicle-treated cells. Therefore, it is possible that the regulation of this metabolic 
pathway at the transcriptional level has had an effect on the metabolism of 
cholesterol ester species. However, it is also true that the increase in cellular lipid 
content with PA-treatment has flowthrough effects on cellular lipid metabolism as 
the cellular lipid pool reaches a state of metabolic equilibrium – and therefore the 
contribution of transcriptional regulation of these pathways is inconclusive at this 
stage. 
 
Despite the measured steady state of cholesterol and bile acids in this study, no 
conclusions can be drawn about the metabolic flux though these pathways until 
further analysis is performed. Due to the comprehensive transcriptional decreases 
observed in the cholesterol and bile acid metabolic pathways, both the synthesis 
and degradation of these metabolites could have been affected. Therefore, total 
levels of cholesterol and bile acids may not change, despite changes in metabolic 
flux through the pathway. Stable isotope labelling of key intermediates or 
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precursors of this pathway such as acetyl-CoA and cholesterol, alongside the cellular 
treatments used in this chapter (vehicle, PA and PAMN) would allow for the rate of 
flux though these pathways to be determined. This would resolve the unanswered 
questions remaining with regards to cholesterol and bile acid synthesis. Recently, a 
conference paper presented by Dr Carsten Schmitz-Peiffer of the Garvan Institute 
Of Medical Research at the Australian Diabetes Society’s 2012 annual meeting 
showed similar pathway regulation of acetyl-CoA and cholesterol metabolism in 
high-fat fed PKCε-/- mice compared with high fat fed wild type control mice (the 
model recently published in [94]). Consistent with the findings of the current study, 
the presented paper did not observe any changes to intrahepatic total cholesterol 
levels. Metabolic flux through this pathway was determined, by using 14C-acetate as 
a precursor for cholesterol synthesis. PKCε-/- liver cells were incubated with 14C-
acetate for 4 – 20 h, followed by Folch extraction of lipids, thin layer 
chromatography, and exposure to film for radioactive imaging. Altered metabolic 
flux through this pathway to cholesterol was found in PKCε-/- liver cells compared 
with wild type cells. The same analysis could be performed on PA- and PAMN-
treated FAO hepatoma cells in order to determine if the pathway regulation 
described in Chapter 4 is consistent with an altered metabolic flux through this 
pathway. 
 
The transcriptional regulation of PI metabolism was described in Chapter 3 in 
response to PA-treatment. A comprehensive analysis of the PI content of vehicle-, 
PA- and PAMN-treated cells identified PI 38:5, which decreased with PA-treatment 
and had a trend (p=0.0691 compared with PA-treated)  for an increase following 
PAMN-treatment. While the metabolism of some PI species and the relevant 
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enzymes involved have been previously studied [281], the contribution of specific PI 
species in insulin signalling and hepatic glucose production remains unresolved. For 
this reason, further study was completed which identified the side chain identity of 
PI 38:5. Taken together, the product ion scans indicate the major identity of PI 38:5 
across the three treatment groups was C18:1 (oleic acid) and C20:4 (arachidonic 
acid). The reduction in this C18:1 containing species is particularly relevant in the 
context of DAG metabolism as outlined below, where a general increase in DAG 
species with C18:1 side chains was identified in response to PA-treatment (Fig. 5.2 
b). A lower level of the side chains C16:2 (hexadecadienoic acid) and C22:3 
(docosatrienoic acid) were identified in vehicle treated cells, indicating a second 
potential minor identity for this species. The identification of the side chains of PI 
38:5 is the first characterisation of a specific PI species of importance in the insulin 
signalling cascade. Further experimentation will be required to confirm this finding, 
such as to determine whether the identity of the side chains in PI species affects 
their ability to be phosphorylated (PIP2 to PIP3 phosphorylation) in response to 
insulin. This could be achieved by utilising commercially available antibodies for PIP2 
and PIP3. These antibodies allow for the immunoprecipitation of the PIP2 and PIP3 
pools from basal and insulin stimulated FAO cells, which could then be extracted 
and undergo lipidomic analysis as described in this chapter. This would indicate for 
the first time whether the identity of the side chains of PI species are important in 
their ability to become phosphorylated in response to insulin. In addition, the same 
experiment could then be performed on vehicle-, PA- and PAMN-treated cells in the 
presence and absence of insulin to determine whether this hypothesis is true of the 
model detailed in this thesis. 
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Increased levels of DAGs, TAGs, and cholesterol esters were all observed with the 
induction of insulin resistance and elevated glucose production in the liver cells. The 
role that these species play in the induction of elevated glucose production in the 
liver remains unresolved. Mice which lack the microsomal triglyceride transfer 
protein (Mttp) in the liver (a protein that blocks hepatic VLDL secretion) display 
steatosis characterised by accumulation of TAG, DAG and ceramide species, while 
retaining normal glucose homeostasis [282]. However, given that incubating hepatic 
cells with lipids as in this study, and both high fat feeding in mice [144] and lipid 
infusions in mice [111] and human patients [283] have been shown to cause 
increased hepatic glucose production and insulin resistance, it is clear that 
individual lipid metabolites are capable of inducing insulin resistance and high 
glucose production in the liver. The identity of such species however remains 
elusive. By looking for species that were reduced with PAMN-treatment, we 
propose that we can identify potential mediators of glucose production. 
 
The role of TAGs as a mostly neutral storage pool for lipids makes it unlikely that 
any of these species is directly involved in the induction of insulin resistance or the 
dysregulation of glucose production as observed in this model, however 
metabolism of TAG species towards other more toxic species – such as DAGs – 
makes the capacity of the TAG storage pool an important element in the 
development of lipid-induced metabolic disorders. 
 
DAG species are a plausible candidate for this effect due to their role in PKCε 
activation [284], and subsequent Ser307 phosphorylation of IRS-1 [84], leading to 
inhibition of downstream signalling. Three DAG species in this study were found to 
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decrease with PAMN-treatment – 18:1 18:1, 18:0 18:1 and 18:1 20:0. Similarly two 
TAG species followed this profile – 18:0 18:1 18:1 and 18:0 18:0 18:1, as well as one 
cholesterol ester – 18:1. Sung et al [269] have reported that the ability of lipids to 
activate PKC isoforms is proportional to the degree of unsaturation of the lipid 
species. A lowering in levels of oleic acid containing lipid species in cells treated 
with PAMN may therefore lead to a lowering of glucose production by reducing 
metabolically toxic DAG species responsible for PKCε activation. The increase in 
DAG incorporation of C18:1 in these cells with PA-treatment follows the decrease in 
the C18:1 containing PI 38:5, indicating a potential metabolic shift in the storage of 
oleic acid away from this PI species and towards DAG incorporation. 
 
In light of the known effect of DAGs on inducing insulin resistance and elevated 
glucose production in the liver, it may at first seem contradictory that the decrease 
in glucose production observed with PAMN-treatment was not accompanied by a 
restoration of normal TAG and DAG levels. However the main effect of PAMN-
treatment in the current study was to lower basal glucose production, and insulin 
resistance remained in the PAMN-treated cells. Therefore, by treating with 
metformin and sodium salicylate, we appear to have bypassed the insulin resistant 
insult to independently lower glucose production in the face of PA-treatment. The 
disconnect between basal (insulin free) and insulin-stimulated (0.1 nM insulin) 
glucose production presented here is not completely true of the in vivo condition, 
where a basal level of insulin will be present even in the fasted state. However, 
decreasing the baseline glucose production (as with metformin treatment) in an in 
vivo diabetic state remains an effective therapy against T2D [200]. 
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 Early studies performed in the 90s showed in vivo increases in total ceramide levels 
in both the muscle and the liver of obese, insulin resistant Zucker rats compared 
with lean, control animals [96]. In the intervening years, ceramide accumulation 
was shown to play a critical role in the development of insulin resistance in muscle 
[152]. The link between ceramide accumulation and insulin resistance in the liver 
however has not been as clearly defined, with recent studies reporting hepatic 
accumulation of ceramide in high fat fed acid sphingomyelinase (Asm) knockout 
mice, despite the mice maintaining the same blood glucose levels during a GTT and 
ITT as knockout animals on normal chow, and wild type controls on a high fat diet  
[97] – indicating that the accumulation of hepatic ceramide does not induce insulin 
resistance in these mice. Recent studies have shown that HepG2 cells possess the 
ability to actively secrete ceramide in a dose and time dependant manner, despite 
maintaining relative stability in intracellular levels [100]. This evidence suggests the 
liver possesses an ability to sense rising intracellular ceramide levels and actively 
excrete ceramide to preserve a stable intracellular concentration. It is therefore 
possible that the liver has an ability to excrete potentially harmful ceramide 
metabolites as a protective mechanism [100]. This hypothesis may explain the 
relative stability in intracellular ceramide levels in the current study in the face of 
PA-treatment. Measurement of extracellular ceramide levels would need to be 
performed in vehicle-, PA- and PAMN-treated conditioned media in order to 
determine if this mechanism was contributing to the relative stability of intracellular 
ceramide levels in the current study. 
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The transcriptional regulation of Pepck has been widely regarded as the rate 
limiting step of de novo glucose production by the liver for the past 30 years [285]. 
Pepck has been reported to be overexpressed across multiple rodent models of 
diabetes where elevated hepatic glucose production is present [286]. Given the 
multilayered regulatory control of Pepck expression [287], and the apparent parallel 
between Pepck expression levels and hepatic glucose output, expression levels of 
Pepck has widely been used as an indicator of hepatic glucose production. 
Interestingly, the increase in basal glucose production observed with PA-treatment 
in this study was in the absence of changes in either Pepck or G6Pase gene 
expression levels, as was the observed decrease in basal glucose production with 
the addition of metformin and sodium salicylate. Previous studies in primary rat 
hepatocytes found that the metformin induced decrease in glucose production 
occurred with decreased G6Pase expression and no change to Pepck expression 
[164] – consistent with the findings of this study for Pepck expression but in 
contrast to the measure G6Pase expression. Further, a study by Burgess et al. [288] 
showed that in mice with varying degrees of Pepck expression in the liver, a 90% 
reduction in Pepck gene expression only resulted in a 40% decrease to flux through 
the hepatic glucose production pathway. Therefore, the use of Pepck gene 
expression as a proxy for hepatic glucose production is not always accurate and 
should be interpreted as a relevant mechanism for elevated glucose production 
only when the relevant rate of glucose production has been measured. 
 
The metabolic fate of PA in PA-treated cells appears to lie in both direct TAG 
incorporation (Fig. 4.1 b) as well as metabolism to longer chain and unsaturated 
species (Fig. 4.10). The reduction in glucose production observed with PAMN-
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treatment occurred independently of changes to TAG species with PA side chains, 
suggesting that these TAG species are not playing a significant role in the regulation 
of glucose homeostasis. This further adds evidence to the role of non-PA containing 
species, generated as a consequence of increased PA metabolism, in the regulation 
of glucose homeostasis in this model. 
 
In Chapter 4 the reversal of high glucose production in the liver was characterised 
by transcriptional regulation of cholesterol and bile acid biosynthetic pathways. 
While the total levels of cholesterol and bile acids remained unchanged with PA- 
and PAMN-treatment, it is possible that metabolic flux through these pathways has 
been altered, and the emerging role of this system in regulation of glucose 
metabolism in the liver makes it an attractive target for therapeutic intervention. A 
detailed profile of lipid metabolites across both PA-treated (insulin resistant, high 
glucose producing) and PAMN-treated (low glucose producing) cells was also 
compiled. The identification of multiple lipid species, mostly containing C18:1 side 
chains, regulated in parallel with a reduction in glucose production indicates 
potential mediators of both insulin resistance and regulation of glucose production 
in the liver. Therefore, the main aim for this chapter – utilising a mass spectroscopic 
based lipidomic analysis of vehicle, PA- and PAMN-treated cells in order to 
determine whether the changes observed in transcriptional regulation as outlined 
in Chapter 4 affect the metabolism of lipids in these cells – has been successfully 
completed. The secondary aim of this chapter – to utilise specific targeted 
approaches to investigate the metabolism of cholesterol and bile acids – was also 
successfully completed.  
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Chapter 6 –Conclusions and Future Directions 
 
The overall aim of this project was to investigate the utility of whole genome 
microarray techniques to (1) identify candidate GES genes as a new and unbiased 
screening tool, and (2) to identify metabolic pathway regulation, in a model of lipid-
induced dysregulated glucose metabolism. 
The findings reported here suggest that the transcriptional changes associated with 
PA-induced dysregulation of hepatic glucose production are relatively low 
compared to other models of insulin resistance and dysregulated glucose 
metabolism [141]. Strong evidence was presented in Chapter 4 that the reduction in 
hepatic glucose production by metformin and sodium salicylate comprehensively 
decreased the gene expression levels of all the enzymes regulating the conversion 
of acetyl-CoA to cholesterol, and the effects of these transcriptional changes on 
lipid metabolism were described. These changes could not be measured at the level 
of the metabolite cholesterol using the techniques employed in this study, however 
this research is ongoing, and will be outlined below. Finally, a novel 
phosphatidylinositol species PI 38:5 was identified, and along with two other 
members of the PI family (PI 36:1 and PI 40:4) warrant further investigation as to 
their contribution to insulin signalling and hepatic glucose production. 
This chapter will summarise the findings of this study, and discuss the possible 
significance in vivo. Future studies (1) to identify candidate GES genes for a PA-
induced model of dysregulated glucose production, and (2) to investigate the role of 
phosphatidylinositol and cholesterol metabolism in the regulation of glucose 
production, will be discussed. 
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6.1. Identification of candidate GES genes for confirmation 
in a human cohort 
The DLDA approach utilised in this study identified 14 candidate GES genes. Initial 
analysis of the expression levels of the seven genes, which were mapped to known 
genes using BLAST search, could not be verified by RT-PCR analysis. One major 
reason for lack of correlation between the microarray and RT-PCR analysis was the 
relatively small fold changes observed for the candidate genes following PA-
treatment, reducing the ability to detect differential gene expression [220, 222, 
223]. This varies from previous GES attempts by our laboratory where both a larger 
number of candidate genes, alongside greater fold changes in gene expression 
levels enabled the successful validation of a five gene GES responsive to the pro-
inflammatory cytokine TNFα [141]. Therefore, the identification of additional genes 
to identify a PA-based GES is necessary if this aspect of the project is to be 
completed. This could occur by one of two ways – either identify new genes in the 
current microarray dataset that were not found in the initial DLDA attempt, or 
identify the unknown genes from the original DLDA attempt. 
 
Firstly, by relaxing the stringency of the DLDA analysis, a greater number of 
candidate genes may be identified. By expanding the number of candidate genes via 
this approach, the chance of finding a gene that may be validated by RT-PCR should 
be increased. Unfortunately, the Acuity software package available to our 
laboratory cannot be modified to allow for alternative criteria for gene selection. 
Alternative software packages available to perform this role include GeneSpring 
(Agilent), however these software packages have a significant recurring cost and as 
such remain unavailable for use in this project at this time. An alternative approach 
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could be to exclude all genes with fold changes less than 2.0 from the dataset prior 
to the DLDA, as this is a commonly suggested limit under which decreased 
correlation is observed [224]. However, given the fold-changes observed in the top 
candidate genes identified through DLDA, it is unlikely that there are many genes 
with greater fold-changes, which are highly significant discriminators of all three 
treatments. This approach may therefore limit the number of genes in the dataset 
to a very small subset, thus making any further analysis difficult. 
 
An effective alternative is the use of Bayesian statistical analysis to identify 
candidate genes. The power of this approach is that the strength of the gene set as 
a whole in discriminating between the various biological states can be calculated. 
Although this side of the analysis was completed too late for inclusion in this thesis, 
the identification of candidate genes via this approach is currently ongoing. 
Interestingly, it appears at this early stage that many of the same genes are being 
identified as were described by DLDA in this study – which may somewhat limit this 
approach for candidate gene identification for this model. The correlation between 
DLDA and Bayesian gene identification has been previously described by our group 
[141]. 
 
Identification of the seven genes that were unable to be mapped to known genes 
using a BLAST search may allow for the description of previously unknown genes. 
Initial experimentation would involve extending the 60mer sequence from the 
Agilent microarray for each of the unknown candidate genes, which may yield 
additional information as to the identity of the genes. With additional sequence 
   Chapter 6: Conclusions and future directions 
189 
 
length, possible protein sequences could be identified, and in silico analysis to 
predict if the sequence contains any known or relevant domains. 
 
The San Antonio Family Heart Study data [150] is available for further data mining 
upon identification of alternative putative GES genes. In addition, the use of 
alternative human cohorts would be sought for further validation of putative GES 
genes. 
 
6.2. The role of Anxa3 in dysregulated glucose production 
and whole body insulin resistance 
Further to the development of a GES with the candidate genes, analysis of the 
individual genes that were identified via DLDA in the microarray data may provide 
further insight into the mechanism of action of the PA- and PAMN-treatments 
observed in this study. Anxa3 was identified as a candidate GES gene, and was also 
found to be expressed in human lymphocyte tissue (a pre-requisite for our GES 
development). Human phenotype data was interrogated to observe if the 
expression of Anxa3 was associated with the metabolic syndrome. Despite showing 
a correlation to fasting blood glucose and total serum triglycerides, this was not 
independent of age, sex and BMI. Although expression of this gene was not found 
to be an independent predictor of fasting blood glucose, a role for Anxa3 in 
regulation of glucose metabolism has been described through its inhibitory 
interaction with another of the candidate genes identified in this study – Pla2g1b. It 
is hypothesised that the increase in Anxa3 gene expression observed with PA-
treatment is acting as a cellular defence mechanism against excessive cellular lipid 
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levels. Following the regulation to lipid metabolism with PAMN-treatment, Anxa3 
gene expression levels decrease due to other defences against PA-stress being 
present (altered lipid metabolism). 
 
To further assess the ability of Anxa3 to regulate hepatic glucose production a 
number of additional experiments will need to be performed. Both gain- 
(overexpression) and loss- (knockdown) of-function studies for Anxa3 will be 
required to answer these questions. Overexpression of a HA-tagged Anxa3 has been 
achieved using the pcDNA3.1/Zeo plasmid to transfect human embryonic HEK293T 
kidney cells [289]. In addition, the use of a lactacystin-inducible Anxa3 pT-Rex-
DEST30-ANXa3 plasmid has been described in primary cortical neurons from mouse 
embryos [290]. Knockdown of Anxa3 has been achieved with RNA interference 
(RNAi) in primary parenchymal rat hepatocytes [291]. The validation of 
overexpression and knockdown of Anxa3 has been successfully achieved in these 
studies using RT-PCR (for mRNA) and western blotting (protein levels). In both gain- 
and loss-of-function conditions, the effects of Anxa3 overexpression or deficiency 
on glucose production would be assessed. It is proposed that increasing the gene 
expression of Anxa3 would inhibit a PA-induced increase to glucose production. It is 
further proposed that in Anxa3-deficient cells, basal glucose production would 
increase, and PA-induced glucose production would be further increased. Western 
blotting and/or RT-PCR of key insulin signalling proteins such as IRS-2, AKT, Foxo1, 
Pepck and G6Pase would identify whether any observed phenotypes act 
independent to the effects of insulin, as suggested by the results observed in 
PAMN-treatment FAO cells. In the knockdown experiments, it could be determined 
whether Anxa3 expression is required for the actions of either PA or metformin and 
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sodium salicylate on glucose production in FAO cells. The use of an inducible Anxa3 
construct (for example, the lactacystin-inducible Anxa3 plasmid described above 
[290]) would allow for the role of Anxa3 in the induction and/or reversal of PA-
dysregulated glucose production to be temporally distinguished, by inducing Anxa3 
gene expression alongside either PA- or PAMN-treatment. Finally, if Anxa3 was 
found to modulate glucose production, further analysis would be performed to 
determine if the actions of Anxa3 are in fact due to its inhibitory role on Pla2g1b as 
proposed in Chapter 3. 
 
6.3. The contribution of the cholesterol metabolism 
pathway to whole body glucose metabolism 
Evidence has been presented in Chapter 4 for widespread transcriptional regulation 
of cholesterol metabolism following PAMN-treatment. Comprehensive decreases in 
the gene expression levels for all of the members of the metabolic pathways in the 
terpenoid backbone biosynthesis and steroid biosynthesis pathway linking acetyl-
CoA to cholesterol was identified. The transcriptional alterations in these pathways 
may impact upon the generation and degradation of available cholesterol and bile 
acids, and as such may be responsible for the regulation of glucose production in 
FAO cells.  
 
Given the inability to demonstrate altered levels of total cholesterol or bile acid in 
this study, further analysis is required to confirm the importance of these metabolic 
pathways in hepatic glucose production. Given the transcriptional regulation 
described in Chapter 4, it appears that metabolism at both the level of synthesis 
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and degradation of these metabolites could have been affected. Therefore, it is 
possible that while total levels of cholesterol and bile acids may not change, 
metabolic flux through these pathways may be altered. Dr Carsten Schmitz-Peiffer 
of the Garvan Institute Of Medical Research has established protocol for measuring 
metabolic flux using 14C-acetate as a precursor for cholesterol synthesis, which 
could be adapted for future use in the current study. Briefly, vehicle-, PA- and 
PAMN-treated FAO hepatoma cells in 6 cm dishes are incubated for 2 h in serum 
free RPMI medium, and then incubated for 4 – 20 h with and without 1 nM insulin 
in the presence of 3 μCi 14C-acetate. Cells are then washed well in ice-cold 1 x PBS 
pH 7.4, scraped into 250 μL 1 M NaCl, and lipids isolated using a standard Folch 
extraction. 10 μL of each sample, and TAG, DAG, cholesterol and cholesterol ester 
standards, are spotted onto a silica gel TLC plate and resolved using hexane/diethyl 
ether/acetic acid (80:40:4). Once dry, the TLC plate is exposed to film for 1 – 2 
weeks at -80OC, and densitometry is used to calculate the relative incorporation of 
14C into the different lipid species over time. 
  
The identification of the cholesterol biosynthetic pathway discussed in this study 
has further implications for the importance of wider lipid metabolism in the 
regulation of de novo glucose production in the liver. The comprehensive down-
regulation of this pathway in response to metformin and sodium salicylate 
identified this pathway as a major regulated metabolic network in the lowering of 
hepatic glucose production. This finding offers the potential for novel therapeutic 
targets for the control of elevated hepatic glucose output. 
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6.4. Confirming the role of PI side chains in the insulin 
signalling cascade 
Evidence identifying the metabolism of PI species as a potential mediator of the PA-
induced glucose dysregulation was described in Chapter 4. The contribution of 
transcriptional regulation of PI metabolism was confirmed by employing mass 
spectroscopic analysis of PI species in vehicle-, PA- and PAMN-treated cells, which 
identified three PI species regulated by PA-treatment: PI 38:5, PI 36:1 and PI 40:4. 
Further analysis revealed the predominant side chain identity of PI 38:5 to be oleic 
acid (C18:1) and arachidonic acid (C20:4), and similar analysis could be employed to 
determine the side chain identity of the two other PI species. The contribution of 
side chain identity to the ability of PI species to undergo phosphorylation and 
contribute to insulin signalling has not been previously investigated – possibly due 
to the lack of technological advances employed in this study which enabled the 
identification of multiple individual lipid species and their side chains. A study by 
Wang et al. in 2000 used biotinylated PIP3 species with short, water soluble acyl side 
chains (C4 and C8) as an affinity ligand to determine novel binding partners [292]. 
The authors note that binding affinity between di-palmitoyl PIP3 (PI with two C16:0 
side chains) and the SH2 domain of the p85 subunit of PI3K decreased as the length 
of the acyl moiety was shortened – however this observation was included as 
unpublished data. The binding affinity of PIP2 – and thus the ability to transduce 
insulin-stimulated signalling through this pathway was not mentioned. If this 
unpublished finding is accurate, then it correlates with the hypothesis that PI side 
chains affect binding affinity to other ligands, or in other phosphorylation states. 
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As discussed briefly in Chapter 5, determination of whether the side chain identity 
of a PI species affected the ability of that PI species to be phosphorylated (PIP2 to 
PIP3 phosphorylation) is required. Initially, immunoprecipitation using the PIP2 and 
PIP3 antibodies would allow for isolation of the PIP2 and PIP3 pools following the 
presence or absence of insulin stimulation of FAO cells. A Folch extraction of these 
lipid pools would be performed, followed by mass spectroscopic analysis of the side 
chains in each pool. This would indicate for the first time whether the longer side 
chain containing species showed an increased ability to undergo insulin-stimulated 
phosphorylation. To confirm whether this method of regulation plays a role in the 
model as presented in this thesis, western blotting experiments utilising PIP2 and 
PIP3 antibodies would identify if a defect at the level of PIP2 to PIP3 phosphorylation 
does exist following PA-treatment. If this was shown to be the case, the same 
immunoprecipitation experiment as described above could then be performed on 
vehicle-, PA- and PAMN-treated cells in the presence and absence of insulin-
stimulation to determine whether this hypothesis is true of the model detailed in 
this thesis. 
 
6.5. Summary 
As noted in Chapter 4, pathway regulation observed at the gene expression level 
between vehicle- and PA-treatment was different to the regulation between PA- 
and PAMN-treatment. Given this distinction, it is hypothesised that restoring 
dysregulated pathways induced by PA-treatment offers only a limited scope for 
discovering new therapeutic interventions. By observing regulated pathways in the 
reversal of PA-induced dysregulated glucose production (as with PAMN-treatment 
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in the current study), alternative pathways not observed with PA-alone can be 
found. The major limitation of this finding is the limited number of vehicle-samples 
(n=8) compared with PA- and PAMN-samples (n=20), which may have impacted on 
the regulated pathways identified between vehicle- and PA-treatments, given the 
subtle fold-changes observed for the most discriminating genes (see Chapter 3). The 
discovery of additional pathways regulated by PA-treatment would either (i) 
confirm the distinction between the PA-induced and PAMN-reversed dysregulation 
to glucose production, or (ii) identify co-regulated pathways between these two 
states – which would confirm the identified pathways as critical for the 
development of new targeted therapeutics. 
 
Evidence for altered gene expression levels for the pathways regulating acetyl-CoA 
metabolism and cholesterol synthesis was described in Chapter 4. Acetyl-CoA 
accumulation has previously been shown to regulate glucose production through 
allosteric activation of pyruvate carboxylase [112], while cholesterol depletion has 
been shown to alter lipid transport through disruption of caveolae lipid rafts and 
associated inhibition of CD36/FAT-mediated lipid transport [256, 258]. This study is 
the first (to our knowledge) to implicate both of these metabolites in the reversal of 
PA-induced dysregulated glucose production, and highlights these metabolic 
pathways as avenues for targeted therapies against elevated glucose production 
(Fig. 6.1). Three novel phosphatidylinositol species have been identified in the 
current study – PI 38:5, PI 36:1 and PI 40:4 – and further experiments to investigate 
the contribution of side chain identity on the insulin signalling cascade and hepatic 
glucose production have been outlined. 
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FIGURE 6.1: Proposed regulation of lipid metabolism and glucose 
production with PA- and PAMN-treatment. 
Proposed regulation of lipid metabolism and hepatic glucose production following 
PA- (blue) or PAMN-treatment (red). Following PA-treatment, acetyl-CoA levels 
increase, leading to allosteric activation of pyruvate carboxylase, and therefore an 
increased rate of glucose production. Downstream generation of cholesterol 
stabilises lipid transport, allowing for further PA uptake in a positive feedback 
mechanism. PAMN-treatment reduces the rate of cholesterol synthesis, inhibiting 
lipid transport and reducing PA uptake – thereby reducing allosteric activation of 
pyruvate carboxylase and lowering glucose production. 
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Despite being unable to identify a PA-based GES, the identification of two genes 
with potential therapeutic potential – Anxa3 and Pla2g1b – validates the approach 
used in GES development. In addition, the data from the current study has multiple 
future uses. Firstly, generation of a PA-based GES is ongoing utilising a Bayesian 
approach to gene identification. Secondly, the current lipidomic dataset allows for 
the potential development of a lipid signature, discriminating between PA-induced 
dysregulated glucose production and the restored metabolic state. 
 
The findings detailed in this thesis, and summarised in this chapter, detail novel 
regulatory processes involved in the reversal of dysregulated glucose metabolism as 
a consequence of lipid overload. These findings significantly contribute to the 
current understanding of lipid-induced dysregulated glucose metabolism, and offer 
new targets for the development of novel therapeutics for the treatment of obesity-
driven type 2 diabetes. 
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APPENDIX 1 – In vitro model development of PA-
induced dysregulation of glucose homeostasis in 
muscle cell lines. 
 
a1.1. Introduction 
Appendix 1 outlines the initial experiments conducted to develop an in vitro model 
of PA-induced dysregulation of glucose homeostasis in a muscle cell line. As 
described in Chapter 2, the initial aim of this study was to develop an in vitro 
cellular model of PA-induced insulin resistance, followed by the restoration of the 
impairment in insulin action by trialling known anti-diabetic and insulin sensitising 
agents. This appendix will therefore outline the different muscle cell lines (C2C12, 
L6 and L6 stably overexpressing a haemaglutinin epitope on an exofacial loop of 
GLUT4), and differing insulin signalling endpoints measured (glycogen synthesis, 2-
DOG uptake, and HA-GLUT4 translocation, respectively), in the attempt to replicate 
previously described models of PA-induced insulin-resistance. 
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a1.2. Methods 
 
a1.2.1. Cell culture 
C2C12 mouse myoblasts [293] were cultured in low glucose Dulbecco's Modified 
Eagle Medium (DMEM, 5.56 mM D-glucose, GIBCO Invitrogen, Melbourne, VIC, 
Australia) supplemented with 10% (v/v) Foetal Bovine Serum (FBS, GIBCO 
Invitrogen) at 37oC and 5% CO2. After reaching 100% confluence, C2C12 myoblasts 
were cultured in low glucose DMEM supplemented with 2% Horse Serum (HS, 
GIBCO Invitrogen) at 37oC and 5% CO2 to induce cell cycle withdrawal and 
differentiation into myotubes [294]. Cells were allowed to differentiate for 5 days 
before treatment began. Media was replenished every 24 h. 
L6 rat myoblasts [295] were cultured in high glucose DMEM (25mM D-glucose, 
GIBCO Invitrogen) supplemented with 10% (v/v) FBS at 37oC and 5% CO2. After 
reaching 100% confluence, L6 myoblasts were cultured in high glucose DMEM 
supplemented with 2% HS at 37oC and 5% CO2 to induce differentiation into 
myotubes. Treatment commenced after 3 days differentiation. Media was 
replenished every 24 h. L6 myoblasts stably overexpressing a haemaglutinin epitope 
on an exofacial loop of GLUT4 (HA-GLUT4-L6 cell line kindly provided by Dr Cordula 
Hohnen-Behrens and Prof David James, Garvan Institute, Sydney, NSW, Australia, 
[296]) were cultured in either low-glucose DMEM or alpha-MEM (GIBCO Invitrogen) 
supplemented with 10% (v/v) FBS at 37oC and 5% CO2. Media was replenished every 
24 h. 
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a1.2.2. Cell treatments 
C2C12 and L6 myotubes were treated with vehicle (pH 7.4, 0.0285% (v/v) Ethanol 
(EtOH), 25 μM Bovine Serum Albumin, BSA Albumin, Fraction V, USB Corporation, 
OH, USA) or 0.05-0.3 mM PA (PA, pH 7.4, dissolved in 0.0285% EtOH and 25 μM 
BSA) for 24 or 48 h. HA-GLUT4-L6 myoblasts were treated for 16 h with vehicle (pH 
7.4, 0.7% (v/v) EtOH, 5% wt/vol BSA) or 0.3-0.75 mM PA (dissolved in 0.7% (v/v) 
EtOH and 5% wt/vol BSA). The proposed treatment regime for the final model is 
described in Fig. a1.1. 
 
a1.2.3. Glycogen synthesis measurement in C2C12 myotubes 
Glycogen synthesis was measured as described previously [152]. PA-treated 
myotubes in 24-well plates were incubated for 2 h in 200 μL serum-free DMEM 
containing [U-14C]-D-glucose (1 mCi/ml) in the absence or presence of 100 nM 
insulin and 0.05-0.3 mM PA. Cells were washed twice in 200 μL of ice-cold 1 x PBS 
pH 7.4, and then lysed in 300 μL 1 M KOH. Cell lysate was transferred to 1.5 mL 
eppendorf tube, and 5 μL of 25 mg/mL glycogen in sterile filtered H2O added to 
each tube. Sample extract was then incubated for 10 min at 100OC. 50 μL of 
saturated Na2SO4 solution was added to each tube followed by 950 μL of 100% v/v 
ice-cold EtOH to induce glycogen precipitation. Samples were vortexed and 
incubated at -80OC for 30 min. Samples were centrifuged at 18,000 x g for 10 min, 
and supernatant aspirated. Pellets were washed by resuspension in 100 μL H2O, 
followed by sonication at 50 Hz for 2 min in an Unisonics FXP 8M Sonicator 
Waterbath (Unisonics, Sydney, Australia) until the pellet had dissolved. 900 μL of 
100% v/v EtOH was added to each sample, which were then vortexed and incubated 
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at -80OC for 30 min.  Samples were centrifuged at 18,000 x g for 10 min, followed by 
aspiration of the supernatant. The pellet was then dissolved in 100 μL of water and 
sonicated once more to fully dissolve the precipitate. Samples were mixed with 1.2 
mL of scintillate (Ultima Gold, PerkinElmer Life Sciences, Waltham, MA, USA) and 
counted for radioactivity. Counts per min were measured by a TriCarb 2900TR-LSA 
scintillation counter (PerkinElmer Life Sciences). 
 
a1.2.4. 2-Deoxyglucose uptake In L6 myotubes 
Glucose transport was measured as 2-deoxyglucose uptake (2-DOG) as described 
previously [297]. Treated L6 myotubes in 24-well plates were washed twice in PBS 
(GIBCO Invitrogen) containing 0.2% (w/v) RIA-grade BSA, 0.5 mM MgCl2, and 0.9 
mM CaCl2. Insulin (Humulin R; Novo Nordisk, Baulkham Hills, Australia) at 0 or 100 
nM was added for 30 min at 37°C. Uptake of 50 μM 2-DOG and 0.5 μCi 2-deoxy-[U-
3H]glucose (NEN, PerkinElmer Life Sciences, Melbourne, Australia) per well was 
measured over the final 10 min of insulin-stimulation. The reaction was stopped by 
addition of 200 μL of ice cold 1 x PBS pH7.4 containing 80 μg/ml phloretin (Sigma-
Aldrich), and cells were then solubilised in 0.03% (w/v) SDS (GIBCO Invitrogen). 
Counts per min were measured by a 2900TR-LSA scintillation counter. 
 
a1.2.5. HA-GLUT4 translocation measurement in stable L6- 
GLUT4 myoblasts 
Translocation of GLUT4 to the plasma membrane was measured as previously 
described [298]. L6 myoblasts that stably overexpress HA tagged-GLUT4 (HA-GLUT4) 
were seeded into gelatin-coated black-well with clear-bottom 96-well plates. 
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Optimisation of the translocation assay was performed to determine duration (5 – 
30 min) and concentration (1 – 1000 nM insulin) of insulin-stimulation, as well as 
the serum starvation conditions. The serum starvation buffers tested were 2 h 
incubation with Krebs Ringer Phosphate buffer (KRP, pH 7.4, 12.5 mM HEPES, 120 
mM NaCl, 6 mM KCl, 1.2 mM MgSO4, 1 mM CaCl2, 0.4 mM NaH2PO4, 0.6 mM 
Na2HPO4, 0.2% BSA w/v) or alpha-MEM media, pH 7.4 containing 0.2% w/v BSA and 
20 mM HEPES, or an overnight incubation with bicarbonate free alpha-MEM media, 
pH 7.4 containing 0.1% w/v FCS.  This was followed by the addition of insulin (1 – 
1000 nM) over 5 – 30 min at 37O C. The maximum insulin-stimulated HA-GLUT4 
translocation and minimal basal HA-GLUT4 translocation was achieved at 200 nM 
insulin for 20 min at 37OC. Serum starvation for 2 h in alpha-MEM gave the greatest 
insulin stimulatory response for HA-GLUT4 translocation. 
Following serum starvation and insulin-stimulation, cells were then fixed with 3% 
(w/v) paraformaldehyde on ice for 15 min and for a further 30 min at 22 C and 
quenched with 50 mM glycine for 5 min at 22 C. Cells were washed twice with 1 x 
PBS pH7.4 and then blocked in the absence of 0.1% (w/v) saponin (to measure HA-
GLUT4 at the cell surface) or presence of saponin (to measure total cellular HA-
GLUT4). The primary antibody, anti-HA.11-purified monoclonal antibody (2 μg/ml; 
Covance, Vienna), or mouse IgG1κ MOPC21 as a control non-relevant isotype-
specific antibody (2 μg/ml; Sigma) in PBS containing 2% (v/v) normal swine serum 
(DakoCytomaton, Glostrop, Denmark) was added for 45 min at 22 C. The cells were 
washed 3 times with PBS and blocked again in the presence of saponin (to 
permeabilise all cells so that the background labelling of secondary antibody is 
similar for all cells). Cells were incubated for 45 min at 22OC away from light with 
the secondary antibody (20 μg/ml Alexa 488-conjugated goat anti-mouse 
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fluorescein isothiocyanate antibody; Molecular Probes) to detect anti-HA.11 
antibody. Cells were washed four times with PBS, the fluorescence intensity 
(excitation 485 nm, emission 520 nm) was measured with the bottom reading mode 
in a Fusion A1536 fluorescence plate reader (Packard Bioscience, Melbourne, 
Australia) using Fusion Instrument Control MFC Application software (Packard 
Bioscience). The percentage of HA-tagged GLUT4 at the cell surface was calculated 
by dividing the mean anti-HA fluorescence units for each treatment in the absence 
of saponin (minus non-specific anti-MOPC fluorescence units) by the mean anti-HA 
fluorescence units in the presence of saponin (minus non-specific anti-MOPC 
fluorescence units) multiplied by 100.  
 
a1.2.6. Statistical analysis 
Statistical analysis was performed using Statistical Package for the Social Sciences 
(SPSS) version 20.0 (IBM). Data were first analysed for normality using a one-sample 
Kolmogorov-Smirnov test. All data was determined to be normally distributed. Data 
were then either analysed using independent samples Students T-test, or a one-way 
ANOVA. Homogeneity of variance was determined using Levene’s Test, and post-
hoc analysis of ANOVA used either Fisher’s least significant difference (LSD, for 
homogeneous variance) or Games-Howell (for non-homogeneous variance). Data 
were considered significant at p<0.05. Data are presented as mean ± SEM unless 
otherwise stated. 
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FIGURE a1.1: Schematic representation of the 48 h treatment regime for 
the induction and reversal of PA-induced dysregulation of insulin 
sensitivity.  
Proposed treatment regime for the induction and reversal of insulin resistance in 
muscle myotubes and myoblasts. Induction of insulin resistance over 48 h PA-
treatment. Reversal of PA-induced insulin resistance to be achieved in the final 24 h 
of PA-treatment. 
Insulin sensitive 
Insulin resistant 
Insulin re-
sensitised 
First 24 h of 
treatment 
Final 24 h of 
treatment 
In vitro cellular 48 h treatment 
Vehicle Vehicle 
PA PA 
PA PA + “reversal 
Confirmation of 
insulin sensitivity: 
(2-DOG uptake, 
glycogen synthesis, 
HA-GLUT4 
translocation) 
 
RNA extraction and 
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a1.3. Results 
 
a1.3.1. Effects of PA-treatment on basal and insulin-stimulated 
glycogen synthesis in C2C12 myotubes 
The initial attempt to model hyperlipidemia-induced “insulin resistance” in vitro 
used C2C12 myotubes with the incorporation of [U-14C]-D-glucose into glycogen over 
2 h as an endpoint measurement of insulin action. It has previously been shown in 
this cell line [152] that 0.75 mM PA-treatment overnight (16 h) caused ≈50% 
decrease in insulin- (100 mM) stimulated (100 nM) glycogen synthesis – completely 
ablating the effects of insulin-stimulation on glycogen synthesis. Following 24 h 
incubation with vehicle, 100 nM insulin-stimulated glycogen synthesis was 
increased by 40 ± 5% versus basal glycogen synthesis (p=0.0006). Following 24 h 
treatment with 0.05, 0.1, 0.2 or 0.3 mM PA, no significant difference was found 
between any treatment groups and vehicle-treated cells for either basal or insulin-
stimulated glycogen synthesis (Fig. a1.2 a), indicating that  no defect to glycogen 
synthesis was observed with PA-treatment at 24 h. Treatment with PA and vehicle 
was then performed for 48 h. After 48 h treatment with vehicle, insulin-stimulated 
glycogen synthesis was not significantly different to basal glycogen synthesis (Fig. 
a1.2 b). Treatment for 48 h with 0.1 mM PA did not significantly change either basal 
or insulin-stimulated glycogen synthesis compared to the corresponding vehicle-
treated cells (p=0.571 and p=0.0.897 respectively).  
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FIGURE a1.2: Inhibition of glycogen synthesis by PA in C2C12 myotubes.  
(a) C2C12 myotubes were treated with 0.05 – 0.3 mM PA for 24 h. Basal (black bars) 
and 100 nM insulin-stimulated (white bars) glycogen synthesis was measured 
(passage 13, day 7 post-differentiation). Glycogen levels synthesised from glucose in 
vehicle-treated, basal cells was equal to 4.70 ± 0.19 nM glucose converted to 
glycogen. (b) C2C12 myotubes were treated with 0.05 – 0.3 mM PA for 48 h. Basal 
(black bars) and 100 nM insulin-stimulated (white bars) glycogen synthesis was 
measured (passage 13, day 7 post differentiation). Glycogen levels synthesised from 
glucose in vehicle-treated, basal cells was equal to 3.41 ± 0.08 nM glucose 
converted to glycogen. Data expressed as mean ± SEM. *p<0.05 when compared to 
basal, vehicle-treated cells. †p<0.05 when compared to insulin-stimulated vehicle-
treated cells. Each experiment was performed once in triplicate. 
a 
b 
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Following 48 h treatment with 0.2 mM PA, basal glycogen synthesis was lowered by 
70 ± 7% compared with vehicle-treated cells (p=0.0001). Treatment with 0.3 mM PA 
for 48 h decreased both basal glycogen synthesis by 64 ± 2% (p=0.0003 versus basal 
vehicle-treated cells) and insulin-stimulated glycogen synthesis by 70 ± 6% 
(p=0.0001 versus insulin-stimulated vehicle-treated cells, Fig. a1.2 b). While 
impaired insulin-stimulated glycogen synthesis was observed following 0.3 mM PA-
treatment for 48 h, this was preceded by a decrease in basal glycogen synthesis, 
which was also observed with 0.2 mM PA. Treatment with 0.3 mM PA also lead to a 
visible decrease in cell number (light microscopic observation), although whether 
this was due to decreased growth rate, or an increase in cellular death (or both) was 
not measured. These observations, coupled with the decreased basal glycogen 
synthesis indicate that PA-treatment at 0.3 mM might be impacting cellular viability 
as well as insulin sensitivity. For these reasons modelling cellular “insulin resistance” 
using glycogen synthesis in C2C12 cells was not further utilised. 
 
a1.3.2. Effects of PA-treatment on basal and insulin-stimulated 
glucose uptake in L6 myotubes 
The second model used to measure PA-induced impairment to insulin action was 
glucose uptake in L6 myotubes. Glucose uptake was not undertaken in C2C12 
myotubes due to a poor-response to insulin when measuring glucose uptake [152]. 
The ability of to induce “insulin resistance” in L6 myotubes was assessed by 
measuring the uptake of 2-deoxy-[U-14C]-glucose (2-DOG) following insulin-
stimulation (100 nM, 20 min). Insulin had no effect on 2-DOG uptake in either vehicle-
treated cells, (p=0.9721 compared to basal cells), nor PA-treated cells (0.5 – 3 mM), 
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making the determination of PA-induced impairment of insulin action difficult to 
determine. After 24 h treatment with 0.05, 0.1 or 0.2 mM PA, there was no significant 
difference to either basal or insulin-stimulated 2-DOG uptake compared with the 
corresponding vehicle-treated cells (Fig. a1.3 a). Treatment with 0.3 mM PA for 24 h 
caused a 48 ± 13% decrease in basal 2-DOG uptake (p=0.0011) and a 52 ± 6% decrease 
in insulin-stimulated 2-DOG uptake (p=0.0004, Fig. a1.3 a) compared with the 
respective vehicle-treated cells. 
 
After vehicle-treatment for 48 h, insulin-stimulated 2-DOG uptake was increased by 9 
± 1% in vehicle-treated cells (p=0.0092, fig a1.3, b), indicating that the cells were 
minimally responsive to insulin. Following 0.1 mM PA-treatment, basal 2-DOG uptake 
was lowered by 13 ± 2% (p=0.0002) compared to vehicle-treated basal cells, while the 
insulin-stimulated effect on 2-DOG uptake was completely ablated (p=0.5904 
compared to basal 0.1 mM PA-treated cells). Treatment at 48 h with 0.2 mM PA 
decreased 2-DOG uptake by 18 ± 1% (p=0.000001) compared to vehicle-treated basal 
cells, and maintained the ablated response to insulin. Similarly, treatment with 0.3 
mM PA for 48 h decreased glucose uptake by 39 ± 3% (p=2.1x10-15), while insulin was 
ineffective at altering glucose uptake (Fig. a1.3 b). These cells exhibited a lack of insulin 
sensitivity at both 24 and 48 h of vehicle- or PA-treatment, and as such building an in 
vitro model of cellular insulin resistance due to PA was not possible. Numerous 
passages of L6 myoblasts from a range of different frozen cell stocks were used and all 
showed similar results (data not shown). During differentiation, the L6 cells were 
observed to lift from the tissue culture plate surface following 3 days of differentiation, 
and as such, PA incubations had to begin prior to full differentiation of the cells, in 
order for the subsequent insulin bioassay to be performed. The lack of significant 
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insulin response in vehicle-treated cells may therefore in part be explained by the use 
of incomplete differentiated myotubes possessing an immature insulin response. 
Using 2-DOG uptake in L6 myotubes to model PA-induced impairment of insulin action 
was therefore unsuccessful, and was not utilised for further experimentation. 
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FIGURE a1.3: Inhibition of glucose uptake by PA-treatment in L6 
myotubes. 
(a) L6 myotubes were treated with 0.05 – 0.3 mM PA for 24 h. Basal (black bars) and 
2 h insulin-stimulated (100 nM, white bars) 2-DOG uptake was then measured. 
Vehicle-treated, basal 2-DOG uptake was 35 ± 2 pmol 2-DOG transported/min/well. 
(b) L6 myotubes were treated with 0.1 – 0.3 mM PA for 48 h. Basal (black bars) and 
2 h insulin-stimulated (100 nM, white bars) 2-DOG uptake was measured. Vehicle-
treated, basal 2-DOG uptake was 32 ± 1 pmol 2-DOG transported/min/well. Data 
expressed as mean ± SEM. *p<0.05 when compared to basal, vehicle-treated cells. 
†p<0.05 when compared to insulin-stimulated vehicle-treated cells. Each 
experiment was performed twice, in triplicate. 
a 
b 
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a1.3.3. Effects of PA-treatment on basal and insulin-stimulated 
HA-GLUT4 translocation in stable HA-GLUT4-L6 myoblasts 
The final muscle cell-based model for PA-induced insulin resistance measured was 
translocation of the exogenous HA-tagged GLUT4 to the plasma membrane as a 
measure of insulin action. This protocol was optimised prior to experimentation 
(see Methods). The optimum conditions to follow PA-treatment were determined 
to be serum starvation for 2 h in bicarbonate-free alpha-MEM with 0.2% BSA, 
followed by 200 nM insulin-stimulation for 20 min at 37OC. A similar protocol which 
differed only in the timing of serum starvation (16 h) was also used for 
experimentation, which gave similar results (data not shown). 
Following 16 h vehicle-treatment, insulin-stimulation (200 nM, 20 min) increased 
the amount of HA-GLUT4 at the plasma membrane by 15 ± 1% (of total HA-GLUT4) 
in vehicle-treated cells (p=0.0002 versus basal vehicle-treated, Fig. a1.4). Treatment 
with 0.3 mM PA for 16 h did not affect basal HA-GLUT4 translocation, however, 
insulin-stimulated HA-GLUT4 was decreased by 7 ± 1% (p=0.0363 versus insulin-
stimulated vehicle-treated), remaining elevated over basal 0.3 mM PA-treated cells 
(p=0.0087). Treatment with 0.75 mM PA reduced basal HA-GLUT4 at the plasma 
membrane by 12 ± 2% (p=0.0016 versus basal 0.3 mM PA-treated) and further 
reduced insulin-stimulated HA-GLUT4 by 19 ± 1% (p=1.6x10-5 versus insulin-
stimulated 0.3 mM PA-treated, Fig. a1.4). Overall, a minimal effect on insulin action 
was observed with 0.3 mM PA, while treatment with 0.75 mM PA completely 
ablated the insulin response as well as lowering basal HA-GLUT4 translocation. 
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FIGURE a1.4: PA-induced inhibition of HA-GLUT4 translocation to the 
plasma membrane in stable infected HA-GLUT4-L6 cells. 
Effects of 0.3 and 0.75 mM PA-treatment for 16 h on HA-GLUT4 translocation. Cells 
were serum starved for 2 h in bicarbonate free alpha-MEM with 0.2% BSA, then 
incubated for 20 min in the absence (black bars) or presence (white bars) of 200 nM 
insulin at 37OC prior to performing the HA-GLUT4 translocation assay. Data 
expressed as mean ± SEM. *p<0.05 when compared to basal, vehicle-treated cells. 
†p<0.05 when compared to insulin-stimulated vehicle-treated cells. ††p<0.05 when 
compared to 0.3 mM PA-treated, insulin-stimulated cells. Each experiment was 
performed three times, in triplicate. 
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The dynamic range of the responses to both insulin and PA were too narrow for 
further manipulations with known anti-diabetes compounds. In addition, the low 
percentage of HA-GLUT4 translocation observed in basal treated cells during 
optimisation of the protocol (26 ± 1%) was not observed in vehicle- (54 ± 1%) or PA- 
(54 ± 2% and 42 ± 2%) treated cells. The effects of ethanol (from the vehicle-
treatment) may in part explain this finding (see Discussion). Due to the narrow 
dynamic range and high basal HA-GLUT4 translocation to the plasma membrane, 
modelling HA-GLUT4 translocation as a measure of PA-induced impaired insulin 
action was not utilised for further study. 
An alternative cellular model - an insulin-responsive liver cell line (rat hepatoma 
FAO, see Chapter 2) [42] was used to model impairment of insulin action due to PA, 
rather than in vitro muscle cell lines.  
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a1.4. Discussion 
The three muscle cell based models of insulin action detailed in this chapter were 
unable to demonstrate PA-induced insulin resistance. The effect of PA on glycogen 
synthesis in C2C12 cells was mainly on basal synthesis, and only affected insulin-
stimulated glycogen synthesis at 0.3 mM, at which basal glycogen synthesis was less 
than half that of vehicle-treated cells (Fig. a1.2). The large reduction in basal 
measurements indicated that the effects of PA in these cells may have been 
negatively impacting cellular viability. The second muscle cell model described was 
2-DOG uptake in L6 myotubes. At both 24 and 48 h treatment, the largest 
significant insulin response in vehicle-treated cells was 9 ± 1% (Fig. a1.3). Given this 
lack of insulin response, these cells were not suitable for use in modelling insulin 
resistance. Likewise, in HA-GLUT4 overexpressing L6 cells, the response to insulin-
stimulation was a 15% increase in HA-GLUT4 translocation to the plasma 
membrane. This was also coupled with constitutive elevated basal HA-GLUT4 at the 
plasma membrane, which was higher than observed while optimising the protocol 
(26 ± 1%). One explanation for the lack of effect may be the effects of EtOH (in the 
vehicle) on GLUT4 translocation. It has been reported that ethanol at similar 
concentrations to the vehicle (120 mM) has been shown to modulate glucose 
uptake in primary cultured rat skeletal muscle cells [299], as well as increase 
translocation of GLUT4 to the plasma membrane [300], which may explain not only 
this difference but also the lack of a significant insulin stimulatory effect in both the 
glycogen synthesis and 2-DOG uptake models as well. 
Both glycogen synthesis in C2C12 myotubes and glucose uptake in L6 myotubes 
were not insulin sensitive in the experiments performed in this study. While these 
models have been shown to be insulin sensitive in previous research, with insulin-
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stimulated responses of 2 fold in C2C12 myotubes [152] and 2.5 fold in L6 myotubes 
[301] these results could not be replicated. The inability to reproduce a consistent 
response to insulin in these cells makes them unsuitable for the development of the 
model for the purposes of this study. Despite this conclusion however the ability of 
these models to characterise signalling defects underlying lipid-induced insulin 
resistance remains a valid though limiting utility of the models.   
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APPENDIX 2 – Reversal of 48 h PA-treatment 
induced high glucose production in FAO hepatoma 
cells by combination treatment using metformin 
and sodium salicylate. 
 
 
 
 
 
a 
b 
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FIGURE a2.1: Combination reversal of PA-induced glucose dysregulation 
using 0.1 mM metformin and 2 – 3 mM sodium salicylate in FAO hepatoma 
cells. 
(a) Basal (black bars) and 0.01 nM insulin-stimulated (white bars) glucose 
production following 48 h treatment with PA, with metformin and sodium salicylate 
added in the final 24 h of treatment. Vehicle-treated, basal glucose production was 
equal to 31.44 ± 1.58 μg glucose / mg protein. (b) Effect of PA, metformin and 
sodium salicylate on cellular viability after 48 h treatment, with metformin and 
sodium salicylate added in the final 24 h of treatment. (c) Effects of PA metformin 
and sodium salicylate on LDH ratio after 48 h treatment, with metformin and 
sodium salicylate added in the final 24 h of treatment. Average LDH ratio 
(extracellular:intracellular) for basal, vehicle-treated cells was 0.147 ± 0.010. Data 
expressed as mean ± SEM. *p<0.05 for basal PA-treated cells when compared to 
basal vehicle-treated cells. †p<0.05 for basal PA, metformin and/or sodium 
salicylate treated cells when compared to basal PA-treated cells. ††p<0.05 for 
insulin-stimulated cells when compared to each individual treatments basal treated 
cells. M p<0.05 for basal or insulin-stimulated PA with metformin and sodium 
salicylate treated cells when compared to relevant metformin alone treated cells. N 
p<0.05 for basal or insulin-stimulated PA with metformin and sodium salicylate 
treated cells when compared to relevant sodium salicylate alone treated cells.  Each 
experiment was performed three times, in triplicate. 
c 
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FIGURE a2.2: Combination reversal of PA-induced glucose dysregulation 
using 0.25 mM metformin and 1 – 5 mM sodium salicylate in FAO 
hepatoma cells. 
(a) Basal (black bars) and 0.01 nM insulin-stimulated (white bars) glucose 
production following 48 h treatment with PA, with metformin and sodium salicylate 
added in the final 24 h of treatment. Vehicle-treated, basal glucose production was 
equal to 35.03 ± 2.01 μg glucose / mg protein. (b) Effect of PA, metformin and 
sodium salicylate on cellular viability after 48 h treatment, with metformin and 
sodium salicylate added in the final 24 h of treatment. (c) Effects of PA metformin 
and sodium salicylate on LDH ratio after 48 h treatment, with metformin and 
sodium salicylate added in the final 24 h of treatment. Average LDH ratio 
(extracellular:intracellular) for basal, vehicle-treated cells was 0.134 ± 0.007. Data 
expressed as mean ± SEM *p<0.05 for basal PA-treated cells when compared to 
basal vehicle-treated cells. †p<0.05 for basal PA, metformin and/or sodium 
salicylate treated cells when compared to basal PA-treated cells. ††p<0.05 for 
insulin-stimulated cells when compared to each individual treatments basal treated 
cells. M p<0.05 for basal or insulin-stimulated PA with metformin and sodium 
salicylate treated cells when compared to relevant metformin alone treated cells. N 
p<0.05 for basal or insulin-stimulated PA with metformin and sodium salicylate 
treated cells when compared to relevant sodium salicylate alone treated cells. Each 
experiment was performed three times, in triplicate. 
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FIGURE a2.3: Combination reversal of PA-induced glucose dysregulation 
using 0.5 mM metformin and 3 – 5 mM sodium salicylate in FAO hepatoma 
cells. 
(a) Basal (black bars) and 0.01 nM insulin-stimulated (white bars) glucose 
production following 48 h treatment with PA, with metformin and sodium salicylate 
added in the final 24 h of treatment. Vehicle-treated, basal glucose production was 
equal to 37.91 ± 2.66 μg glucose / mg protein. (b) Effect of PA, metformin and 
sodium salicylate on cellular viability after 48 h treatment, with metformin and 
sodium salicylate added in the final 24 h of treatment. (c) Effects of PA metformin 
and sodium salicylate on LDH ratio after 48 h treatment, with metformin and 
sodium salicylate added in the final 24 h of treatment. Average LDH ratio 
(extracellular:intracellular) for basal, vehicle-treated cells was 0.122 ± 0.002. Data 
expressed as mean ± SEM. *p<0.05 for basal PA-treated cells when compared to 
basal vehicle-treated cells. †p<0.05 for basal PA, metformin and/or sodium 
salicylate treated cells when compared to basal PA-treated cells. ††p<0.05 for 
insulin-stimulated cells when compared to each individual treatments basal treated 
cells. M p<0.05 for basal or insulin-stimulated PA with metformin and sodium 
salicylate treated cells when compared to relevant metformin alone treated cells. N 
p<0.05 for basal or insulin-stimulated PA with metformin and sodium salicylate 
treated cells when compared to relevant sodium salicylate alone treated cells. Each 
experiment was performed three times, in triplicate. 
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APPENDIX 3 – Genes identified through DLDA. 
Table a4.1: Genes identified via DLDA and relevant 60mer sequences from Agilent Whole Rat Genome (4x44k) Oligo Microarray 
Slides (G4131F). 
Gene Name Reference Number Agilent ProbeID Sequence 
Anxa3 ref|NM_012823 A_43_P11577 ATTGTCAAGCATATACAAGAGGCGTATGAACAGGCGCTGAAAGCTGACTTGAAGGGTGAT 
Anxa3 ref|NM_012823 A_44_P301936 GTCAGAAGGACATTGAGGACAGCATTAAAGGAGAATTATCTGGGCATTTTGAAGACCTGC 
Anxa3 ref|NM_012823 A_44_P325508 AAGACCTACTAATGATTTTTTATTTGGCTTAGGAAGTTGGAATCTGTGTTGTTCAAAGCC 
Gstm3 ref|NM_020540 A_44_P391068 GATCTCTGCTTACATGAAGAGTAGCAGCTTTCTCCCAAGACCTGTGTTTACTAAGATACC 
Pla2g1b ref|NM_031585 A_43_P15319 AAGACCTTGACACCAAGAAACACTGTTAGGCTGTCACCCCACTTCCTGTCTATGCCGTCC 
Rab33a ref|NM_001108257 A_42_P522374 GTCACCAAGATGACCTCCTTCACCAACTTAAAAATGTGGATCCAGGAATGCAATGGGCAT 
RGD1560824_predicted ref|XR_007343 A_44_P401035_8232 ATAGACAACCCCTACGACCAACACATACTCAAACACAAGAATGTGATCACCTGCAGTGAC 
Serpina5 ref|NM_022957 A_42_P759524 TCAGGGTAAAAGTGTTCCACCATGAACAAAGGTATCAAATCACAAACCTGGCTGACTGCA 
Slc2a2 ref|NM_012879 A_44_P488355 CCCATTATCGACATGTTTTGGGTGTTCCTCTGGATGACCGAAGAGCTACCATTAACTATG 
Slc2a2 ref|NM_012879 A_44_P226612 GGAGAGCTTTCAACATATCACTGCTCTTAAAAGCACGTGACTAAGAAATCTGAAGCTACA 
Snn ref|NM_001034083 A_44_P255109 TAAGTGGAAGGGATGACATTCCTGATCAATAAATGCTGAATGACATTCAAGTTCATTTTG 
AA998612 tc|TC590201 A_42_P591516 TCTGTAACTTTGTCCTTAACCATCAAATGCTGTGCTATTCTAGTATCAAAACATGATGTC 
DY472907 gb|FQ217834 A_44_P329389 TTATCCGCGACAATTTTACCTTGCCTATACTGTATACAACTGATTTCTAAAACTGTAGAC 
TC603506 tc|TC603506 A_44_P837764 TTTTTTCCTCGTCATAACTTGCGTATTAGGAATGGTACATGACTTGGTTCAACTGTCGGT 
TC612212 tc|TC612212 A_44_P626893 AACTTTTCAAAACCTCCGTAAATGTGGTAAACTAAGATGTAAATGAGCCCTAAGAAATGC 
TC628671 tc|TC628671 A_44_P577880 CACACAGCATAAGTTAGCCAGGTAGACACCTCTACCTTATTAAACTTTCTGTCCAGCTAG 
TC641785 tc|TC641785 A_44_P610017 GGCTCTGAGGTAAATCAGGTGTGATTTTTGCATTAGTTTAGAAAATATGTAAGTGAAAGG 
Anxa3, annexin a3/LC3, lipocortin 3; Slc2a2, solute carrier family 2 (facilitated glucose transporter), member 2/GLUT2, Glucose transporter 2; Gstm3, 
glutathione S-transferase mu 3; Pla2g1b, phospholipase A2, group IB; Rab33a, RAB33A, member RAS oncogene family; Serpina5, serpin peptidase 
inhibitor, clade A, member 5; Snn, stannin.
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APPENDIX 4 – KEGG pathways identified through 
GSEA as being differentially regulated between 
vehicle- and PA-treated cells. 
 
FIGURE a4.1: Cell cycle pathway. 
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FIGURE a4.2: Oocyte meiosis. 
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FIGURE a4.3: Toll-like receptor signalling pathway. 
 
FIGURE a4.4: Renal cell carcinoma. 
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FIGURE a4.5: Leukocyte transendothelial migration. 
 
FIGURE a4.6: Colorectal cancer. 
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FIGURE a4.7: Neutrophin signalling pathway. 
 
FIGURE a4.8: Progesterone-mediated oocyte maturation. 
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FIGURE a4.9: Antigen processing and presentation. 
 
 
FIGURE a4.10: Prostate cancer. 
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FIGURE a4.11: Inositol phosphate metabolism. 
 
 
 
FIGURE a4.12: Melanogenesis. 
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FIGURE a4.13: GnRH signalling pathway. 
 
FIGURE a4.14: RNA degradation. 
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FIGURE a4.15: Wnt signalling pathway. 
 
 
 
FIGURE a4.16: Focal adhesion. 
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FIGURE a4.17: NOD-like receptor signalling pathway. 
 
 
   Appendix 5 
233 
 
APPENDIX 5 – KEGG pathways identified through 
GSEA as being differentially regulated between PA- 
and PA with metformin and sodium salicylate-
treated cells. 
 
FIGURE a5.1: Metabolism of xenobiotics by cytochrome P450. 
 
FIGURE a5.2: Drug metabolism – cytochrome P450. 
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FIGURE a5.3: Complement and coagulation cascades. 
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FIGURE a5.4: Porphyrin and chlorophyll metabolism. 
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FIGURE a5.5: Biosynthesis of unsaturated fatty acids. 
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FIGURE a5.6: Retinol metabolism. 
 
 
 
FIGURE a5.7: Drug metabolism – other enzymes. 
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FIGURE a5.8: Arachidonic acid metabolism. 
 
 
FIGURE a5.9: Glutathione metabolism. 
 
 
   Appendix 5 
239 
 
FIGURE a5.10: Systemic lupus erythematosus. 
 
 
 
 
   Appendix 5 
240 
 
FIGURE a5.11: Butanoate metabolism. 
 
 
FIGURE a5.12: Synthesis and degradation of ketone bodies. 
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FIGURE a5.13: Fatty acid metabolism. 
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FIGURE a5.14: Sphingolipid metabolism. 
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FIGURE a5.15: Linoleic acid metabolism. 
 
FIGURE a5.16: Nicotinate and nicotinamide metabolism. 
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FIGURE a5.17: Valine, leucine and isoleucine degradation. 
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FIGURE a5.18: RIG-1-like receptor signalling pathway. 
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FIGURE a5.19: Pentose and glucuronate interconversions. 
 
 
FIGURE a5.20: Primary bile acid synthesis. 
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APPENDIX 6 – Side chain determination of PI 38:5 
using the production ion scan application of liquid 
chromatography, electrospray ionisation-tandem 
mass spectrometry (LC ESI-MS/MS) analysis of 
intracellular lipid fractions. 
 
FIGURE a6.1: Identification of the side chains of PI38:5 in human plasma as 
proof of principle. (a) Precursor ion scan for identification of PI38:5 by mass and 
retention time. (b) Product ions for identification of side chain fragments. 
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FIGURE a6.2: Identification of the side chains of PI38:5 in vehicle-treated 
cells. (a) Precursor ion scan for identification of PI38:5 by mass and retention time. 
(b) Product ions for identification of side chain fragments. 
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FIGURE a6.3: Identification of the side chains of PI38:5 in PA-treated cells. 
(a) Precursor ion scan for identification of PI38:5 by mass and retention time. (b) 
Product ions for identification of side chain fragments. 
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FIGURE a6.4: Identification of the side chains of PI38:5 in PAMN-treated 
cells. (a) Precursor ion scan for identification of PI38:5 by mass and retention time. 
(b) Product ions for identification of side chain fragments. 
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